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Introduction 
Chapter 1 
Renal artery stenosis, a narrowing of the luminal diameter of the renal artery, has 
been a subject of clinical research for several decades. Nevertheless, this 
condition still poses a challenge to the medical profession because the 
consequences of the presence of stenosis are not straightforward. Renal artery 
stenosis can occur alone, or in association with hypertension or renal 
insufficiency or both.1 Thus, renal artery stenosis is a potential cause of secondary 
hypertension, and successful treatment of renovascular hypertension can lead to a 
substantial reduction of cardiovascular morbidity and mortality.2 However, the 
coexistence of renal artery stenosis and hypertension is often accidental, which 
means that an anatomic stenosis is not always the cause of the hypertension.3 For 
this reason, relief of the stenosis will not result in a normalization or even 
improvement of blood pressure levels in many cases. Renal artery stenosis can 
also lead to a progressive deterioration of the renal function,4,5 and has been 
recognized as an increasingly important cause of end-stage renal disease.6 
Progression of renal dysfunction varies among patients with renal artery stenosis, 
however, and leads to end-stage renal disease in only a minority of casesJ,S 
Because of the complex associations between renal artery stenosis, hypertension 
and renal failure, the most effective way to diagnose and treat renal artery stenosis 
is still unclear. At the start of the studies described in this thesis, the clinical 
management of patients with renal artery stenosis was focused on the treatment 
of hypertension. Only recently, the focus has shifted towards the preservation of 
renal function. 
Prevalence, etiology and natural history 
The prevalence of renal artery stenosis in the general population is unknown. 
Most studies involve selected populations with risk factors for renal artery 
stenosis. An early prospective series of hospital autopsies showed a prevalence of 
24%, with a marked increase among older patients.9 Renal artery stenosis was 
found to be more prevalent in patients with vascular disease such as 
cardiovascular disease,10,l1 stroke,12 and peripheral vascular disease.13,14 Among 
patients with hypertension, the prevalence of renal artery stenosis depends on the 
clinical setting. The prevalence is less than 1% in unselected hypertensive 
patients, about 5% in hospital-based populations, and up to 40% in patients 
referred to hypertension clinics.15 Several clinical flndings suggestive of 
renovascular hypertension have been identifled, such as cigarette smoking, 
sudden or recent onset of hypertension, presence of an abdominal bruit, severe 
retinopathy, vascular disease outside the kidney, drug-resistant hypertension, and 
increased serum creatinine levels.3,16-21 
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Many studies have described the progressive nature of renal artery stenosis.4,5,Z2,23 
Progression of stenosis occurred in approximately half of the patients in a period 
between 3 to 5 years. The incidence of end-stage renal disease has not been 
clearly established. It was estimated that renal artery stenosis accounted for 14% 
to 16% of new patients entering dialysis programmes in the US in the mid 
1990s,24 and this proportion is increasing.6 
The most common cause of renal artery stenosis is atherosclerosis in 75% to 
90% of the cases.1•17 Atherosclerotic renal artery stenosis is typically found in 
elderly patients, who often have comorbidity.25,26 The remainder of the cases of 
renal artery stenosis are mainly caused by fibromuscular dysplasia, a vascular 
disease affecting small to medium-sized vessels_27 Fibromuscular dysplasia is the 
common cause of renal artery stenosis in young to middle-aged patients, and is 
found predominantly among women.zs 
Diagnosis 
In the early 1990s, at the start of the studies described in this thesis, intra-arterial 
digital subtraction angiography was considered the reference standard in the 
diagnosis of renal artery stenosis. The advantages of this procedure are that it 
generally provides clear images of the renal arteries and that it can be combined 
with a percutaneous intervention if a treatable stenosis is found. The 
disadvantages of angiography are that it is invasive, expensive, and is associated 
with a risk of serious complications such as anaphylactic reactions, contrast-
induced nephropathy, renal artery dissection and cholesterol embolization_2,29,30 
Furthermore, there is no consensus what degree of stenosis reflects a clinically 
significant stenosis: levels from SO% to 75% have been used in various studies.2,3l 
More importantly, the use of intra-arterial angiography as the reference standard 
is questionable, because it provides information only on the presence of an 
anatomic lesion. Thus, one cannot differentiate an incidental lesion from one 
producing reversible renovascular hypertension or ischemic nephropathy on the 
basis of angiography.z 
Because the prevalence of renal artery stenosis among unselected patients 
with hypertension is low, and because intra-arterial angiography is an invasive and 
expensive diagnostic test, only hypertensive patients with an increased risk of 
renal artery stenosis should be selected for intra-arterial angiography.32 Selection 
criteria have been suggested on the basis of clinical characteristics, such as a 
sudden onset of hypertension or malignant hypertension.zo and hypertension 
resistant to two-drug treatrnent_33 No studies have been performed, however, to 
quantify the exact increase in the risk of stenosis for any of these clinical 
characteristics. 
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Various tests have been proposed for assessmg the presence of a 
functionally significant stenosis, such as the captopril renin challenge test,34 
captopril stimulated renal vein renin sampling,35 and captopril renography.36 Of 
these 'functional' tests, only captopril renography is used as a screening test for 
renovascular hypertension on a large scale. The usefulness of captopril 
renography for this purpose is questionable, however, because the diagnostic 
accuracy of captopril renography varied widely between studies_37·39 In part, this 
may be caused by a lack of interobserver agreement in the evaluation of captopril 
renography, because the interpretation is a complex task.40,4l The interobserver 
agreement of captopril renography, however, has not been studied as yet. 
Treatment 
Several forms of intervention are available to revascularize the renal artery. 
Initially, surgical revascularization was the only invasive treatment option. This 
procedure is associated with significant perioperative morbidity and mortality 
rates especially in elderly patients with comorbid disease.42-45 Since the 
introduction of balloon angioplasty for renal artery stenosis46, this less invasive 
procedure became the preferred treatment. Balloon angioplasty was shown to be 
equally effective compared to surgery with respect to blood pressure control and 
the preservation of renal function.47,4S 
For patients with fibromuscular dysplasia, it has been established that 
balloon angioplasty is the treatment of choice. In these patients, angioplasty is 
successful for the treatment of hypertension.49· 53 For patients with atherosclerotic 
renal artery stenosis, however, the benefit of balloon angioplasty is disappointing 
with respect to both the technical success rate and blood pressure outcomes after 
successful procedures.S4 Moreover, restenosis occurs frequently in this type of 
patients, especially if the stenosis is located in the ostium of the renal artery.55 
Until the start of the studies described in this thesis, the supremacy of angioplasty 
over medication in the treatment of hypertension in patients with atherosclerotic 
renal artery stenosis had not been confirmed in randomized controlled trials. 
Also, the use of stents in renal arteries was in an experimental stage by that time, 
and results of randomized comparisons between treatment with angioplasty and 
treatment with additional stent placement were not available. 
Research questions addressed in the thesis 
The studies described in this thesis started in the early 1990s and addressed 
questions on both the diagnosis and the treatment of renal artery stenosis. 
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Research questions concerning diagnosis: 
What is the interobserver agreement of captopril renography for the 
detection of renal artery stenosis? 
What is the value of clinical characteristics for predicting the probability of 
renal artery stenosis in patients suspected of renal artery stenosis? 
Research questions concerning treatment: 
Are the clinical outcomes for patients with hypertension and atherosclerotic 
renal artery stenosis after balloon angioplasty better than those after 
antihypertensive-drug therapy? 
What is the cost-effectiveness of different treatment strategies for patients 
with hypertension who are suspected of renal artery stenosis? 
The DRASTIC study 
The studies described in this thesis were based, entirely or in part, on the data of 
the Dutch Renal Artery Stenosis Intervention Cooperative ('DRASTIC') study.56 
Between January 1993 and November 1998, this prospective randomized trial 
was conducted in 26 hospitals in the Netherlands. The study aimed to assess the 
prevalence of renal artery stenosis in patients with well-defmed drug-resistant 
hypertension, and to determine the predictive value of clinical characteristics and 
diagnostic tests in these pre-selected patients. With regard to treatment, the study 
aimed to compare the effects of balloon angioplasty and antihypertensive 
medication on blood pressure in patients with atherosclerotic renal artery 
stenosis. 
In the diagnostic phase of the study (Figure 1.1), 1205 patients aged between 
18 and 7 5 years were included who were referred for analysis of hypertension to 
one of the participating centers. Only patients with a normal or mildly impaired 
renal function were included. Patients without a known diagnosis (N=1133) were 
randomly allocated to one of two standardized antihypertensive drug regimes, if 
possible. The blood pressure was monitored at 3 consecutive visits. Drug-
resistant hypertension was established if the diastolic blood pressure remained 95 
mm Hg or more despite standardized medication. Patients with drug-resistant 
hypertension (N=455) and patients with a rise in serum creatinine concentration 
after use of an angiotensin-converting-enzyme (ACE) inhibitor (N=43) 
underwent diagnostic workup. The diagnostic workup involved various 
laboratory tests, non-invasive tests for renal artery stenosis (the captopril renin 
challenge test and captopril renography), and intra-arterial angiography (the 
reference standard). Renal artery stenosis, defined as a narrowing of lumen 
diameter of 50% or more on angiography, was found in 107 of the 478 patients 
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who underwent angiography (22%)_57 Atherosclerosis was the underlying cause of 
stenosis in 81% of the patients with renal artery stenosis. 
Recruitment of hypertensive patients (N=1205) 
Assignment to standardized antihypertensive 
drug regimen (N=1133) 
Hypertension 
controlled 
(N=635) 
Drug-resistant 
hypertension during 3 
control visits (N=455) 
Renal function impairment 
after ACE-inhibitor therapy 
(N=43) 
'Functional' tests: 
captopril test, 
captopril renography, 
renal vein renin sampling 
Figure 1.1. Design of the diagnostic phase of the DRASTIC study. 
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In the therapeutic phase of the study, 106 patients with atherosclerotic renal 
artery stenosis were randomly allocated to either balloon angioplasty (N=56) or 
medication (N=50). After 3 months of follow-up, the blood pressure and renal 
function were evaluated. In accordance with the study protocol, 22 patients 
randomized to medication (44%) underwent balloon angioplasty after 3 months 
because of persistent hypertension or deterioration of the renal function. Blood 
pressure and renal function were evaluated again 12 months after randomization. 
Outline of the thesis 
The first part of the thesis describes three studies on non-invasive diagnostic tests 
to select patients suspected of renal artery stenosis for renal intra-arterial 
angiography. Chapter 2 studies the interobserver agreement of captopril 
renography as a possible explanation for differences in diagnostic accuracy of this 
test for finding renal artery stenosis. In Chapter 3, an alternative for the available 
non-invasive tests is presented. This chapter describes the development of a 
clinical prediction rule for renal artery stenosis based on readily available clinical 
characteristics. In Chapter 4, the prediction rule is validated in a sample of new 
patients in a different setting. 
The second part of the thesis describes several studies on the treatment of 
hypertensive patients diagnosed with atherosclerotic renal artery stenosis. In the 
Chapters 5 and 6, the clinical outcomes after balloon angioplasty are compared to 
those after medical treatment followed by angioplasty if needed, for patients with 
hypertension resistant to a two-drug regimen and atherosclerotic renal artery 
stenosis. Chapter 5 describes the blood pressure and renal function outcomes of 
a randomized comparison of the two treatment strategies for the study group as a 
whole. The purpose of Chapter 6 was to identify subgroups of patients for whom 
immediate intervention might be indicated. In the Chapters 7 and 8, the quality of 
life of patients with hypertension is studied. In Chapter 7, a questionnaire for 
measuring quality of life in patients with hypertension is validated. Chapter 8 
studies the effect of treatment on health-related quality of life in patients with 
hypertension and renal artery stenosis. In Chapter 9, a decision analytical 
approach is followed to determine the optimal treatment strategy for patients 
with atherosclerotic renal artery stenosis. In this chapter, the cost-effectiveness of 
seven treatment strategies for patients with atherosclerotic renal artery stenosis is 
compared. Data of the DRASTIC study and literature data on long-term 
consequences renal artery stenosis are combined to estimate the optimal 
treatment strategy for patients with hypertension who have renal artery stenosis 
demonstrated on computed tomography angiography or magnetic resonance 
angiography. 
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In Chapter 10, the main findings of the preceding chapters are summarized 
and discussed, and the diagnostic workup and treatment for renal artery stenosis 
are elaborated on. Finally, conclusions and recommendations are given. 
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Abstract 
Background: Captopril-stimulated renography is widely used to screen selected 
groups of hypertensive patients for renal vascular disease. Evaluation of the test is 
a complex task. Lack of interobserver agreement on the assessment and 
interpretation of renographic parameters may contribute to differences in 
sensitivity and specificity between studies. 
Methods: Three experienced nuclear medicine physicians evaluated 658 renograms 
of 503 hypertensive patients suspected of having renal vascular disease from a 
large Dutch multicenter study (the Dutch Renal Artery Stenosis Intervention 
Cooperative [DRASTIC] study). Interobserver ~oreement on several renographic 
parameters was assessed by the K statistic and the intraclass correlation coefficient 
(ICC). 
Results: The interobserver agreement on the time to excretion was high: The 
pooled ICC was 0.90. The pooled K was :?:0.65 for the pattern of the time-activity 
curves, the visual aspect of the renographic images (visible uptake and kidney 
size), and the ju<\.,oment on the presence of renal artery stenosis. However, the 
interobserver agreement on cortical retention and pelvic retention by visual 
inspection of the images was rather low (pooled K=0.46 and 0.52, respectively). 
Pelvic retention was found to complicate the interpretation of renography. 
Conclusions: Interobserver agreement on most of the renographic parameters was 
satisfactory, but the assessment of cortical retention was more difficult, in 
particular, in the presence of pelvic retention. Captopril renography should be 
interpreted with caution if pelvic retention is suspected. Interobserver variability 
offers one of several explanations for the differences in diagnostic test 
performance that are found between studies. 
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Introduction 
Captopril-stimulated renography is a noninvasive test that is widely used to screen 
selected groups of hypertensive patients for the presence of renal vascular disease. In 
patients with renovascular hypertension, captopril induces changes in the renographic 
images of the kidney distal to the stenosis by revealing decreased uptake or delayed 
excretion with cortical retention (or both). Accordingly, the time-activity curves may 
reveal these alterations. Evaluation of renographic images and time-activity curves is 
encouraged in the invest\,aation of renal vascular disease.l-3 Patients with such 
captopril-induced changes on the renogram are generally expected to benefit from 
intervention with balloon angioplasty or with stent insertion.4-6 
Interpretation of captopril renography is not a straightforward task. The 
nuclear medicine physician must assess several renographic parameters and 
subsequently integrate this information to form a judgment on the presence of 
renal vascular disease. Efforts have been made to standardize the test.1,7-9 These 
guidelines focus mainly on the procedure and not on interpretation of the results. 
Moreover, diagnostic criteria are not uniform, and different renographic 
parameters are considered. The diagnostic performance of captopril renography 
has been variously described with sensitivity ranging between 70% and 100% and 
specificity ranging between 60% and 100%.6,10,11 A lack of interobserver 
agreement on interpretation of the test results may have contributed to these 
differences. Despite the vast literature on captopril renography for diagnosing 
renal vascular disease, the interobserver variability has not yet been described. 
In this study, 3 experienced nuclear medicine physicians, working in 
different university hospitals, evaluated 658 renograms of 503 patients suspected 
of having renal vascular disease. We analyzed the interobserver agreement on the 
assessment of renographic parameters and the agreement on the judgment on the 
presence of hemodynamically significant renal artery stenosis. 
Patients and methods 
Study design 
The study was part of the Dutch Renal Artery Stenosis Intervention Cooperative 
(DRASTIC) study. The aim of this multicenter study was to optimize the 
diagnosis and treatment of renal artery stenosis.12 The DRASTIC study included 
1205 hypertensive patients, 18-75 years old, who had been referred for 
unsatisfactory control of blood pressure or an adverse drug effect during the 
course of antihypertensive treatment or for analysis of possible secondary 
hypertension. Exclusion criteria were suspected secondary hypertension other 
than renal vascular disease, unstable coronary artery disease, heart failure, renal 
failure (serum creatinine ;;:::200 ).lmol/L [2.26 mg/ dL]), and inadequate 
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contraception. Patients with drug-resistant hypertension (diastolic blood pressure 
:2:95 mm Hg on 2 drugs during 3 visits) (N=455) or with a rise in serum creatinine 
concentration after angiotensin-converting enzyme (ACE) inhibitor therapy 
(N=43) as well as patients in whom renal artery stenosis had been diagnosed 
before their referral to the participating center (N=72) underwent diagnostic 
workup for renal artery stenosis. Patients with atherosclerotic renal artery 
stenosis, defined as :2:50% reduction of lumen diameter according to renal digital 
subtraction angiography (gold standard test), were randomly assigned to either 
the balloon angioplasty (N=56) or the medical treatment (N=50) group. 
Captopril renography was performed and evaluated by the local nuclear medicine 
physicians in 22 participating hospitals. In the di~onostic workup, the sensitivity 
and specificity for finding stenosis according to the local nuclear medicine 
physician were 72% and 90%, respectively.11 Furthermore, renography was 
performed to evaluate treatment after 3 and 12 months of follow-up. 
Renographic protocol 
The protocol for conducting the renographic procedures reflected the guidelines 
of the consensus report on ACE inhibitor renography.? In patients who were 
receiving long-term ACE inhibitor treatment, the ACE inhibitor was withheld for 
at least 24 hours before renography was performed. According to the protocol, 
an oral dose of 50 mg captopril was given 1 hour before the examination in 95% 
of the procedures to induce asymmetry in uptake and intrarenal transit between 
the kidneys in case of renal vascular disease. In the remaining 5% of the 
procedures, the physician reduced the dose of captopril to 25 mg to prevent 
hypotension. To ensure adequate absorption of captopril, patients were required 
to fast during the 4 hours preceding renography. Sufficient hydration was 
guaranteed by oral administration of 0.5 L of tap water. Blood pressure was 
measured with an automatic device before administration of captopril and every 
5-10 minutes for 2 hours after administration of captopril. Renography was 
performed with the patient in supine position, and the detector placed 
posteriorly. After intravenous administration of 75-100 MBq 99mTc-mercapto-
acetyltriglycine, data were collected in 10-second frames during a 20-minute 
period, and sequential analog images obtained every minute. The time-activity 
curves were generated using regions of interest over the whole kidney.1 
Study 
In this study on interobserver agreement, 658 renograms of 503 patients with 2 
native kidneys were reevaluated by 3 experienced nuclear medicine physicians 
(referred to as physicians A, B, and C) who were working in different university 
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hospitals at the time. Of these renograms, 487 were obtained during the 
diagnostic workup of patients with and without renal artery stenosis. The 
remaining renograms were obtained during follow-up of patients with stenosis: 
82 renograms after 3 months of follow-up and 89 renograms after 12 months of 
follow-up. 
Renographic evaluation 
The renograms were evaluated independently, and the physicians were unaware 
of patient characteristics and hospital source. The 3 physicians had no additional 
clinical information, such as the blood pressure response to captopril and the 
diuresis during the procedure. Before evaluation, the physicians discussed which 
renographic parameters of the renographic images and time-activity curves would 
be assessed and how these features would be scored. 
The following parameters were scored from the renographic images by each 
individual observer, separately for the left and right kidneys: visible uptake 
(scored as present or absent); time to excretion (scored as number of minutes 
until radioactivity appeared in the renal pelvis, determined by visual evaluation of 
the 1-minute sequential images, if available; if the excretory phase started only 
after 20 minutes, no excretory phase was registered); and kidney size (scored as 
normal or small). Cortical retention and pelvic retention (scored as present or 
absent) were determined by visual inspection. The presence of pelvic retention 
was assessed because this was considered to complicate the renographic 
evaluation of the images and the time-activity curves of the whole kidneys.J,13 The 
pattern of the time-activity curves was scored in 6 ordered categories as proposed 
by Fommei et al.10 (O=normal, 1=minor abnormalities, 2=marked delayed 
excretion rate with preserved washout phase, 3=delayed excretion rate without 
washout phase [accumulation curve], 4=renal failure pattern with measurable 
kidney uptake, and 5=renal failure pattern without measurable kidney uptake 
[blood background-type curve]). Interobserver agreement was not applicable for 
the time to peak activity (T rna.,) and the relative (individual kidney) uptake because 
these diagnostic criteria were calculated by the computer. 
Finally, the judgment on the presence or absence of renal artery stenosis was 
assessed for each kidney. No specific diagnostic criteria were defined to reflect 
the clinical practice. The judgment on the presence of stenosis was scored as 1 of 
5 ordered categories (1 =certainly stenosis, 2=probably stenosis, 3=indeterminate, 
4=probably no stenosis, and 5=certainly no stenosis; in the case of a blood 
background-type curve, the diagnosis was scored as indeterminate). 
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Inte:robserver agreement 
We used the K statistic to assess interobserver agreement on the renographic 
parameters that were measured on a nominal scale. K reflects the proportion of 
the maximally achievable agreement that is realized on top of the agreement that 
is expected by chance.14-16 K values usually range from 0 (indicating chance 
agreement only) to 1 (indicating perfect agreement). The only meaningful 
interpretation of negative values of K is that the level of agreement is what would 
be expected by chance aloneP In general, K values of <0.40 are considered as 
low and values of >0.80 are considered as high.15,l6,lS Because the value of K 
decreases if the number of ordinal categories is increased, we calculated weighted 
K values for the pattern of the time-activity curves and the ju~oment on the 
presence of stenosis to adjust for the seriousness of different levels of 
dis~oreement. 1 9-21 Linear weights were used: w(ij) = 1 - I i - j I / ( c - 1), where i and 
j are the sequence numbers of the categories, and c is the number of categories. 
Interpretation of weighted K is like that of unweighted K.15 
The interobserver agreement on the time to excretion, which was measured 
on an interval scale, was expressed as the intraclass correlation coefficient (ICC). 
The ICC takes into account systematic differences between observers and ranges 
from -1 (perfect disagreement) to 1 (perfect agreement), with 0 indicating only 
random concordance.22,23 Although there are no universal standards, values of 
ICC of <0.40 are considered as low and values of >0.75 are considered as high.24 
Interobserver agreement on renographic parameters was calculated by 
kidney and on the ju~oment on the presence of stenosis by kidney as well as by 
patient. Interobserver ~oreement was assessed for each pair of observers. A 
pooled estimate was also calculated on the basis on the mean observed agreement 
and the mean amount of agreement expected under the null model of 
independence. A 95% confidence interval (CI) was calculated for each estimate. 
Estimates of the ICC were calculated with SPSS software (release 9.0.0; SPSS, 
Chicago, IL) and estimates of K were calculated with AGREE Statistical Software 
(version 7.001; ProGAMMA, Groningen, The Netherlands). 
Finally, the probability that a physician judged stenosis to be absent given 
the fact that another did so, corrected for chance agreement, was calculated using 
the average conditional probability of the absence of stenosis and the average 
expected probability of stenosis. Similar probabilities were calculated for the 
ju~oment on the presence of unilateral stenosis and for the judgment on the 
presence of bilateral stenosis. These probabilities can be interpreted as a K-per-
outcome category. 
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Results 
Patients 
All patients whose renograms were evaluated had drug-resistant hypertension. 
Their diastolic blood pressure was 105 ± 9 mm Hg (mean± SD), despite the use 
of 2 ± 1 antihypertensive drugs. At study entry, the renal function was normal or 
mildly impaired: The patients had a serum creatinine concentration of 95 ± 27 
flmol/L and their creatinine clearance was 85 ± 33 mL/min (Table 2.1). In 5 
patients the serum creatinine concentration had increased to > 1 SO flmol/L 
during follow-up. 
Renographic images 
The 3 nuclear medicine physicians did not note any uptake on the renographic 
images of 1%-3% of the kidneys (Table 2.2). Physician C reported the absence of 
uptake twice as often as physicians A and B. The pooled K-value for visual uptake 
was 0.65 (95% CI, 0.51-0.80). A small kidney size was scored more frequently by 
physician A than by the other physicians (25% vs. 18% and 17%). The pooled K 
was 0.70 (95% CI, 0.66-0.74). Because 1-minute images were not obtained 
routinely in every hospital, the beginning of the excretory phase was assessed for 
approximately half of the renograms. The beginning of the excretory phase was 
estimated to start, on average, after 4.29-4.43 minutes. The pooled ICC was 0.90 
(95% CI, 0.89-0.91). Cortical retention was reported in 2-3 times as many kidneys 
by physician A than by the other physicians. The pooled K was 0.46 (95% CI, 
0.42-0.51). Pelvic retention was reported least by physician B (12% vs. 21% and 
18%). The pooled K for pelvic retention was 0.52 (95% CI, 0.47-0.56). 
Table 2.1. Characteristics at entry of 503 patients evaluated for renal artery 
stenosis. 
Characteristic Percentage of patients or mean ± SD 
Age, years 
Male 
Systolic blood pressure, mm Hg 
Diastolic blood pressure, mm Hg 
No. of antihypertensive drugs 
Serum creatinine, J.lmol/L 
Creatinine clearance, mL/ min 
Referred by general practitioner 
Stenosis 2:50% on angiography 
52± 13 
57 
171 ± 23 
105 ± 9 
2±1 
95 ± 27 
85 ± 33 
51 
30 
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Table 2.2. Interobserver agreement on renographic parameters. 
Renographic parameter Physician No.(%) Physicians Agreement* 
(no. of kidneys studied) with feature 
or mean± SD 
Renographic images 
No visible uptake A 14 (1.1) AandB 0.81 (0.66-0.96) 
(N=1306) B 18 (1.4) BandC 0.59 (0.43-0.76) 
c 32 (2.5) AandC 0.60 (0.44-0.77) 
Pooled 0.65 (0.51-0.80) 
Small kidney A 323 (25) AandB 0.69 (0.64-0.74) 
(N=1271) B 229 (18) BandC 0.79 (0.74-0.83) 
c 210 (17) AandC 0.64 (0.59-0.69) 
Pooled 0.70 (0.66-0.74) 
Time to excretion (min) A 4.29 ± 1.47 AandB 0.88 (0.86-0.90) 
(N=708) B 4.34 ± 1.65 B andC 0.95 (0.94-0.96) 
c 4.43 ± 1.67 AandC 0.88 (0.86-0.89) 
Pooled 0.90 (0.89-0.91) 
Cortical retention A 350 (28) AandB 0.37 (0.31-0.42) 
(N=1238) B 119 (10) BandC 0.63 (0.56-0.70) 
c 165 (13) AandC 0.46 (0.41-0.52) 
Pooled 0.46 (0.42-0.51) 
Pelvic retention A 257 (21) AandB 0.48 (0.41-0.54) 
(N=1256) B 147 (12) B andC 0.46 (0.40-0.53) 
c 231 (18) AandC 0.59 (0.54-0.65) 
Pooled 0.52 (0.47-0.56) 
Time-activity curves 
Pattern of the curve A (See Figure 2.1) AandB 0.74 (0.70-0.77) 
(N=1274) B BandC 0.60 (0.57-0.64) 
c AandC 0.63 (0.60-0.67) 
Pooled 0.65 (0.62-0.68) 
Conclusion on presence of stenosis 
On the original A (See Figure 2.2) AandB 0.05 (0.01-0.09) 
5-point scale t B BandC 0.14 (0.10-0.17) 
(N=1316) c AandC 0.32 (0.27-0.37) 
Pooled 0.16 (0.13-0.18) 
Collapsed into A 293 (22) AandB 0.62 (0.57-0.68) 
a 2-point scale * B 184 (14) BandC 0.66 (0.60-0.71) 
(N=1316) c 256 (20) AandC 0.69 (0.64-0.74) 
Pooled 0.66 (0.62-0. 70) 
* K with 95% CI, except for time to excretion, where ICC with 95% CI is shown. 
t 1=certainly stenosis, 2=probably stenosis, 3=indeterminate, 4=probably no stenosis, 
5=certainly no stenosis. 
* 
Indication for stenosis=certainly or probably stenosis or indeterminate, no indication 
for stenosis=certainly or probably no stenosis. 
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Physician B 
Physician A 
* O=normal, 1 =minor abnormalities, 2=marked delayed excretion rate with preserved 
washout phase, 3=delayed excretion rate without washout phase (accumulation curve), 
4=renal failure pattern with measurable kidney uptake, S=renal failure pattern without 
measurable kidney uptake (blood background-type curve) 
Figure 2.1. Interobserver agreement on pattern of time-activity curves for 1274 
kidneys according to 3 nuclear medicine physicians. 
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Time-activity curves 
Systematic differences occurred between observers in assigning a pattern to the 
time-activity curves (Table 2.2; Figure 2.1). Physician C reported more abnormal 
time-activity curves than physicians A and B. Furthermore, physician A reported 
more abnormal curves than physician B. The pooled value for the weighted K was 
0.65 (95% CI, 0.62-0.68). 
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* 1 =certainly stenosis, 2=probably stenosis, 3=indeterminate, 4=probably no stenosis, 
S=cettainly no stenosis 
Figure 2.2. Interobserver agreement on judgment on presence of renal artery 
stenosis for 1316 kidneys according to 3 nuclear medicine physicians. 
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Judgment on presence of stenosis by kidney 
The pooled value of the weighted K for the judgment on the presence of stenosis 
for separate kidneys, as measured on a 5-point scale, was 0.16 (95% CI, 0.13-0.18) 
(Table 2.2). Physician B was more outspoken in assigning scores than physicians 
A and C: Physician B was certain of the presence of stenosis in 4% of the kidneys 
compared with 2% and <1% (physicians A and C, respectively) and was certain 
of the absence of stenosis in 59% of the kidneys compared to 6% and 18% 
(physicians A and C, respectively) (Figure 2.2). When the judgment on the 
presence of stenosis was dichotomized into certainly or probably stenosis or 
indeterminate versus certainly or probably no stenosis, an indication for stenosis 
was found in 14%-22% of the kidneys. The pooled K for the dichotomized 
judgment was better than that on the 5-point scale: 0.66 (95% CI, 0.62-0.70) 
versus 0.16 (95% CI, 0.13-0.18). 
K was calculated separately for those kidneys on which all 3 physicians 
agreed that pelvic retention had or had not occurred. For kidneys showing pelvic 
retention (N=90), K for the dichotomized judgment on the presence of stenosis 
was significantly lower than that for kidneys without pelvic retention (N=909): K 
ranged between -0.07 and 0.12 for kidneys with pelvic retention (pooled estimate, 
0.06; 95% CI, -0.04 to 0.15) and between 0.69 and 0.77 for kidneys without pelvic 
retention (pooled estimate, 0.73; 95% CI, 0.68-0.78). 
Judgment on presence of stenosis by patient 
The 3 physicians found an indication for stenosis (certainly or probably stenosis 
or indeterminate) in 20-28% of the renograms. The pooled K was 0.70 (95% CI, 
0.64-0.76). Furthermore, we studied the agreement on whether there was no 
indication for stenosis or was an indication for unilateral stenosis or an indication 
for bilateral stenosis (Figure 2.3). An indication for bilateral stenosis was judged 
variously: Physician B suspected bilateral stenosis in 4% of the patients, whereas 
physicians A and C suspected bilateral stenosis to be present more frequently (in 
12% and 11%, respectively). When 1 of the 3 physicians judged that stenosis was 
absent, the probability that a second physician concluded the same was, on 
average, 0.70 (95% CI, 0.61-0.79). When 1 of the 3 physicians judged that 
unilateral stenosis was present, the probability that a second physician reached the 
same conclusion was, on average, 0.65 (95% CI, 0.61-0.70). For the presence of 
bilateral stenosis, this probability was, on average, 0.48 (95% CI, 0.43-0.52). 
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Figure 2.3. Interobserver agreement on absence of renal artery stenosis (No 
RAS) or presence of unilateral (URAS) or bilateral (BIRAS) stenosis according to 
3 nuclear medicine physicians on basis of conclusion per kidney. 
Discussion 
In this study, the interobserver 2-oo-reement on captopril renography was studied in 
658 renograms of patients with drug-resistant hypertension and a normal or 
mildly impaired renal function. Three experienced nuclear medicine physicians 
assessed renographic parameters that have been recommended for evaluation1,2,7 
and judged whether hemodynamically significant renal artery stenosis was present 
or absent. For most of these parameters and for the judgment on presence of 
stenosis, the interobserver agreement was satisfactory. The agreement on cortical 
retention was relatively low, however. 
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Except for the time to excretion, the interobserver agreement was assessed 
by the K statistic. Although K is most commonly used to measure interobserver 
agreement in categorical data, one has to bear in mind, however, that the 
interpretation of K is complicated by some of its properties_16.1?,25 First, the value 
of K strongly depends on the underlying prevalence of the parameter under study. 
For instance, a high value of K for agreement on the absence of visible uptake is 
harder to achieve than for agreement on small kidney size because the latter is 
much more common. Second, although K does not identify systematic differences 
between observers (bias), K will be lower if such bias is present. This is also the 
case for the ICC, which was used to assess interobserver agreement in continuous 
data. Therefore, it should be noted that systematic differences between the 
observers in the assessment of several parameters were found - for instance, for 
the judgment on the presence of stenosis (Figure 2.2). Third, the way one values 
discrepancies between categories and consequently chooses the weights for the 
calculation of weighted K is arbitrary. For instance, by choosing linear weights in 
the calculation of K for the time-activity curves, we assumed that disagreement 
between normal curves and curves with minor abnormalities (curve types 0 and 
1) is as serious as disagreement between renal failure patterns with and without 
measurable kidney uptake (curve types 4 and 5). 
The pattern of the time-activity curves, which is considered to be an 
important diagnostic parameter,2,l3 was scored in 6 ordered categories.10 The 
weighted K value for the pattern of the time-activity curves was moderately high, 
especially when one considers that the distinction between some of these types of 
curves is difficult to make. The interobserver agreement on visible uptake and on 
kidney size was also satisfactory but could have been affected negatively by the 
low prevalence of these features.17·25 The interobserver agreement on time to 
excretion as assessed from the renographic images was high. Yet, the relative 
(individual kidney) uptake and the Tmax are the most reliable parameters in terms 
of interobserver agreement because the computer calculates them. 
With 99mTc-mercaptoacetyltriglycine, which is almost completely cleared by 
tubular secretion, renovascular hypertension can usually be detected by cortical 
retention after ACE inhibition.? Delayed excretion can also be caused by pelvic 
stasis, however. In kidneys without a dilated renal pelvis, pelvic retention will be 
observed because of low diuresis. The patients in this study drank 0.5 L of tap 
water 30-60 minutes before the renography. Perhaps a more abundant diuresis 
could be achieved by giving 10 mL/kg of body weight. Another cause of low 
diuresis is the fact that some of the patients were on diuretics. These patients may 
produce less urine during the renography.9 The identification of cortical retention 
is difficult in the presence of pelvic retention.1·13 The complicating role of pelvic 
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retention in the evaluation of captopril renography was evident in our study. For 
cortical and pelvic retention, the interobserver agreement on the assessment of 
the presence or absence of these phenomena was not satisfactory. Probably, this 
can be improved by the assessment of the time-activity curves of the renal cortex. 
Which renographic parameters should be used then as diagnostic criteria in 
the evaluation of renal vascular disease? The diagnostic performance and the 
interobserver variability should be included in this consideration. When ranked 
according to the sum of sensitivity and specificity in a by-patient analysis, the 
order of the renographic parameters was virtually the same for the 3 nuclear 
medicine physicians (data not shown). However, one must bear in mind that by 
this way of ranking the sensitivity and the specificity are valued equally. The 
parameter with the best diagnostic performance was asymmetry in renal uptake. 
The fact that the individual kidney uptake is measured objectively adds to its 
usefulness as a diagnostic criterion. Time to excretion as assessed from the 
renographic images, an abnormal pattern of the time-activity curves, and cortical 
retention ranked somewhat lower in terms of diagnostic performance. On the 
basis of the interobserver variability of these parameters, the first 2 are also 
important diagnostic criteria but the last should be given less weight. The lowest 
diagnostic performance was found for the visual assessment of the kidneys on the 
renographic images (i.e., no visible uptake or asymmetry in kidney size) and Tma.,. 
Diagnostic information is lost if one focuses on just 1 or 2 parameters when 
evaluating the test results. To maximize the diagnostic value of the test, all 
parameters might be brought together in multivariate models, one predicting the 
outcome of angiography and one predicting the response to treatment as primary 
outcome measures for the value of renography. These models may be used then 
to support decision-making by nuclear medicine physicians. 
The 3 evaluating physicians judged the presence of stenosis on a 5-point 
scale, which was collapsed into suspect or indeterminate versus not suspect to 
reflect which patients would normally be referred to further diagnostic workup. 
The interobserver agreement on the presence of stenosis was moderate. When 1 
physician judged stenosis to be absent, the probability that a second physician 
concluded the opposite was 30%. It would seem that the interobserver agreement 
found in this study represents the maximum achievable because the evaluating 
physicians in this study were well trained and experienced and had deliberated 
their way of scoring beforehand. On .the other hand, the renograms were not 
always obtained according to the protocol (1-minute images were not always 
acquired) and were not self-managed by the evaluating physicians. Also, to reflect 
the common clinical practice, di~onostic criteria for identifying stenosis were not 
specified before evaluation. Thus, the interobserver agreement found in this study 
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could possibly be improved by performing the procedure and evaluation in a 
uniform manner. 
Conclusion 
The interobserver agreement on most renographic parameters was satisfactory. 
Important parameters for establishing the diagnosis of stenosis with high 
interobserver agreement were the relative (individual kidney) uptake, the pattern 
of the rime-activity curves, and the time to excretion. The assessment of cortical 
retention by visual inspection of the images was more difficult - in particular, in 
the presence of pelvic retention - and should be given less weight in the 
evaluation. Captopril renography should be interpreted with caution if pelvic 
retention is present. Besides differences in patient selection, study design, and 
diagnostic criteria, interobserver variability offers an explanation for differences 
in diagnostic performance of captopril renography between studies. 
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Abstract 
Background: Renal artery stenosis is a rare cause of hypertension. The gold 
standard for diagnosing renal artery stenosis, renal angiography, is invasive and 
costly. 
Of?Jective: To develop a prediction rule for renal artery stenosis from clinical 
characteristics that can be used to select patients for renal angiography. 
Design: Logistic regression analysis of data from a prospective cohort of patients 
suspected of having renal artery stenosis. A prediction rule was derived from the 
regression model for use in clinical practice. 
Setting: 26 hypertension clinics in the Netherlands. 
Patients: 477 hypertensive patients who underwent renal angiography because they 
had drug-resistant hypertension or an increase in serum creatinine concentration 
during therapy with angiotensin-converting enzyme inhibitors. 
Results: Age, sex, atherosclerotic vascular disease, recent onset of hypertension, 
smoking history, body mass index, presence of an abdominal bruit, serum 
creatinine concentration, and serum cholesterol level were selected as predictors. 
The regression model was reliable (goodness-of-fit test, P=0.81) and 
discriminated well between patients with stenosis and those with essential 
hypertension (area under the receiver-operating characteristic curve, 0.84). The 
diagnostic accuracy of the regression model was similar to that of captopril 
renography, which had a sensitivity of 72% and a specificity of 90%. 
Conclusions: In the diagnostic workup of patients suspected of having renal artery 
stenosis, the clinical prediction rule can be considered as an alternative to 
renography. It can help to select patients for renal angiography in an efficient 
manner by reducing the number of angiographic procedures without the risk for 
missing many renal artery stenoses. 
38 
Prediction rule for renal artery stenosis 
Introduction 
Renal artery stenosis impairs blood flow to the kidney and can consequently 
cause renovascular hypertension and renal failure. 1•2 Although the prevalence of 
this condition among patients with hypertension is low, therapeutic options for 
relieving renal artery stenosis, such as renal angioplasty and stenting, make the 
search for renal artery stenosis worthwhile.Z-4 Renal angiography is the gold 
standard for diagnosing renal artery stenosis, but it is a costly and mvaslVe 
procedure that can involve serious complications.s,6 
To diagnose renal artery stenosis efficiently, angiography should be used 
selectively. Most physicians rely on captopril renography as a selection criterion, 
but the diagnostic accuracy of this test is low (sensitivity, 65% to 77%; specificity, 
90%).7·8 As an alternative, clinical characteristics can be used to select 
hypertensive patients for angiography.9 Patients with normal renal function 
whose blood pressure can be controlled with one or two drugs can be excluded 
from angiography.9,lO In the remaining patients (those with drug-resistant 
hypertension), such clinical characteristics as atherosclerotic vascular disease, 
smoking history, and presence of an abdominal bruit can be used to estimate a 
patient's probability of renal artery stenosis.11-14 This estimate can then be used in 
selection for angiography. 
We analyzed the clinical characteristics of 477 patients with drug-resistant 
hypertension or an increase in serum creatinine concentration during therapy with 
angiotensin-converting enzyme (ACE) inhibitors who participated in the Dutch 
Renal Artery Stenosis Intervention Cooperative (DRASTIC) study.9 We 
developed a clinical prediction rule for quantifying the probability of renal artery 
stenosis15 and demonstrated the potential consequences of this rule for clinical 
practice by applying it to our patients. 
Patients and methods 
Patients 
The DRASTIC study is a prospective cohort study conducted at 26 departments 
of internal medicine with an interest in hypertension throughout the 
Netherlands.9 The diagnostic phase of the study was designed to find an optimal 
strategy for diagnosing renal artery stenosis. In the DRASTIC study, 1133 
hypertensive patients 18 to 75 years of age with preserved renal function (serum 
creatinine concentration :;:;200 ).lmol/L [2.26 mg/ dL]) were enrolled. These 
patients were referred for analysis of hypertension by general practitioners (55%) 
or hospital specialists (45%), in most cases because their hypertension was 
difficult to treat with antihypertensive drugs. Sixty percent of patients were from 
four hospitals. After giving written informed consent, patients were randomly 
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assigned to one of two standard protocols with antihypertensive drugs: 
amlodipine, 10 mg, plus atenolol, 50 mg, in patients older than 40 years of age or 
enalapril, 20 mg, plus hydrochlorothiazide, 25 mg, in patients older than 40 years 
of age. Blood pressure was measured with a standard sphygmomanometer at 
three consecutive visits at least 1 week apart. Measurements were taken three 
times per visit after a 5-minute rest with the patient in the sitting position. 
Patients were selected for diagnostic workup if they had drug-resistant 
hypertension, defined as a mean diastolic blood pressure per visit of 9 5 mm Hg 
or more while receiving the standard drug regimen during all three visits or 
prescription of an additional drug regardless of blood pressure response. Patients 
were also selected if the serum creatinine concentration increased 20 1-1mol/L 
(0.23 mg/ dL) or more during therapy with ACE inhibitors. In these patients, 
intra-arterial digital subtraction angiography and other, non-invasive tests were 
performed. In accordance with the study protocol, patients who responded well 
to standard treatment were not evaluated further. The diagnostic phase of the 
study was followed by a therapeutic phase in which patients with atherosclerotic 
stenosis were randomly assigned to receive medication or renal angioplasty. 
Defmitions 
After performing a literature study, we selected 12 clinical characteristics 
indicative of renovascular disease (predictors)1°-11-16·26: age, sex, ethnicity (black or 
other), signs and symptoms of atherosclerotic vascular disease (femoral or carotid 
bruit, angina pectoris, claudication, myocardial infarction, cerebrovascular 
accident, or vascular surgery), recent onset of hypertension (within the past 2 
years), family history of hypertension (parents, siblings, or children with 
hypertension), smoking history (ever or never), obesity (body mass index ;:::25 
kg/ m2), abdominal bruit, advanced hypertensive retinopathy (fundus grade III or 
IV), serum creatinine concentration, and hypercholesterolemia (serum cholesterol 
level >6.5 mmol/L [251.35 mg/ dL]) or use of cholesterol-lowering agents). 
These characteristics were used to predict the presence of renal artery stenosis. A 
patient was considered to have renal artery stenosis when the angiogram showed 
at least one stenosis of 50% or more in a renal artery according to the local 
radiologist. 
Model development 
Data are presented as a proportion or as the mean ± SD. The univariable 
association between clinical characteristics and presence of renal artery stenosis 
was studied by computing the value and 95% confidence interval (CI) of the odds 
ratio. In a multivariable analysis, clinical characteristics were combined as 
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predictor variables in a logistic regression model predicting the presence of renal 
artery stenosis (outcome)_27 For each patient in the multivariable analysis, the 
probability of renal artery stenosis was calculated from the regression model 
(predicted probability). The reliability, discriminative ability, and validity of the 
model were assessed. The technical appendix gives details on model development 
and evaluation. 
To enable the use of the regression model in clinical practice, a prediction 
rule was constructed for predicting renal artery stenosis in future patients with 
drug-resistant hypertension or an increase in serum creatinine concentration 
during therapy with ACE inhibitors. For the presence or level of each clinical 
characteristic in the regression model, a score was calculated on the basis of the 
regression coefficients (see technical appenc:li'C). These scores were added into a 
sum score. All possible sum scores and their corresponding predicted 
probabilities of renal artery stenosis were combined in a graph with 95% Cis of 
the predicted probabilities. 
Results 
Statistical analyses 
Angiography was performed in 439 patients with drug-resistant hypertension and 
39 patients with an increase in serum creatinine concentration during therapy 
with ACE inhibitors. The procedure failed in 1 patient. For the remaining 477 
patients, angiography showed renal artery stenosis in 107 patients (22%), of 
whom 90 (84%) had atherosclerotic stenosis and 17 (16%) had fibromuscular 
dysplasia. Bilateral stenoses were found in 27 of 107 affected patients (25%). 
Captopril renography was performed in 458 patients; it had a sensitivity of 72% 
and a specificity of 90% for the diagnosis of renal artery stenosis. 
Table 3.1 shows the univariable distribution of the clinical characteristics for 
patients with renal artery stenosis and those with essential hypertension. Most 
clinical characteristics were indicative of renal artery stenosis (P<0.05 or 
borderline significant) except sex, recent onset of hypertension, and presence of 
advanced hypertensive retinopathy. More young women without signs of 
atherosclerotic disease were found among patients with fibromuscular dysplasia 
than among those with atherosclerotic stenosis, but abdominal bruits occurred 
with the same frequency in both groups (29% and 27%, respectively). 
The results of multivariable analysis are also shown in Table 3.1. Advanced 
hypertensive retinopathy was not studied any further because this clinical 
characteristic was missing for 43% of the patients. Data on 11 clinical 
characteristics of 460 patients were considered predictive of renal artery stenosis. 
Ethnicity and family history of hypertension were removed from the regression 
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Table 3.1. Associations of clinical characteristics with renal artery stenosis. 
Clinical characteristic Patients with Patients with Univariable Multivariable 
renal artery essential odds ratio odds ratio 
stenosis hypertension (95% CI) * (95% CI) t 
(N=107) (N=370) 
Proportion or mean ± SD 
Age, years 57± 12 50± 12 1.6t 1.8 t§ 
(1.3- 2.0) (1.3- 2.6) 
Men 51 58 0.8 0.4 
(0.5 -1.2) (0.2- 0.7) 
Black ethnicity 1 7 0.1 -II 
(0.0- 0.9) 
Atherosclerotic 63 28 4.5 1.8 
vascular disease (2.9- 7.2) (1.0- 3.3) 
Recent onset of 39 34 1.2 1.9 
hypertension (0.8- 1.9) (1.1 - 3.4) 
Family history of 57 67 0.7 -II 
hypertension (0.4- 1.0) 
Ever smoked 79 65 2.1 1.6'1! 
(1.2- 3.4) (1.1- 2.6) 
Obesity 40 70 0.3 0.4 
(0.2- 0.4) (0.2- 0.6) 
Abdominal bruit 27 4 9.2 5.4 
(4.6 -18.3) (2.4 -12.2) 
Hypertensive 22 21 1.1 -II 
retinopathy (0.6- 2.1) 
Serum creatinine, 112 ± 35 89 ±22 1.4 ** 1.4 ** 
J.lmol/L (1.2 -1.5) (1.2 -1.6) 
Hypercholesterolemia 40 30 1.6 1.7 
(1.0- 2.5) (0.9- 3.0) 
Performed in 477 patients. 
t Performed in 460 patients. 
t Per 10-year increase. 
§ Value for a patient who never smoked (value depends on smoking history). 
II Not in the multivariable model. 
'\! Value for a 60-year-old patient (value depends on age). 
** Per 10 J.lmol/L increase. 
model because their contribution to predicting renal artery stenosis was small. 
Because renal artery stenosis is believed to be more prevalent in young women 
and old men, interaction between age and sex was tested; this interaction was not 
statistically significant (P=0.09). We included an interaction term between age and 
smoking because this was the only biologically plausible interaction term that was 
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statistically significant (P=0.01). This interaction term accounts for the fact that 
the predictive value of increasing age was stronger for patients who never 
smoked than for current and former smokers. Finally, the type of standard 
treatment did not provide additional diagnostic information when it was included 
in the regression model (P=0.60). The multivariable odds ratios in Table 3.1 
reflect the predictive effect of the individual clinical characteristics while 
correcting for the other predictors in the multivariable model. For example, the 
multivariable odds ratio for atherosclerotic vascular disease was lower than the 
univariable odds ratio because the model also accounted for the effects of age 
and smoking history. 
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Figure 3.1. Agreement between the observed probability of stenosis and the 
probability of stenosis as predicted by the regression model in 460 patients with 
drug-resistant hypertension or an increase in serum creatinine concentration 
during therapy with angiotensin-converting enzyme inhibitors. 
43 
Chapter 3 
Table 3.2. Prediction rule for quantifying the probability of renal artery stenosis. 
Predictor Score* 
Persons who Former or current 
never smoked smoker 
Aget 
20 years 0 3 
30 years 1 4 
40 years 2 4 
50 years 3 5 
60 years 4 5 
70 years 5 6 
Female sex 2 2 
Signs and symptoms of 
atherosclerotic vascular disease :J: 1 1 
Onset of hypertension within 2 years 1 1 
Body mass index <25 kg/ m2 2 2 
Presence of abdominal bruit 3 3 
Serum creatinine concentration t 
40 flmol/L 0 0 
60 flmol/L 1 1 
SO f..Lmol/L 2 2 
100 flmol/L 3 3 
150 f..Lmol/L 6 6 
200 flmol/L 9 9 
Serum cholesterol level >6.5 mmol/L 
or cholesterol-lowering therapy 1 1 
The sum score is obtained by adding all relevant scores. The sum score can be used to 
obtain the predicted probability of renal artery stenosis from Figure 3.2. 
t For intermediate values, the score can be linearly interpolated. 
:J: Femoral or carotid bruit, a%o1na pectoris, claudication, myocardial infarction, 
cerebrovascular accident, or vascular surgery. 
Model performance 
Figure 3.1 shows the agreement between the predicted and the observed 
probabilities. For 204 patients (44%), the predicted probability of stenosis was 
0% to 10%. The predicted probilities of stenosis obtained from the model agreed 
well with the observed frequency of stenosis (goodness-of-fit test, P=0.81). The 
model discriminated well between patients with renal artery stenosis (predicted 
probability, 49% ± 29%) and patients with essential hypertension (predicted 
probability, 15% ± 16%); the area under the receiver-operating characteristic 
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(ROC) curve was 0.84 (95% CI, 0.79 to 0.89). Among patients with stenosis, the 
discriminative ability of the regression model was better for those with 
atherosclerotic stenosis (predicted probability, 52% ± 29%) than for those with 
fibromuscular dysplasia (predicted probability, 34% ± 26%). 
The discriminative ability of the prediction rule differed among the four 
hospitals that included most of the patients. For these hospitals, the area under 
the ROC curve varied from 0.68 to 0.92. This corresponds with the finding that 
the associations between stenosis and clinical characteristics of patients from 
these hospitals were not equally strong or were contradictory. For example, 
atherosclerotic vascular disease was not predictive of stenosis in one hospital and 
was even more prevalent in patients with essential hypertension in another 
hospital. This inconsistency may be explained in part by small sample sizes: The 
numbers of patients included by these four hospitals were 44, 56, 77 and 151. 
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Figure 3.2. Predicted probability of renal artery stenosis in patients with drug-
resistant hypertension as a function of the sum score. The sum score was derived 
from the prediction rule (Table 3.2). Thin lines represent 95% Cis. 
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Table 3.3. Implications of using the prediction rule in clinical practice. 
Predicted probability at Sensitivity* Specificity t Patients 
which angiography is undergoing 
performed angiography 
% 
;:::o 100 0 100 
;:::10 90 47 61 
;::: 20 81 73 40 
;::: 30 68 87 25 
;:::40 59 92 20 
;::: 50 44 96 14 
;::: 60 33 98 9 
;::: 70 24 99 6 
;::: so 17 99 4 
;::: 90 7 100 2 
Patients with stenosis identified by angiography. 
t Patients with essential hypertension who did not undergo angiography. 
Using the model in clinical practice 
In the prediction rule for renal artery stenosis, a score was assigned to the level or 
presence of each clinical characteristic in the regression model (Table 3.2). The 
scores were added into a sum score that, through the logistic formula, 
corresponded with a predicted probability of renal artery stenosis. In Figure 3.2, 
the predicted probabilities and their 95% Cis can be derived from the sum scores 
in a graphical manner. For instance, the sum score for a 46-year-old male patient 
who smoked in the past; has no signs or symptoms of atherosclerotic vascular 
disease; received a diagnosis of hypertension 1 year ago; has a body mass index of 
23 kg/m2, no abdominal bruit, a serum creatinine concentration of 112 !lmol/L 
(91.27 mg/ dL), and a serum cholesterol level of 5.4 mmol/L (208.82 mg/ dL); 
and does not take cholesterol lowering drugs is 11 (4.5 + 0 + 0 + 1 + 2 + 0 + 3.5 
+ 0). The scores for age and creatinine concentration were obtained by linear 
interpolation. Figure 3.2 shows that the predicted probability of renal artery 
stenosis for this patient is 25% (CI, 13% to 43%). The probability can also be 
calculated by using the formula given in the technical appendix. 
The probability of stenosis according to the prediction rule can be used to 
select patients for renal angiography. If angiography is performed only in patients 
with a probability of stenosis above a certain cut-off level, the number of 
angiograms performed in the total group of patients will be reduced. Table 3.3 
shows the results of using different cut-off levels for the predicted probability of 
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stenosis. The first row in Table 3.3 gives the scenario of performing angiography 
in every patient and therefore identifying all patients with stenosis (sensitivity, 
100%). If angiography is performed only in patients whose predicted probability 
of stenosis is, for example, 10% or more, the number of patients undergoing 
angiography will be reduced to 61%. However, 1 of every 10 stenoses will be 
missed (sensitivity, 90%). With increasing cut-off levels, the number of patients 
undergoing angiography is reduced more and more; as a consequence, however, 
the number of missed stenoses increases. When a probability of 30% was chosen 
as the cut-off level, the diagnostic accuracy of the prediction rule (sensitivity, 
68%; specificity, 87%) approximated that of captopril renography (sensitivity, 
72%; specificity, 90%) in our patient population. 
Discussion 
We developed a clinical prediction rule to predict the presence of renal artery 
stenosis from the clinical characteristics of 477 patients with drug-resistant 
hypertension or an increase in serum creatinine concentration during therapy with 
ACE inhibitors who participated in a prospective study on diagnosis and 
treatment of renal artery stenosis (the DRASTIC study).9 By attributing a score to 
the presence or absence of nine clinical characteristics, a sum score was obtained 
that corresponded to a probability of renal artery stenosis. The prediction rule 
proved to be reliable and discriminated well between patients with renal artery 
stenosis and those with essential hypertension. By applying the prediction rule in 
clinical practice to select patients for renal angiography, the number of 
angiograms obtained may have been reduced considerably in a cost-effective 
manner. 
Clinical characteristics have been mentioned before as a means of identifying 
patients with renal artery stenosis.16,Z0-23 Several studies have described the relative 
frequency of characteristics in patients with renal artery stenosis and those with 
essential hypertension, such as age, duration of hypertension, atherosclerosis, 
cigarette smoking, and presence of an abdominal bruit. Some of these clinical 
characteristics are interrelated, such as those suggestive of atherosclerotic vascular 
disease. In our multivariable model, we assessed the independent associations 
between clinical characteristics and the presence of renal artery stenosis. 
Moreover, our simple prediction rule enables the clinician to quantify the 
probability of stenosis for any specific patient. Unlike other studies describing 
schemes for selecting patients suspected of having renal artery stenosis on the 
basis of their clinical characteristics, 10,11 our study provides quantitative insight 
into the potential consequences of applying our selection criteria. 
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The prediction rule predicts the presence of anatomic renal artery stenosis in 
patients with preserved renal function (serum creatinine concentration ::;;200 
~-tmol/L [2.26 mg/ dL]) who have drug-resistant hypertension or an increase in 
serum creatinine concentration during therapy with ACE inhibitors. The 
prediction rule should not be applied if other secondary causes of hypertension 
are not adequately ruled out (such as parenchymal renal disease) and should not 
be applied to patients with impaired renal function in general. Our study group 
included some patients who received more medication than the standarclized 
schemes allowed because their blood pressure was very high. Regardless of their 
blood pressure response to the additional drugs, these patients were considered 
to be resistant to the standarclized regimen and underwent angiography. The 
prediction rule can therefore be used for patients in whom blood pressure control 
was achieved with more than two drugs, provided that control could not be 
achieved on a two-drug regimen. Before introduction on a wide scale, the model 
must be tested further to establish whether its predictions are valid in other 
settings. 
Although the clinical characteristics of patients with atherosclerotic stenosis 
and those with fibromuscular dysplasia clearly differ somewhat, the prediction 
rule can be used to predict the presence of either type of renal artery stenosis. 
Some clinical characteristics (such as the presence of an abdominal bruit) were 
found to be relevant for both patients groups, but in other respects (such as signs 
of atherosclerotic vascular disease), patients with fibromuscular dysplasia 
resembled those with essential hypertension more closely than they resembled 
those with atherosclerotic stenosis. Thus, patients with fibromuscular dysplasia 
are not a distinct group of patients that can be excluded before the prediction rule 
is applied in clinical practice. For example, only 4 of the 17 patients with 
fibromuscular dysplasia in our study group were women younger than 40 years of 
age. We decided not to exclude patients with fibromuscular dysplasia from the 
analysis because the prediction rule should be applicable to all future patients who 
present themselves in our clinics. Although the prediction rule performed 
somewhat better for patients with atherosclerotic stenosis than for patients with 
fibromuscular dysplasia, the predicted probability in the latter group was 
significantly higher than that of patients with essential hypertension. Thus, the 
prediction rule distinguished well between both groups of patients with stenosis 
and patients with essential hypertension. 
In this analysis, anatomic renal artery stenosis was predicted from clinical 
characteristics. We acknowledge that prediction of functional stenosis (that is, 
renovascular hypertension) would have been preferable. Unfortunately, no good 
definition of renovascular hypertension exists. This condition is often defined as 
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being characterized not only by the presence of renal artery stenosis but also by 
the cure of the hypertension after repair of the stenosis. However, several factors 
may explain why relief of renal artery stenosis that has caused hypertension does 
not always result in cure of hypertension, such as advanced-stage hypertension 
(third phase of two-kidney, one-clip Goldblatt hypertension), technical failure of 
the intervention, or restenosis. The most important objection to the use of blood 
pressure response to intervention is that it is a diagnosis made a posteriori. 
Therefore, the most practical approach is to search for renal artery stenosis 
instead of renovascular hypertension. 
This prediction rule is a practical and simple tool for selecting patients with 
drug-resistant hypertension or an increase in serum creatinine concentration 
during therapy with ACE inhibitors. To obtain the probability of stenosis for a 
specific patient, information is needed on nine clinical characteristics; this 
information is generally readily available in clinical practice. After prespecified 
scores are added to form a sum score, the corresponding probability of stenosis 
can be read from a graph. The usefulness of the prediction rule was shown in our 
data set. The prediction rule was almost as accurate as captopril renography 
(sensitivity, 72%; specificity, 90%) in predicting renal artery stenosis if 
angiography was performed in patients for whom the rule predicted a probability 
of stenosis greater than 30%. In contrast to renography, however, the results of 
the prediction rule are immediately available and free. We therefore conclude that 
the prediction rule can be used as an alternative to renography in the selection of 
hypertensive patients for renal angiography, provided that the predictions prove 
to be valid in other settings. Embedded in the diagnostic workup of hypertensive 
patients who do not respond well to antihypertensive drugs, the prediction rule 
can help to reduce the number of negative angiograms without missing many 
patients with renal artery stenosis. 
Technical appendix 
Model development 
Deletion of cases with missing data may cause a bias and increases variance.28 For 
40 patients for whom one clinical characteristic was missing, the value was 
therefore predicted from the other clinical characteristics by multiple regression 
on values of the other predictors and was subsequently imputed.28,29 Values for 
17 patients for whom more than one value was missing were not imputed 
because the predicted values for these predictors would have been less reliable. 
These 17 patients were excluded from the multivariable analysis. 
Age and serum creatinine concentration were entered into the logistic 
regression model as continuous variables. We studied whether transformations of 
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these variables offered a better fit. Smoking was dichotomized as ever or never 
smoked; the fit of more complex classifications, such as never, past or present 
smoker or number of pack-years was also studied. Advanced hypertensive 
retinopathy was not included in the multivariable analysis because this 
characteristic was missing in a substantial number of the patients (43%). Nine 
clinical characteristics were selected for the regression model by backward 
deletion of the least significant characteristics, done by using the Akaike 
Information Criterion.3° As a result, ethnicity and family history of hypertension 
were dropped from the model (P>0.20). Interaction between clinical 
characteristics in predicting renal artery stenosis was studied in two ways to 
control for deviation from the additivity assumption.28 First, a likelihood ratio test 
on all first-order interaction terms was performed (P=0.63). Second, biologically 
plausible interaction terms were tested, which led to the inclusion of age x 
smoking in the model (P=0.01). 
Model evaluation 
The reliability of the regression model was evaluated by using the Hosmer-
Lemeshow goodness-of-fit test.27 The discriminative ability of the regression 
model was evaluated by the area under the ROC curve and its 95% CP1•32 The 
ROC curve is a plot of the false-positive rate (1 minus the specificity) against the 
true-positive rate (sensitivity), evaluated for consecutive cut-off points of the 
predicted probability. The area under the ROC curve can be interpreted as the 
probability that the regression model will assign a higher probability of stenosis to 
a randomly chosen patient with renal artery stenosis than to a randomly chosen 
patient with essential hypertension. The area can range from 0.5 to 1 (no to 
optimal discriminative ability) for sensible models. 
The internal validity of the regression model28·33 was assessed by using 
bootstrapping techniques, including variable selection.34 Random bootstrap 
samples were drawn with replacement from the full sample (200 replications). 
The discriminative ability of the regression models was determined on the 
bootstrap samples and on the full sample, in which predictions were based on the 
regression models fitted on the bootstrap samples. This validation replicates the 
situation in which the prediction model based on our patients is applied to a 
group of similar patients. The area under the ROC curve was 0.84 on the full data 
set and 0.82 after this procedure. Next, four hospitals that included most of the 
patients were left out of the sample one by one, and regression models were fitted 
on the remaining data. The discriminative ability of these models was externally 
assessed on the hospital not included in the fitting procedure. This procedure 
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replicates the situation in which the prediction model is applied in another 
hospital with a patient population that may be somewhat different. 
Derivation of scores in the prediction rule 
The multivariable logistic regression model can be written as: 
predicted probability of stenosis = 1 I 1 + e- CLPJ , 
where linear predictor LP = -7.859 + 0.059 x age+ 0.033 x (75- age) x ever 
smoked- 0.996 x sex + 0.585 x atherosclerotic vascular disease + 0.642 x 
recent onset- 1.027 x obesity + 1.693 x abdominal bruit + 0.502 x 
hypercholesterolemia + 0.032 x serum creatinine concentration. 
(In this formula, sex is coded as 1 for male, and as 0 for female; all other 
dichotomous predictors are coded as 1 when present, and as 0 when absent). 
The regression coefficients were multiplied by a shrinkage factor of 0.88, which 
was derived from bootstrapping procedures. Shrinkage of the regression 
coefficients aims to improve calibration of predictions in future patients: that is, 
to prevent low predictions that are too low and high predictions that are too 
high.2S,35 The intercept was adjusted so that the sum of predicted probabilities 
equalled the number of events (1 06 patients with stenosis in a total of 460 
patients). The shrunk formula was: 
P(stenosis) = 111 + e-CLPs), 
where LPs = -7.033 + 0.052 x age+ 0.029 x (75- age) x ever smoked 
- 0.877 x sex+ 0.515 x atherosclerotic vascular disease+ 0.565 x recent 
onset- 0.904 x obesity+ 1.490 x abdominal bruit+ 0.441 x 
hypercholesterolemia + 0.028 x serum creatinine concentration. 
This formula can be used to calculate the exact probability of stenosis. The 
average standard error (SE) of the rounded linear predictor values was used to 
calculate the 9 5% Cis of the predicted probabilities (1 I 1 + e -cus± 1.96 x SEJ). 
For presentation as a prediction rule, the rescaled regression coefficients were 
multiplied by 2 and were rounded to simplify the computation for clinical 
practice. 
Software 
Descriptive analyses were performed by SPSS statistical software (SPSS, Inc., 
Chicago, Illinois). Imputation of missing values, logistic regression, and validation 
were carried out in the Design Library for S-plus by using the transcan, impute, 
lrm, and validate functions_36 
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Abstract 
Background· We previously developed a prediction rule to estimate the probability 
of renal artery stenosis. This rule should be validated before it can be used reliably 
to select patients with hypertension for renal angiography. We determined the 
validity of the prediction rule in recently treated patients in other settings. 
Methods: We studied three aspects of validity (agreement between predicted and 
observed probability of stenosis, discriminative ability, and clinical usefulness) in 
180 consecutive patients with drug-resistant hypertension without severe renal 
failure, who visited 6 hypertension clinics in the Netherlands. Thirty-five patients 
(19%) had a stenosis of 50% or more on intra-arterial angiography. 
Results: The clinical characteristics in the rule (age, sex, vascular disease, recent 
onset of hypertension, smoking, body mass index, abdominal bruit, serum 
creatinine concentration, and hypercholesterolemia) had similar predictive value 
in the validation sample and development sample. The predicted probabilities of 
stenosis ~crreed well with the observed probabilities (Hosmer-Lemeshow 
goodness-of-fit test, P=0.87). The prediction rule discriminated reasonably 
between patients with and without stenosis in the validation sample with an area 
under the receiver operating characteristic curve of 0.71. If only patients with 
predicted probabilities of stenosis of 5% or higher were referred for renal 
angiography, the number of referrals was reduced by 20%, while 9% of patients 
with a stenosis were missed. 
Conclusions: The prediction rule was valid in more recently treated patients in other 
settings. If used conservatively, the rule can reliably exclude a small proportion of 
patients from angiography. 
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Introduction 
Renal artery stenosis may cause hypertension and renal failure. Many of the 
patients with renal artery stenosis who have hypertension or renal insufficiency 
can be treated successfully with balloon angioplasty, with or without stenting.l 
For this reason, the presence of renal artery stenosis should be evaluated in 
patients with renal failure and in patients whose hypertension cannot be 
controlled adequately by aggressive medical therapy. The reference test for 
fmding renal artery stenosis, intra-arterial subtraction angiography, is, however, an 
invasive and costly procedure. 
Clinical characteristics are useful to select patients with hypertension for 
renal angiography.2-4 We previously developed a clinical prediction rule to identify 
patients with a high risk of renal artery stenosis on the basis of their clinical 
characteristics (Chapter 3). The rule was developed in a sample of 460 patients 
with drug-resistant hypertension and normal or mildly impaired renal function. 
The predictions of the rule were internally validated for this patient group. The 
prediction rule seems to be accepted on a wide scale.S-16 
Before the rule can be applied reliably in clinical practice, the validity of its 
predictions should be tested in other groups of similar patients and in other 
settings.17,1S The purpose of this study was to determine the validity of the 
prediction rule in patients who were more recently treated in other hospitals than 
the patients in the development sample. 
Patients and methods 
Development of the prediction rule 
The prediction rule was developed in a sample of 460 patients (Chapter 3), who 
participated in a large multicenter study in the Netherlands designed to evaluate 
the diagnostic workup and treatment of patients suspected of having renal artery 
stenosis (the 'DRASTIC' study).19 Patients were included if they had persistent 
hypertension (defined as a diastolic blood pressure of 95 mm Hg or higher) 
despite a standardized two-drug regime and a normal or mildly impaired renal 
function (defmed as a serum creatinine concentration of 200 f.lmol/L or less). 
The rule predicted the presence of angiographically proven renal artery stenosis 
of at least 50% in lumen diameter (outcome) according to the local radiologist. It 
included the following risk factors for renal artery stenosis (predictors): age, sex, 
signs and symptoms of vascular disease, recent hypertension, smoking history, 
obesity, abdominal bruit, serum creatinine concentration and 
hypercholesterolemia. Logistic regression coefficients for the clinical predictors 
were estimated. To facilitate practical use, a simple score chart was constructed 
on the basis of the regression coefficients. The risk score for an individual patient 
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(see Table 3.2, Chapter 3) can be used to read the patient's probability of stenosis 
from a graph (see Figure 3.2, Chapter 3). 
Validation of the prediction ru1e 
The validation sample consisted of 180 patients who participated in a prospective 
multicenter cohort study in the Netherlands designed to compare the value of 
computed tomography angiography (CTA) and magnetic resonance angiography 
(MRA) to that of conventional intra-arterial subtraction angiography for the 
diagnosis of renal artery stenosis (the 'RADISH' study; paper submitted for 
publication). The study was approved by the Medical Ethics Committee at each 
of 6 participating centers. Written informed consent was obtained from all 
patients. In the study, 402 consecutive patients were referred for evaluation of 
hypertension between November 1998 and November 2001. These clinics had 
previously contributed 12% of the patients in the development sample. Of the 
402 patients, 213 met the inclusion criterion of drug-resistant hypertension 
(defined as a diastolic blood pressure of 95 mm Hg or higher, despite the use of 
two or more antihypertensive drugs) and a normal or mildly impaired renal 
function (defined as a serum creatinine concentration lower than 200 1-Lmol/L). 
Eleven patients were excluded from the validation sample because conventional 
angiography (the reference test) was not performed and 16 patients were 
excluded because of missing data on one or more of the clinical predictors. Six 
patients with an increase in the serum creatinine concentration after use of an 
angiotensin-converting-enzyme inhibitor were also excluded from the validation 
sample, because this is considered an indication for angiography given the high 
risk of renal artery stenosis.20 Of the remaining 180 patients, complete data on 
clinical predictors and renal artery stenosis (outcome) were available. The 
predictors were defined as in the development sample except for vascular disease 
and smoking history (see Table 4.1 for details). Renal artery stenosis was defined 
as stenosis of at least 50% in lumen diameter proven by conventional intra-
arterial subtraction angiography according to a panel of three radiologists. The 
treating physician prospectively collected data on predictors and outcome on 
standardized case record forms. 
Data analysis 
We refitted the logistic regression model in the validation sample to compare the 
value of the predictors for renal artery stenosis in the validation sample to that of 
these predictors in the development sample. To assess the validity of the 
published prediction rule (i.e., without refitting the regression model) in the 
validation sample, we studied the agreement between the predicted and observed 
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probabilities of stenosis ('reliability' or 'calibration'), and the ability of the model 
to distinguish between patients with stenosis and those without stenosis 
('discrimination').18·21 The agreement between predicted and observed 
probabilities was evaluated visually in a calibration plot. The U-statistic was used 
to test whether the agreement between predicted and observed probabilities was 
different from perfect agreement, i.e. a line with intercept equal to 0 and 
calibration slope equal to 1.22 The agreement was also evaluated with the 
Hosmer-Lemeshow goodness-of-fit test.23 The discriminative ability of the 
prediction rule was inspected visually by plotting the distribution of patients with 
stenosis and of patients without stenosis in the calibration plot. Further, we 
compared the predicted probabilities for the patients with and those without 
stenosis, and the predictions for patients with atherosclerotic stenosis and those 
with fibromuscular dysplasia by Student's T-test. The discriminative ability was 
quantified with the area under the receiver operating characteristic (ROC) curve.24 
Finally, we assessed the potential impact of the prediction rule on the decision-
making process ('clinical usefulness').21 Clinical usefulness was evaluated by 
calculating the sensitivity and specificity in relation to the reference test 
(conventional angiography) for several cut-off points of the probability of 
stenosis according to the prediction rule. For each cut-off point, we calculated the 
likelihood ratio for a positive and a negative test result, and the proportion of 
patients that would undergo angiography. 
Results 
Validation sample 
The prevalence of renal artery stenosis in the development sample was similar to 
that in the validation sample, but the proportion of patients with stenosis caused 
by fibromuscular dysplasia rather than atherosclerosis was higher in the validation 
sample (Table 4.1). The patients in the validation sample had a higher systolic and 
diastolic blood pressure despite a higher amount of antihypertensive medication. 
Most predictors were equally prevalent in the samples, except a history of 
smoking, presence of vascular disease, and presence of an abdominal bruit, which 
were less prevalent in the validation sample. 
Predictors of stenosis 
The predictive value of most predictors of renal artery stenosis in the validation 
sample was similar to that in the development sample (fable 4.2). Presence of an 
abdominal bruit and presence of hypercholesterolemia, however, seemed 
negatively associated with stenosis in the validation sample. The odds ratios for 
these predictors were far from statistically significant. 
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Table 4.1. Clinical characteristics ill the development sample and ill the 
validation sample. 
Clinical characteristic 
Renal artery stenosis* 
Fibromuscular dysplasia 
Academic hospital 
Systolic blood pressure, mm Hg 
Diastolic blood pressure, mm Hg 
Antihypertensive drugs, number 
Age, years 
Male sex 
Signs/ symptoms of vascular disease 
Recent onset of hypertension § 
History of smoking 
Obesity *• 
Abdominal bruit 
Serum creatinine, flmol/L 
Hypercholesterolemia 
Development sample 
(N=460) 
Validation sample 
(N=180) 
Number (%) or mean ± SD 
106 (23) 
17/106 (16) 
221 (48) 
169 ± 25 
105 ± 11 
2±1 
51± 12 
253 (55) 
165 (36) t 
162 (35) 
316 (69) II 
288 (63) 
42 (9) 
94± 27 
142 (31) :j::j: 
35 (19) 
13/35 (37) 
161 (89) 
183 ± 24 
110±13 
3±1 
52± 11 
96 (53) 
38 (21) t 
68 (38) 
50 (28) 11 
134 (74) 
5 (3) tt 
97 ± 24 
50 (28) §§ 
stenosis of 50% or more on angiography. 
t presence of one or more of the following: femoral or carotic bruit, angina pectoris, 
claudication, myocardial infarction, stroke, vascular surgery. 
t presence of one or more of the following: atherosclerosis, vascular disease, 
an.:,oina pectoris, myocardial infarction, coronary heart disease, stroke, cerebral 
infarction, peripheral vascular disease, iliac stenosis, coronary artery bypass grafting. 
§ onset within the last 2 years. 
II current or former smoker. 
11 current smoker or patient who quitted smoking within the past 6 months. 
*' body mass index >25 kg/m2 
tt this proportion is an underestimation because presence of an abdominal bruit was not 
registered systematically. 
:J:l: serum cholesterol >6.5 mmol/L and/ or use of cholesterol-lowering drugs. 
§§ serum cholesterol >6.5 mmol/L and/ or use of cholesterol-lowering drugs, or 
described as hypercholesterolemic or hyperlipidemic. 
Reliability 
The agreement between the predicted probabilities and the observed frequency of 
stenosis is shown in Figure 4.1. The deviations from the ideal line were 
statistically non-significant (U -statistic, P=0.06; Hosmer-Lemeshow goodness-of-
fit test, P=0.87). It appeared that the predicted probabilities of stenosis in the 
lower range were somewhat too low. 
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Table 4.2. Associations between clinical characteristics and presence of renal artery 
stenosis, expressed as multivariable odds ratio (95% confidence interval) in the 
development sample and the validation sample. 
Clinical characteristic Development sample 
(N=460) 
Age, per 10-year increase* 1.8 (1.3-2.6) 
Male 0.4 (0.2-0. 7) 
Signs/ symptoms of vascular disease 1.8 (1.0-3.3) 
Recent onset of hypertension 1.9 (1.1-3.4) 
Smoking t 1.6 (1.1-2.6) 
Obesity 0.4 (0.2-0.6) 
Abdominal bruit 5.4 (2.4-12.2) 
Serum creatinine, per 10 fLmol/L increase 1.4 (1.2-1.5) 
Hypercholesterolemia 1.6 (1.0-2.5) 
Value for a non-smoking patient (value depends on smoking). 
t Value for a 60-year-old patient (value depends on age). 
Discriminative ability 
Validation sample 
(N=180) 
1.5 (1.0-2.5) 
0.5 (0 .2-1.2) 
1.9 (0.7-5.2) 
2.1 (0.9-5.2) 
2.1 (1.2-2.8) 
0.2 (0.1-0.6) 
0.7 (0.1-7.3) 
1.2 (1.0-1.4) 
0.8 (0.3-2.2) 
The predicted probabilities for the patients with stenosis in the validation sample 
were higher (mean ± SD, 26% ± 20%) than for the patients without stenosis 
(13% ± 13%, P=0.001). The distributions of the predicted probabilities for the 
patients with and without stenosis overlapped considerably, however, as shown in 
the calibration plot (Figure 4.1). The predicted probabilities were 14% ± 10% for 
patients with fibromuscular dysplasia and 32% ± 22% for those with 
atherosclerotic stenosis (P=0.003). The area under the ROC curve was 0.71 (95% 
confidence interval, 0.61 to 0.81). 
Clinical usefulness 
When we intend to use the prediction rule to select patients for angiography, we 
need to choose a cut-off level for the predicted probability of stenosis above 
which angiography is performed. When angiography was performed only in 
patients with a probability of stenosis of 5% or higher (score >7, see Figure 3.2, 
Chapter 3), 144 of the 180 patients (80%) would undergo angiography while 3 of 
the 35 patients with a stenosis would be missed (sensitivity, 91 %). The likelihood 
ratio for a positive test result (i.e., a predicted probability of 5% or higher) was 
1.18, and for a negative test result 0.38. For the 26 patients with a stenosis who 
received an intervention, the sensitivity of the prediction rule was 100%. When 
the cut-off level was increased to 10% (score >9, see Figure 3.2, Chapter 3), the 
number of patients undergoing angiography would be reduced to 88 of the 180 
patients (49%), but at the expense of an increased number of patients in whom 
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stenosis would be missed to 10 out of 35 (sensitivity, 71 %). Then, the likelihood 
ratio for a positive test result was 1.65, and for a negative test result 0.51. 
Discussion 
The predicted probabilities of renal artery stenosis provided by the prediction rule 
were reasonably valid. The results agree with a previously published, smaller study 
on the validity of the rule in patients with hypertension refractory to at least two 
antihypertensive drugs.2s Our study, however, gives further insight into the use of 
the prediction rule in daily clinical practice because the earlier study involved 
mainly patients at high risk of renal artery stenosis.25 In our validation sample, the 
prediction rule reliably predicted the presence of stenosis, especially for patients 
with higher risks. The ability of the prediction rule to discriminate between 
patients with stenosis and those without stenosis, however, was considerably 
lower in the validation sample than in the development sample. The area under 
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Figure 4.1. Calibration plot for 180 patients in the validation sample. Each 
square represents 20% of patients with similar predicted probabilities. Vertical 
lines represent 95% confidence intervals. At the bottom, the distribution of the 
predicted probabilities of renal artery stenosis is given for patients with stenosis 
and for those without stenosis. 
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the ROC curve was 0.71 in the validation sample and 0.84 in the development 
sample. 
The patients in the validation sample had a higher blood pressure than the 
patients in the development sample, while more antihypertensive drugs were 
prescribed. This flnding can be explained by the fact that the patients in the 
development sample were assigned to standardized and effective drug regimens, 
and probably complied more to the prescribed medications because they visited 
the hypertension clinic every two weeks to optimize the blood pressure control.2° 
The patients in the validation sample reflected usual clinical practice with regard 
to blood pressure control and medication use. The validation sample was, 
therefore, more representative of the patients for whom the prediction rule was 
developed. 
A limitation of our study was that the validation sample was not optimal for 
validating the prediction rule. Two predictors, smoking and vascular disease, were 
defined differently than in the development sample. This may have influenced 
their predictive value in the validation sample, although this was not apparent 
from the odds ratios. Another limitation of our study was the rather small sample 
size, which caused uncertainty in the evaluation of the rule.26 A possible 
consequence of this limitation was that the odds ratios for the presence of 
abdominal bruit and hypercholesterolemia seemed opposite of what was 
expected, but with wide confidence intervals. 
The proportion of patients with fibromuscular dysplasia among patients 
with stenosis in the validation sample (13/35 or 37%) was over twice as high as in 
the development sample (17 /106 or 16%) and in other patient series (around 
10%).1 The high prevalence of fibromuscular dysplasia seems to be the main 
cause of the disappointing discriminative ability of the prediction rule in the 
validation sample. As in the development sample, the prediction rule 
discriminated less between these patients and patients without stenosis than it did 
between patients with atherosclerotic renal artery stenosis and patients without 
stenosis. This discrepancy is caused by the fact that some of the clinical 
characteristics in the rule are predictive of atherosclerosis rather than of 
fibromuscular dysplasia.2,27 The proportions of missed diagnoses among patients 
with fibromuscular dysplasia (1/13, or 8%, if patients with a predicted probability 
of 5% or higher were referred to angiography) and among patients with 
atherosclerotic renal artery stenosis (2/22, or 9%), however, were similar. This is 
an important finding because intervention in patients with fibromuscular 
dysplasia is generally successful.s,zs If the patients with fibromuscular dysplasia 
were left out of the validation sample, the discriminative ability of the prediction 
rule improved considerably, which was reflected in the increase in the area under 
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the ROC curve from 0.71 to 0.77. In the development sample, the area under the 
ROC curve also increased if patients with fibromuscular dysplasia were excluded, 
but only from 0.84 to 0.86. We therefore may expect that the discriminative 
ability of the prediction rule in most clinical settings is better than in this 
validation study, because the proportion of patients with fibromuscular dysplasia 
is generally lower. 
Before applying the prediction rule, the individual physician should judge if 
his or her patient population is comparable to the patient sample on which the 
prediction rule was based. Also, the definition of the clinical predictors and 
stenosis should be the same. If these conditions are met, the rule will probably 
provide valid predictions for the probability of renal artery stenosis. In clinical 
practice, a conservative cut-off level for the predicted probability might be 
chosen above which patients are referred to angiography. In that case, the 
proportion of missed stenoses is acceptable. When a cut-off level of 5% was 
applied to our validation sample, less than 10% of the patients with stenosis were 
missed while the number of angiographic procedures was reduced by 20%. In the 
development sample, this ratio was twice as favourable. Nevertheless, the 
reduction of the number of angiographic procedures as found in the validation 
sample is worthwhile and seems about what one may expect of a prediction rule 
when dealing with a clinical decision problem that requires a high sensitivity.29,30 
Presently, both computed tomography angiography (CTA) and m~onetic 
resonance angiography (MRA) are used more and more for the diagnosis of renal 
artery stenosis instead of intra-arterial angiography. Advantages include that these 
im~oing tests are minimally invasive and seem to have a high diagnostic accuracy 
compared to intra-arterial angiography.31 .32 If replacement of intra-arterial 
angiography by one or both of these modalities proves to be justified in 
unselected patient series, selection of patients is still warranted because these 
procedures are expensive, require injection of intravenous contrast media, and 
their availability may be limited in some settings. Whether the prediction rule 
could be used validly to select patients for CTA and MRA requires further study. 
Our study suggests that the prediction rule is valid in patients who were more 
recently treated in other settings. The prediction rule can be used reliably to select 
patients with drug-resistant hypertension for angiography, provided that it is used 
conservatively in order not to miss too many patients with stenosis. In that case, the 
usefulness of the prediction rule in clinical practice is limited, however, because the 
rule indicates only a small proportion of the patients in whom angiography should not 
be performed. 
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Abstract 
Background: Patients with hypertension and renal artery stenosis are often treated 
with percutaneous transluminal renal angioplasty. However, the long-term effects 
of this procedure on blood pressure are not well understood. 
Methods: We randomly assigned 106 patients with hypertension who had 
atherosclerotic renal artery stenosis (defined as a decrease in luminal diameter of 
50% or more) and a serum creatinine concentration of 200 f-Lmol/L (2.3 mg/ dL) 
or less to undergo percutaneous transluminal renal angioplasty or to receive drug 
therapy. To be included, patients also had to have a diastolic blood pressure of 
95 mm Hg or higher despite treatment with two antihypertensive drugs or an 
increase of at least 20 f-Lmol/L (0.2 mg/ dL) in the serum creatinine concentration 
during treatment with an angiotensin-converting enzyme inhibitor. Blood 
pressure, doses of antihypertensive drugs, and renal function were assessed at 3 
and 12 months, and patency of the renal artery was assessed at 12 months. 
Results: At baseline, the mean (± SD) systolic and diastolic blood pressures were 
179 ± 25 and 104 ± 10 mm Hg, respectively, in the angioplasty group and 180 ± 
23 and 103 ± 8 mm Hg, respectively, in the drug-therapy group. At 3 months, the 
blood pressures were similar in the two groups (169 ± 28 and 99 ± 12 mm Hg, 
respectively, in the 56 patients in the angioplasty group and 176 ± 31 and 101 ± 
14 mm Hg, respectively, in the 50 patients in the drug-therapy group; P=0.25 for 
the comparison of systolic pressure and P=0.36 for the comparison of diastolic 
pressure between the two groups); at the time, patients in the angioplasty group 
were taking 2.1 ± 1.3 defined daily doses of medication and those in the drug-
therapy group were taking 3.2 ± 1.5 daily doses (P<0.001). In the drug-therapy 
group, 22 patients underwent balloon angioplasty after 3 months because of 
persistent hypertension despite treatment with 3 or more drugs or because of 
deterioration in renal function. According to intention-to-treat analysis, at 12 
months, there were no significant differences between the angioplasty and drug-
therapy groups in systolic and diastolic blood pressures, daily drug doses, or renal 
function. 
Conclusion: In the treatment of patients with hypertension and renal artery 
stenosis, angioplasty has little advantage over antihypertensive-drug therapy. 
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Introduction 
Experiments conducted by Goldblatt and colleagues1 on the effects of renal 
artery constriction in animals led to the recognition that renal artery stenosis may 
cause hypertension. Initially, surgical revascularization was the only treatment for 
renal artery stenosis,2,3 but percutaneous transluminal balloon angioplasty,4 with 
or without stent placement, later supplanted surgery as the preferred treatment.5 
In uncontrolled, retrospective studies of balloon angioplasty, 36% to 100% of 
patients with hypertension had some reduction in blood pressure, with the 
highest rates of response in patients with fibromuscular dysplasia,6 but in few 
patients, however, was blood pressure restored to normal levels. In two small, 
randomized studies, the benefit of balloon angioplasty was even smaller,7•8 
suggesting that the general enthusiasm for this procedure may not be justified. 
We report the results of a multicenter, randomized, controlled comparison of 
balloon angioplasty and antihypertensive-drug therapy for the treatment of 
atherosclerotic renal artery stenosis associated with hypertension and normal or mildly 
impaired renal function. 
Patients and methods 
This prospective, randomized study was conducted at 26 centers in the 
Netherlands between January 1993 and November 1998. The study was designed 
to identify patients with hypertension caused by renal artery stenosis and to 
evaluate their treatment. The current report focuses on the treatment phase of the 
study, in which 106 patients with atherosclerotic renal artery stenosis were 
randomly assigned to undergo balloon angioplasty of the renal artery (without 
stent placement) or to receive antihypertensive-drug therapy. The study was 
approved by the institutional review board at each participating center, and all 
patients provided written informed consent. 
The diagnostic phase of the study involved 1205 patients, 18 to75 years old, 
who had been referred to the participating centers because of difficult-to-treat 
hypertension associated with normal or mildly impaired renal function (defmed as 
a serum creatinine concentration of ~200 J...Lmol/L [2.3 mg/ dL]). The diagnostic 
workup included a medical history, a physical examination, and laboratory 
studies, renography after the administration of captopril and renal angiography.9 
Patients were excluded if they had cancer, hypertension caused by a condition 
other than renovascular disease (e.g. renal parenchymal disease, primary 
aldosteronism, or hypercortisolism) or unstable coronary artery disease or heart 
failure, or if they were pregnant. Renal angiography was performed in 543 
patients because their diastolic blood pressure, measured at three consecutive 
outpatient visits one to three weeks apart, was at least 9 5 mm Hg despite 
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treatment with a standardized regimen of two antihypertensive drugs or because 
their serum creatinine concentration on the second or third visit had risen by at 
least 20 J-Lmol/L (0.2 mg/ dL) during treatment with an angiotensin-converting 
enzyme inhibitor. Of these 543 patients, 169 were found to have ostial or 
nonostial renal artery stenosis (defined as a decrease in lumen diameter of ~50%) 
and thus were considered candidates for the treatment phase. 
Patients were excluded from the treatment phase of the study if they had any 
of the following: a single functioning kidney and a serum creatinine concentration 
greater than 150 J-Lmol/L (1.7 mg/ dL); an affected kidney that was less than 
8.0 em long, as determined by ultrasonography; total occlusion of the renal artery; 
an aortic aneurysm necessitating surgery; or renal artery stenosis due to 
fibromuscular dysplasia. For the treatment phase, 106 patients were eligible and 
were randomly assigned to undergo balloon angioplasty or to receive 
antihypertensive-drug therapy. Block randomization was used to ensure that the 
groups contained roughly equal numbers of patients, with stratification according 
to institution and several clinical variables.10 Stratification variables were the 
serum creatinine concentration (<120 J-Lmol/L [1.4 mg/dL] vs. ~120 to 200 
J-Lmol/L), the type of antihypertensive-drug therapy received during the diagnostic 
phase of the study (amlodipine and atenolol vs. enalapril and 
hydrochlorothiazide), and the extent of renal artery stenosis (unilateral vs. 
bilateral). Randomization was performed by computer at the coordinating center 
(Erasmus University Hospital, Rotterdam), without investigators' knowledge of 
patients' groups at the time of assignment. 
Treatment and follow-up 
Patients assigned to the drug-therapy group and, if necessary, those assigned to 
the angioplasty group, received antihypertensive-drug therapy according to a 
stepwise protocol, with a target diastolic blood pressure of less than 95 mm Hg. 
Drug therapy consisted of the two-drug regimen the patient had been receiving 
during the diagnostic phase of the study; if necessary, a dose could be increased 
or another drug added. 
Blood pressure was measured by standard sphygmomanometry every one to 
three months, and always at months 3 and 12, with the patient seated after a five-
minute rest; three measurements were made at least one minute apart, and the 
values were recorded to the nearest 2 mm Hg and then averaged.ll Three and 
12 months after randomization, blood pressure was also measured with an 
automatic device (Datascope, Montvale, N J .) at five-minute intervals for 60 
minutes. In addition, at 3 and 12 months, serum creatinine was measured and 
renography was performed after the administration of captopri1.12 In both the 
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angioplasty group and the drug-therapy group, renal angiography was repeated at 
12 months. 
Patients assigned to the angioplasty group were given 300 mg of aspirin 
daily, starting the day before angioplasty and continuing for six months. 
Antihypertensive-drug therapy was discontinued on the day of the procedure to 
prevent hypotension and was subsequently resumed if necessary. If, after three 
months, the patient's diastolic pressure was 95 mm Hg or higher or the serum 
creatinine concentration had risen by at least 20 f.Lmol/L, the treating physician 
decided whether to recommend a second balloon angioplasty, stent deployment, 
or bypass surgery. 
Patients assigned to the drug-therapy group underwent balloon angioplasty 
if, after three months, their diastolic pressure was 95 mm Hg or higher despite 
treatment with three or more drugs or if there was evidence of progressive 
renovascular occlusive disease. Progressive renovascular occlusive disease was 
defined as an increase of at least 20 f.lmol/L in the serum creatinine concentration 
or worsening of the time-activity curve on renography; worsening was defmed as 
a change in the time-activity curve from type 1 or 2 to type 3, 4, or 5 or a change 
in the curve from type 3 to type 4 or 5 (type 1 indicates minor abnormalities, type 
2 delayed excretion with washout, type 3 delayed excretion without washout, type 
4 renal failure with measurable uptake by the kidney, and type 5 renal failure 
without measurable uptake).13 Lipid-lowering medication was prescribed for any 
patient who had a serum cholesterol concentration greater than 6.5 mmol/L 
(251 mg/dL). 
Renal angiography, renography and balloon angioplasty 
Angiography was performed before the beginning of the treatment phase and at 
12 months by the femoral approach with the digital-subtraction technique. The 
images were then assessed at each participating center by the radiologist who had 
performed the angiography. All angiograms were subsequently evaluated by three 
independent radiologists, who graded the images according to the severity of 
stenosis, expressed in steps of 10% decrease in luminal diameter. The median 
value of these three grades was then calculated. 
Renography was performed with use of technetium-99m-labeled mercapto-
acetyltriglycine. The nuclear medicine specialists who assessed the renal 
renograms were asked to report the results in terms of the probability of 
renovascular disease (low, indeterminate, or high), according to a consensus 
report on the di~onosis of renovascular disease by renography.14 Renograms 
judged to indicate a high or indeterminate probability of renovascular disease 
were considered abnormal. 
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Outcome measures 
The primary outcome measures were the systolic and diastolic blood pressures at 
3 and 12 months after randomization. The secondary outcome measures were the 
numbers and defined daily doses of antihypertensive drugs (one defined daily 
dose is the average maintenance dose per day in adults),15 the serum creatinine 
conceqtration, the creatinine clearance according to the formula of Cockcroft and 
Gault,16 the results of renography, the presence or absence of patency of the renal 
artery (where patency was defined as stenosis of <50%), and the incidence of 
complications. 
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63 Excluded 
53 with exclusion criteria 
1 0 for other reasons 
~lv 
I 106 Enrolled I 
... v 
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Figure 5.1. Design of the study 
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In a separate analysis, outcomes were assessed in terms of blood pressure 
responses in the two groups. In this analysis, improvement was defined as either 
(1) a decrease of 10 mm Hg or more in diastolic pressure with either no change 
or a decrease in the number of drugs or (2) a decrease in the number of drugs 
without a change in diastolic pressure; worsening was defined as either (1) an 
increase of 10 mm Hg or more in diastolic pressure with either no change or a 
increase in the number of drugs or (2) an increase in the number of drugs without 
a change in diastolic pressure; and cure of hypertension was defined as a diastolic 
blood pressure of less than 9 5 mm Hg without the use of antihypertensive drugs. 
Statistical analysis 
Results are given as means ± SD or as medians and ranges. Results at 12 months 
were analyzed according to the intention-to-treat principle. In addition, results at 
3 and 12 months in the drug-therapy group were analyzed according to whether 
patients underwent angioplasty after three months. Two-sided comparisons 
between groups were made with Student's T-test or the Mann-Whitney test. Chi-
squared testing was used for analysis of categorical data. A paired T-test was used 
to compare the blood pressure values measured at the 3-month and 12-month 
follow-up visits with the values measured at baseline. 
Results 
Of the 169 patients with renal artery stenosis, 53 were excluded on the basis of the 
prespecified exclusion criteria and 10 patients were excluded for other reasons 
(prominent aortic plaques in 2, a serum creatinine concentration >200 ).Lllol/L in 1, 
lack of informed consent in 4, and withdrawal by the internist in 3). Of the remaining 
1 06 patients, 56 were randomly assigned to balloon angioplasty and 50 to 
antihypertensive-drug therapy (Figure 5.1). At baseline, the blood pressure levels and 
doses of antihypertensive drugs (means of the values obtained at the three visits during 
the di~onostic phase) were similar in the two groups, as were other baseline 
characteristics (fable 5.1). Likewise, in the subgroup of patients with impairment of 
renal function related to the use of angiotensin-converting enzyme inhibitors, the 
blood pressure levels and drug doses in the patients randomly assigned to balloon 
angioplasty were similar to those in the patients assigned to antihypertensive-drug 
therapy. 
Renal angiography 
To be included in the study, patients were required to have unilateral or bilateral 
renal artery stenosis of at least 50%, as judged by the radiologist who had 
performed the angiography. In 10 of the 106 patients included (5 in the 
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Table 5.1. Baseline characteristics of the patients. 
Variable 
Clinical data 
Male sex 
Age, years 
Body-mass index, kg/m2 
Cigarette smoking 
Former or current 
Pack-years among those who smoked 
Abdominal bruit 
Diabetes mellitus 
Onset of hypertension <2 yr before enrollment 
Blood pressure, mm Hg 
Systolic 
Diastolic 
Antihypertensive drugs 
No. of defined daily doses 
No. of drugs 
Regimen, no. 
Amlodipine and atenolol 
Enalapril and hydrochlorothiazide 
Other 
Laboratory and angiographic data 
Serum creatinine, flmol/L 
Median 
Range 
Serum creatinine 2:120 fLIDOl/L 
Creatinine clearance, mL/ min 
Serum cholesterol, mmol/L 
Serum cholesterol >6.5 mmol/L 
Abnormal renogram 
Stenosis 
Bilateral 
<70% 
Average decrease in luminal diameter,% 
Inclusion criteria 
Hypertension resistant to standardized medication 
Renal function impairment related to angiotensine-
converting enzyme inhibitors * 
Angioplasty 
group 
(N=56) 
Drug-therapy 
group 
(N=50) 
Number(%) or mean ± SD 
37 (66) 
59± 10 
25.4 ± 3.5 
46 (82) 
22 ± 14 
12/56 (21) 
3 (5) 
19 (34) 
179 ± 25 
104 ± 10 
3.3 ± 1.1 
2.0 ± 0.8 
18 
22 
16 
105 
61-237 
18 (32) 
67 ± 23 
6.3 ± 1.1 
22/56 (39) 
35/54 (65) 
13 (23) 
12 (21) 
76 ± 20 
49 (88) 
7 (12) 
28 (56) 
61 ± 10 
25.2 ± 3.1 
35 (70) 
25 ± 17 
12/48 (25) 
3 (6) 
17 (34) 
180 ± 23 
103 ± 8 
3.2 ± 1.5 
2.0 ± 0.9 
13 
23 
14 
111 
43-203 
21 (42) 
60 ± 24 
6.4 ± 1.2 
18/45 (40) 
32/49 (65) 
11 (22) 
15 (30) 
72 ± 18 
38 (76) 
12 (24) 
In the subgroup with renal function impairment related to the use of angiotensin-converting 
enzyme inhibitors, the systolic blood pressure was 164 ± 25mm Hg and the diastolic blood 
pressure 98 ± 10 mm Hg among the patients assigned to angioplasty, and the respective systolic 
and diastolic pressures were 160 ± 20 and 98 ± 5 mm Hg among the patients assigned to drug-
therapy group; these patients were receiving 2.9 ± 0.4 and 2.9 ± 1.1 defined daily doses, 
respectively. 
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angioplasty group and 5 in the drug-therapy group), however, the stenosis was 
judged to be less than 50% by the panel of three independent radiologists. 
Of the 56 patients in the angioplasty group, 2 received a stent in addition to 
undergoing angioplasty (1 because of a small aneurysm in the distal segment of 
the renal artery and the other because the radiologist had not adhered to the 
protocol). Balloon angioplasty failed for technical reasons in 3 patients with 
unilateral stenosis and on one side in one patient with bilateral stenosis. After 3 
months, surgical revascularization was performed in 2 of the patients in whom 
angioplasty had failed and in one patient in the angioplasty group who had 
persistent hypertension (diastolic pressure, ?:95 mm Hg). 
Renal angiography was repeated 12 months after balloon angioplasty in 48 
of the 56 patients assigned to that group, 4 patients declined to undergo the 
procedure, and it was not requested for 3 of the patients in whom angioplasty had 
failed and for 1 of the patients who had undergone surgical revascularization. Of 
these 48 patients, 23 had at least 50% stenosis of the treated artery, but none had 
total occlusion. 
Of the 50 patients in the drug-therapy group, 28 were treated exclusively 
with antihypertensive drugs during the 12-month follow-up period. Of the 
remaining 22 patients, balloon angioplasty was performed after the 3-month 
follow-up in 14 patients because of persistent hypertension despite treatment 
with three or more drugs and in 8 patients because of progressive renovascular 
occlusive disease (as indicated by an increase of 20 )-Ullol/L or more in the serum 
creatinine concentration or worsening of the time-activity curve on renography). 
At the time of angioplasty, the angiograms of 3 of the 22 patients who underwent 
angioplasty showed total occlusion, so the procedure had to be aborted. 
Renal angiography was repeated 12 months after randomization in 43 of the 
50 patients initially assigned to the drug-therapy group. Angiography showed 
stenosis of 50% or more in 31 of the 43 patients (72%), stenosis that had 
progressed to total occlusion in 4 patients (9%), and stenosis of less than 50% in 
8 patients. Of the 25 patients who underwent repeated angiography and who had 
been treated exclusively with drug therapy, 5 had an increase in stenosis of 20 
percentage points or more, 16 had no change, and 4 had regression of stenosis of 
20 percentage points or more. 
Blood pressure 
Mean systolic and diastolic blood pressure at 3 months did not differ significandy 
between the angioplasty and drug-therapy groups (Table 5.2). At 12 months, intention-
to-treat analysis revealed no significant differences m systolic and 
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Table 5.2. Outcomes at 3 and 12 months in the angioplasty and drug-therapy groups. 
Variable Angioplasty Drug-therapy P value 
Outcomes 3 months after randomization 
Blood pressure, mm Hg * 
Systolic 
Diastolic 
Blood pressure by automatic device, mm Hg 
Systolic 
Diastolic 
Antihypertensive drugs 
group group 
(N=56) (N=50) 
Number (%) or mean ± SD 
169 ± 28 176 ± 31 0.25 
99 ± 12 101 ± 14 0.36 
160 ± 26 163 ± 27 0.61 
89 ± 14 88 ± 13 0.73 
No. of defined daily doses 
No. of drugs 
2.1 ± 1.3 3.2 ± 1.5 <0.001 
Serum creatinine, f.lmol/L 
Median 
Range 
Creatinine clearance, mL/min 
Abnormal renogram 
Outcomes 12 months after randomization 
Blood pressure, mm Hg t 
Systolic 
Diastolic 
Blood pressure by automatic device, mm Hg 
Systolic 
Diastolic 
Antihypertensive drugs 
No. of defined daily doses 
No. of drugs 
Serum creatinine, f.LIDOl/L 
Median 
Range 
Creatinine clearance, mL/min 
Abnormal renogram 
Complications during follow-up 
Occlusion of affected artery 
Rupture of affected artery 
Increase of :2:50% in serum creatinine 
Embolization of cholesterol crystals 
Groin hematoma necessitating transfusion or surgery 
Other+ 
1.9 ± 0.9 
107 
58-166 
70 ± 25 
17 I 47 (36) 
160 ± 26 
93 ± 13 
152 ± 20 
84 ± 10 
2.5 ± 1.7 
1.9 ± 0.9 
104 
52-169 
70 ± 24 
19/53 (36) 
0 
0 
1 (2) 
0 
1 (2) 
1 (2) 
2.5 ± 1.0 0.002 
0.05 
112 
50-232 
59± 23 0.03 
28/40 (70) 0.002 
163 ± 25 0.51 
96 ± 10 0.25 
162 ± 27 0.07 
88 ± 13 0.13 
3.1 ± 2.3 0.10 
2.4 ± 0.9 0.002 
0.11 
110 
50-726 
62 ± 27 0.11 
25/44 (57) 0.04 
4 (8) 
0 
3 (6) 
1 (2) 
2 (4) 
2 (4) 
P<0.001 for the comparison with systolic and diastolic pressure at randomization in the angioplasty 
group; P=0.16 for the comparison with systolic pressure at randomization and P=0.13 for the 
comparison with diastolic pressure at randomization in the drug-therapy group. 
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P=0.001 for the comparison with systolic and diastolic pressure at 3 months in the angioplasty 
group; P=0.001 for the comparison with systolic pressure at 3 months and P=0.002 for the 
comparison with diastolic pressure at 3 months in the drug-therapy group. 
Other complications were symptomatic hypotension at the time of angioplasty in one patient in 
the angioplasty group and angina pectoris in one patient and myocardial infarction in one patient 
in the drug-therapy group. 
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diastolic blood pressure between the drug-therapy group (of which 22 patients 
underwent balloon angioplasty after 3 months) and the angioplasty group. The 
doses of antihypertensive drugs used by the patients in the angioplasty group 
were significantly lower than those used in the drug-therapy group at 3 months, 
but this difference was no longer significant at 12 months. Among patients with 
renal function impairment related to the use of angiotensin-converting enzyme 
inhibitors, the blood pressure levels at 3 and 12 months were similar in the drug-
therapy and angioplasty groups. 
Among the patients who were randomly assigned to the drug-therapy group, 
the systolic and diastolic blood pressures were higher at baseline and at the 3-
month follow-up visit in patients who underwent balloon angioplasty after 3 
months than in those who did not (Table 5.3). Blood pressure decreased after 
angioplasty but was still higher at 12 months in the patients who underwent this 
procedure than in the patients who received drug therapy alone. The doses of 
drugs did not change significantly after balloon angioplasty, and at 12 months 
they were similar in the two subgroups. 
Although there was no significant difference between groups in mean blood 
pressure levels, a favorable effect in the angioplasty group could be identified 
when outcomes were categorized according to blood pressure response, as 
defined in the Methods section. At 12 months, blood pressure control had 
improved in 38 of the 56 patients in the angioplasty group (68%) and in 18 of the 
48 patients in the drug-therapy group who had complete follow-up (38%). 
Conversely, blood pressure control had worsened at 12 months in 5 patients in 
the angioplasty group (9%) and 16 patients in the drug-therapy group (33%) 
(P=0.002). Hypertension was considered cured at 12 months in 4 of the 56 
patients in the angioplasty group (7%) and in none of the patients in the drug-
therapy group. 
In the 54 patients in the angioplasty group in whom balloon angioplasty was 
technically successful, including the 2 patients who also received a stent, neither 
the blood pressure levels nor the defined daily doses of antihypertensive drug at 3 
and 12 months were related to the severity of renal artery stenosis at 
randomization; the blood pressure levels and the drug doses of the 32 patients 
with greater than 70% stenosis did not differ from those of the 20 patients with 
stenosis of 70% or less (data not shown). Blood pressure and drug doses in the 
angioplasty group also were not correlated with the presence or absence of 
stenosis of 50% or greater at 12 months: among the 26 patients (23 in whom 
angiography was repeated and 3 in whom angiography was not repeated and in 
whom there was technical failure) with at least SO% stenosis after 12 months, the 
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Table 5.3. Baseline characteristics and outcomes in patients in the drug-therapy 
group according to whether they underwent angioplasty after 3 months. 
Variable 
Baseline characteristics 
Blood pressure, mm Hg 
Systolic 
Diastolic 
Antihypertensive drugs 
No. of defined daily doses 
No. of drugs 
Serum creatinine, f.UllOl/L 
Median 
Range 
Creatinine clearance, mL/min 
Abnormal renogram 
Outcomes 3 months after randomization 
Blood pressure, mm Hg 
Systolic 
Diastolic 
Antihypertensive drugs 
No. of defined daily doses 
No. of drugs 
Serum creatininqtmol/L 
Median 
Range 
Creatinine clearance, ml/ min 
Abnormal renogram 
Outcomes 12 months after randomization 
Blood pressure, mm Hg 
Systolic 
Diastolic 
Antihypertensive drugs 
No. of defined daily doses 
No. of drugs 
Serum creatinine, f.1mol/L 
Median 
Range 
Creatinine clearance, mL/min 
Abnormal renograms 
Drug therapy with Drug therapy 
angioplasty after 3 alone 
months (N=22) (N=28) 
Number (%) or mean ± SD 
185±22 176±24 
107±7 101±9 
3.6±1.8 2.8±0.9 
2.3±1.0 1.8±0.8 
115 110 
77-203 43-198 
55±21 63±26 
14/21 (67) 18/28 (64) 
190±33 164±24 
111±13 94±9 
3.7±1.6 2.8±1.2 
2.8±1.1 2.2±0.8 
105 112 
66-195 50-232 
58±21 60±24 
10/16 (63) 18/24 (75) 
169±25 * 159±24t 
102±9 * 91±9 t 
3.3±2.8 3.0±1.8 
2.5±1.1 2.4±0.8 
114 108 
53-726 50-176 
58±26 65±27 
10/19 (53) 15/25 (60) 
P<0.001 for the comparison with systolic and diastolic pressure in this subgroup at 3 months. 
Pvalue 
0.21 
0.02 
0.05 
0.08 
0.56 
0.22 
0.86 
0.004 
<0.001 
0.03 
0.02 
0.65 
0.75 
0.49 
0.16 
<0.001 
0.74 
0.81 
0.33 
0.42 
0.63 
P=0.26 for the comparison with systolic pressure and P=0.32 for the comparison with diastolic pressure in 
this subgroup at 3 months. 
mean (± SD) systolic and diastolic blood pressure were 162 ± 21 and 91 ± 
11 mm Hg, respectively, during treatment with 2.3 ± 1.3 defined daily doses, as 
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compared with 159 ± 32 mm Hg (P=0.79) and 96 ± 16 mm Hg (P=0.14), 
respectively, during treatment with 2.9 ± 2.0 defined daily doses (P=0.13) among 
the 25 patients with less than 50% stenosis. In addition, in the angioplasty group, 
the presence of an abnormal renogram at entry did not predict the blood pressure 
level: there were no significant differences in blood pressure or defined daily 
doses of antihypertensive drugs between patients with a normal renogram at 
entry and those with an abnormal renogram. 
Renal function and results of renography 
At 3 months, the median serum creatinine concentration in the angioplasty group 
was lower and the mean creatinine clearance higher than the respective values in 
the drug-therapy group, but at 12 months the values of these variables were 
similar in the two groups, according to intention-to-treat analysis. The percentage 
of abnormal renograms was lower in the angioplasty group than in the drug-
therapy group at both 3 and 12 months (Table 5.2). 
Discussion 
The aim of our study was to determine whether balloon angioplasty offers any 
advantage over drug therapy in the treatment of patients with hypertension 
associated with atherosclerotic renal artery stenosis. We found that both 
approaches resulted in similar decreases in blood pressure, but that angioplasty 
reduced the need for one additional antihypertensive drug given in its usual daily 
dose. Fewer drugs were used in the angioplasty group than in the drug-therapy 
group in part because of the design of the study, and thus this difference does not 
constitute proof of the efficacy of angioplasty. The blood pressure in this group 
might have been lower if the patients had received as many antihypertensive 
drugs as the patients in the drug-therapy group. In very few of the patients in the 
angioplasty group was hypertension cured. 
Several factors may account for the limited efficacy of balloon angioplasty in 
our study. Angioplasty is followed by restenosis in a high proportion of 
patients,17-19 which may adversely affect the blood pressure response. However, 
we found no difference after one year in the blood pressure response between 
patients with stenosis and those without stenosis. Stent placement as an adjunct 
to angioplasty has been reported to lower the incidence of restenosis,20,2l but in 
one study the use of a stent did not result in greater improvement in blood 
pressure or renal function after 6 months than did angioplasty without stenting,20 
a fmding consistent with our results. Whether stenting is better than balloon 
angioplasty, in terms of long-term control of blood pressure and improvement in 
renal function, is not known. 
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Another explanation for the disappointingly small effect of balloon 
angioplasty on blood pressure in our study may be the fact that a substantial 
number of patients in the drug-therapy group underwent balloon angioplasty 
after 3 months because their hypertension persisted despite treatment with 3 or 
more drugs or because they had signs of progressive occlusive renovascular 
disease. As a result, follow-up data on the effects of drug therapy alone in these 
patients were available only at 3 months. When the patients who had initially 
been assigned to the drug-therapy group but who later underwent balloon 
angioplasty were evaluated as a separate subgroup, it appeared that angioplasty 
had had a favorable effect on blood pressure. The important point is that blood 
pressure was not higher at 12 months in the drug-therapy group as a whole than 
in the angioplasty group. Therefore, our results cannot be used as an argument 
against the more conservative, drug-based treatment. 
Our method of selecting patients may also have affected the results. Of the 
106 patients, 10 (5 in each group) had stenosis of the renal artery that was judged 
by an independent panel of three radiologists to be less than 50%. Some 
investigators consider stenosis to be hemodynamically important only if the 
diameter is reduced by more than 60%22.23 or by more than 70%.13,24 However, 
we found no correlation between the blood pressure response and the severity of 
renal artery stenosis at baseline. 
Our study was designed primarily to assess the influence of balloon 
angioplasty on the control of blood pressure, but our data also provide 
information about the effect of this intervention on renal function. Renal 
function appeared to be better in the angioplasty group than in the drug-therapy 
group at 3 months, but not at 12 months. The long-term effects of angioplasty on 
renal function remain to be determined. 
We conclude that it is still prudent to restrict balloon angioplasty (with or without 
the use of a stent) to patients whose hypertension persists despite treatment with 
three or more drugs or who have progressive occlusive renovascular disease (as 
indicated by an increase in the serum creatinine concentration or worsening findings 
on the renogram). 
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Abstract 
Oijective: To identify subgroups of patients with hypertension and atherosclerotic 
renal artery stenosis who may benefit from immediate intervention. 
Methods: In the DRASTIC study, patients with hypertension, significant 
atherosclerotic renal artery stenosis, and a normal or mildly impaired renal 
function were randomized between immediate balloon angioplasty (PTRA; 
N=56) and drug therapy followed by angioplasty after 3 months, if needed (Med-
PTRA; N=50). In this secondary analysis of the data, changes in the renal 
function and blood pressure after 1 year were studied by analysis of covariance in 
the following subgroups: patients with positive captopril-renin challenge test, 
abnormal captopril renogram, recently developed hypertension, bilateral stenosis, 
and severe stenosis. 
Results: We found a benefit of immediate angioplasty only for patients with 
bilateral stenosis. Their creatinine clearance had decreased (mean ± SD: -4.2 ± 
13.5 mL/min) in the Med-PTRA group, whereas it had improved substantially 
(+10.0 ± 15.7 mL/min) in the PTRA group (P=0.02). For patients with unilateral 
stenosis, the change in creatinine clearance did not differ between PTRA and 
Med-PTRA (+4.3 ± 15.5 mL/min and +1.3 ± 12.5 mL/min, respectively). The 
patients with bilateral stenosis also seemed to benefit most from immediate 
intervention with regard to blood pressure controL None of the other subgroups 
had a clear benefit of immediate intervention regarding renal function or blood 
pressure controL 
Conclusions: Intervention should not be postponed in patients with bilateral 
stenosis, even if renal function is normal. Other hypertensive patients with 
atherosclerotic renal artery disease could initially well be treated by aggressive 
multidrug therapy alone unless hypertension persists or renal function 
deteriorates. 
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Introduction 
Renal artery stenosis can lead to secondary hypertension and renal failure, and is 
caused by atherosclerosis in approximately 90% of the patients.1•2 The optimal 
treatment for patients with atherosclerotic renal artery stenosis and hypertension 
without chronic renal insufficiency is still unclear. Three randomized trials, one 
described in Chapter 5 and two other trials,3•4 compared balloon angioplasty with 
conservative treatment. These trials showed that blood pressure was not 
significantly better controlled after balloon angioplasty, although less 
antihypertensive medication was needed. A meta-analysis combining these trials 
also did not show a clear benefit of angioplasty.5 Furthermore, it is unclear 
whether invasive treatment offers an advantage over conservative treatment for 
prevention of renal failure in patients with stable renal function. 6•7 In a 
randomized trial comparing angioplasty with additional stent placement and 
angioplasty alone, additional stent placement did not improve the clinical 
outcomes after 6 months despite a higher rate of technical success and a lower 
rate of restenosis.s 
Since invasive treatment is costly and not without risk,9,lO one may propose 
that it is sensible to treat nonazotemic patients with atherosclerotic renal artery 
stenosis and hypertension by aggressive drug therapy and to perform an 
intervention only if the hypertension persists or if the renal function deteriorates. 
Some subgroups of patients may benefit from immediate intervention, however, 
either because they are likely to have a favorable response to intervention or 
because they are at risk for rapid deterioration of renal function. We explored this 
assumption by studying the changes in blood pressure and renal function after 1 
year of treatment in patients who were randomized between immediate balloon 
angioplasty and drug therapy followed by angioplasty if hypertension persisted or 
renal function deteriorated in the DRASTIC study.11 
Patients and methods 
Study population 
Patients participated in a prospective randomized study that was designed to 
identify patients with renal artery stenosis and to evaluate their treatment (the 
DRASTIC study).11 Patients had been referred because of difficult-to-treat 
hypertension associated with normal or mildly impaired renal function (defined as 
a serum creatinine concentration of 200 fLmol/L [2.3 mg/ dL] or less). The 
patients in the present analysis were from the therapeutic phase of the study, 
which was described in detail in Chapter 5. In total, 106 patients with 
atherosclerotic renal artery stenosis of 50% of lumen diameter or more according 
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to intra-arterial digital subtraction angiography were randomized between two 
treatment strategies: immediate balloon angioplasty (PTRA, N=56) and drug 
therapy followed by balloon angioplasty after 3 months, if needed (M:ed-PTRA, 
N=SO). In accordance with the study protocol, 22 of the 50 patients in the Med-
PTRA group underwent angioplasty after 3 months because of persistent 
hypertension (diastolic blood pressure of 95 mm Hg or higher) despite treatment 
with three or more drugs (N=14), or because of progressive renal failure (as 
indicated by an increase in the serum creatinine concentration of 20 [J-mol/L [0.23 
mg/ dL] or more, or worsening of the time-activity curve on captopril 
renography; N=8). All patients gave written informed consent. Blood pressure 
and renal function after 1 year did not differ significantly between the 
randomized groups (fable 5.2, Chapter 5). 
Clinical data 
In the present study, the clinical outcomes were change in diastolic blood 
pressure and change in creatinine clearance from baseline (before randomization) 
to 1 year. The baseline blood pressure was defined as the average of office blood 
pressure readings at three consecutive visits, and the blood pressure after 1 year 
was defined as the average of all available office blood pressure readings 
measured between 9 and 12 months after randomization (average two visits, 
range 1-4 visits). At each visit, the blood pressure was measured three times using 
a standard sphygmomanometer in sitting position after 5 minutes rest. The 
creatinine clearance at baseline and after 1 year were calculated according to the 
Cockcroft formula.12 Data on diastolic blood pressure and creatinine clearance 
after 1 year were available for 103 and 102 patients, respectively. 
As a rule, the results of subgroup analyses should be interpreted with 
caution.B,l4 To improve the credibility of our analyses, a limited number of 
subgroups were selected on the basis of clinical plausibility. We studied three 
subgroups of patients with a supposedly good response to intervention: those 
with positive captopril-renin challenge test15,16 (1-hour plasma renin 2::50 [J-U /mL; 
this cutoff represents the optimal value for identifying renal artery stenosis in our 
study group),17 those with abnormal renogram after stimulation with captopri1,18 
and those with recently developed hypertension (within the last 2 years).19,20 Two 
subgroups of patients with a supposed risk for rapid disease progression were 
studied: those with bilateral stenosis (2::50% of lumen diameter on both sides), 
and those with severe stenosis (2::80% of lumen diameter).2l,22 Subgroup data 
were available for all patients except for the captopril-renin challenge test and 
captopril renography. These tests were not performed in 28 patients and in three 
patients, respectively, for logistic reasons. 
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Statistical analysis 
We applied analysis of covariance to study the change in diastolic blood pressure 
in the subgroup of patients with a positive captopril-renin challenge test. The 
blood pressure at baseline was included as a covariate in the analysis to adjust for 
its correlation with the blood pressure level after 1 year.23 Mathematically, the 
analysis of treatment effect according to change in outcome with the baseline 
value as covariate is equivalent to the more standard analysis of outcome with the 
baseline value as covariate. To study whether the difference, if any, in the effect 
of the treatment strategies on blood pressure was similar for patients with a 
positive and a negative test captopril-renin challenge test, an interaction term of 
treatment strategy (PTRA or Med-PTRA) with captopril-renin challenge test 
(positive or negative) was tested in an analysis of covariance using all patients_14 
Again, diastolic blood pressure at baseline was included as a covariate. Similar 
analyses were performed to study the effect of treatment on diastolic blood 
pressure for the other patient subgroups, and to study the effect of treatment on 
renal function in all patient subgroups. In the latter analyses, the change in 
creatinine clearance from baseline to 1 year was used as the dependent variable 
(outcome), and the creatinine clearance at baseline was included as a covariate. 
P values <0.05 were considered statistically significant. 
Table 6.1. Baseline characteristics of the patients. 
Characteristic PTRA Med-PTRA 
(N=56) (N=50) 
Number (%) or mean ± SD 
Male sex 
Age, years 
Blood pressure, mm Hg 
Systolic 
Diastolic 
Antihypertensive drugs, number 
Creatinine clearance, mL/ min 
Abnormal captopril test 
Abnormal renogram 
Recent hypertension 
Bilateral stenosis 
Severe stenosis 
37 (66) 
59± 10 
179 ± 25 
104 ± 10 
2.0 ± 0.8 
67 ± 23 
35/45 (78) 
35/54 (65) 
19 (34) 
13 (23) 
38 (68) 
28 (56) 
61 ± 10 
180 ± 23 
103 ± 8 
2.0 ± 0.9 
60 ± 24 
26/33 (79) 
32/49 (65) 
17 (34) 
11 (22) 
26 (52) 
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Table 6.2. Diastolic blood pressure at baseline and change in diastolic blood 
pressure (in mm Hg) after 3 and 12 months of treatment (mean ± SD) in 
subgroups of patients, separately for the PTRA group and for the Med-PTRA 
group. 
No. of patients without 
Characteristic missing data Baseline level 
PTRA Med-PTRA PTRA Med-PTRA 
Positive captopril test 
Yes 35 24 105 ± 9 105 ± 10 
No 10 7 107 ± 13 104 ± 5 
Abnormal renogram 
Yes 35 31 105 ± 9 102 ± 7 
No 19 15 105 ± 11 106 ± 11 
Recent hypertension 
Yes 19 15 104 ± 6 101 ± 8 
No 37 32 105 ± 11 104 ± 9 
Bilateral stenosis 
Yes 13 10 105 ± 9 100 ± 5 
No 43 37 105 ± 10 104 ± 9 
Severe stenosis 
Yes 38 24 103 ± 8 102 ± 7 
No 18 23 108 ± 12 105 ± 10 
Results 
The patients in the PTRA group and in the Med-PTRA group did not differ with 
respect to sex, age, blood pressure, number of drugs and creatinine clearance at 
baseline (Table 6.1). Also, the proportions of patients with positive captopril-
renin challenge test, with an abnormal renogram, with recently developed 
hypertension, with bilateral stenosis, and with severe stenosis were similar in 
these groups. The distribution of these characteristics was similar for the 66 
patients with complete data (data not shown). 
Baseline levels and outcomes after 3 months 
The diastolic blood pressure levels at baseline of patients with a positive 
captopril-renin challenge test, with an abnormal renogram, with recently 
developed hypertension, with bilateral stenosis, or with severe stenosis were fairly 
comparable to those of patients without the respective characteristic (Table 6.2). 
Patients with bilateral stenosis had a lower baseline creatinine clearance on 
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Table 6.2 (continued). 
Change from baseline Change from baseline 
Characteristic to 3 months to 12 months 
PTRA Med-PTRA* PTRA Med-PTRAt 
Positive captopril test 
Yes -6.4 ± 10 -2.5 ± 11 -12 ± 9.6 -7.6 ± 11 
No -3.7 ± 5.4 +3.6 ± 6.9 -10 ± 17 -4.1 ± 8.0 
Abnormal renogram 
Yes -7.0 ± 12 -3.1±9.6 -12 ± 12 -6.9 ± 9.8 
No -5.6 ± 7.2 -1.6 ± 12 -11 ± 12 -7.9 ± 9.8 
Recent hypertension 
Yes -8.8 ± 11 -3.6 ± 10 -15 ± 8.8 -8.5 ± 9.5 
No -4.6 ± 10 -2.1 ± 10 -9.9 ± 12 -6.6 ± 9.7 
Bilateral stenosis 
Yes -5.9 ± 11 +1.1±11 -12 ± 11 -4.0 ± 8.5 
No -6.0 ± 10 -3.6 ± 10 -11±11 -8.1 ± 9.8 
Severe stenosis 
Yes -5.5 ± 11 -0.1 ± 10 -12 ± 11 -6.8 ± 10 
No -7.0±10 -5.1 ± 9.8 -11 ± 13 -7.6 ± 9.3 
Clinical outcome after drug therapy only. 
t Clinical outcome after drug therapy followed by angioplasty after 3 months, 
if needed. 
average than those with unilateral stenosis (Table 6.3; P<0.0001). Also, the 
average baseline creatinine clearance was lower in patients with severe stenosis 
compared to patients with moderate stenosis (P=0.02). The baseline creatinine 
clearance levels were equal for the patients in the other subgroups. 
Three months after randomization, the improvement in blood pressure 
(Table 6.2) and in creatinine clearance (Table 6.3) tended to be larger in the 
PTRA group. At that point in time, all patients in the Med-PTRA group had been 
treated by drug therapy only. In accordance with the study protocol, a number of 
patients in the Med-PTRA group received angioplasty after 3 months because of 
persistent hypertension or deterioration of renal function: 13/26 (50%) and 5/7 
(71 %) of patients with positive and negative captopril-renin challenge test, 
respectively; 14/32 (44%) and 7/17 (41 %) of patients with an abnormal and a 
normal renogram, respectively; 7/17 (41 %) and 15/33 (46%) of patients with 
recent and longer existing hypertension, respectively; 6/11 (55%) and 16/39 
(41 %) of patients with bilateral and unilateral stenosis, respectively; and 15/26 
89 
Chapter 6 
Table 6.3. Creatinine clearance at baseline and change in creatinine clearance (in 
mL/min) after 3 and 12 months of treatment (mean ± SD) in subgroups of 
patients, separately for the PTRA group and for the Med-PTRA group. 
No. of patients "\Nithout Baseline level 
Characteristic missing data 
PTRA Med-PTRA PTRA Med-PTRA 
Positive captopril test 
Yes 34 26 69 ± 22 57± 23 
No 10 7 68 ± 29 68 ± 18 
Abnormal renogram 
Yes 34 31 65 ± 22 56± 24 
No 19 15 69 ± 24 65 ± 23 
Recent hypertension 
Yes 19 14 78 ± 16 55± 17 
No 36 33 61 ± 23 61 ± 27 
Bilateral stenosis 
Yes 13 11 53± 18 42 ± 15 
No 42 36 71 ± 22 65 ± 24 
Severe stenosis 
Yes 37 25 63 ± 21 52± 17 
No 18 22 73 ± 24 67 ± 29 
(58%) and 7/24 (29%) of patients with severe and moderate stenosis, 
respectively. These differences were not statistically significant except for the 
difference between the patients with severe stenosis and those with moderate 
stenosis (P=0.04). 
Outcomes after 1 year 
Blood pressure 
After 1 year, the diastolic blood pressure had decreased on average in both 
treatment groups. The drop in blood pressure level in the PTRA group seemed 
somewhat larger than in the Med-PTRA group: 11.6 ± 11.3 mm Hg and 7.2 ± 9.6 
mm Hg (mean ± SD). This difference was not statistically significant after 
adjustment for blood pressure at baseline, however (P=0.06). The apparent 
benefit in the PTRA group was largest in the patients with bilateral stenosis 
90 
Benefit of immediate intervention 
Table 6.3 (continued). 
Characteristic Change from baseline Change from baseline 
to 3 months to 12 months 
PTRA Med-PTRA* PTRA Med-PTRAt 
Positive captopril test 
Yes +6.1 ± 14 +1.2 ± 11 +5.1 ± 16 +3.0 ± 18 
No -1.4 ± 6.8 +5.7 ± 2.9 +0.5 ± 9.0 +4.8 ± 9.6 
Abnormal renogram 
Yes +4.6 ± 12 +0.3 ± 9.7 +3.6 ± 16 +0.5 ± 14 
No +4.9 ± 13 +0.2 ± 8.2 +3.8 ± 10 +6.6 ± 18 
Recent hypertension 
Yes +2.8 ± 15 +4.6 ± 9.3 +3.7 ± 16 +6.0 ± 17 
No +4.9 ± 11 -1.3 ± 8.7 +3.2 ± 13 +0.7 ± 15 
Bilateral stenosis 
Yes +9.5 ± 17 -0.4 ± 7.4 +10.0 ± 16 :j:§ -4.2 ± 14 
No +2.4 ± 9.4 +0.7 ± 9.8 +1.3 ± 13 +4.3 ± 16 
Severe stenosis 
Yes +4.2 ± 13 +1.6 ± 9.8 +3.0 ± 16 +1.9±17 
No +4.3 ± 8.6 -0.9 ± 8.4 +4.1 ± 8.3 +2.8 ± 14 
Clinical outcome after drug therapy only. 
t Clinical outcome after drug therapy followed by angioplasty after 3 months, if needed. 
:J: P=0.03 for PTRA vs. Med-PTRA in patients with bilateral stenosis. 
P=0.007 for interaction of treatment arm (PTRA or Med-PTRA) and bilateral 
stenosis (yes or no) (see Patients and methods) 
(Table 6.2): 12.2 ± 11.3 mm Hg for patients in the PTRA group and 4.0 ± 8.5 
mm Hg for patients in the Med-PTRA group (P=0.07). The benefit of PTRA 
over Med-PTRA within this subgroup seemed higher than for patients with 
unilateral stenosis, but was not statistically significant (interaction, P=0.46). For 
the other subgroups (patients with a positive captopril-renin challenge test, 
patients with an abnormal renogram, patients with recent hypertension, and 
patients with severe stenosis), the differences between PTRA and Med-PTRA 
were smaller and also not statistically significant. 
Renal function 
After 1 year, the creatinine clearance had somewhat increased on average in both 
treatment groups: 2.3 ± 15.4 mL/min and 3.4 ± 13.7 mL/min. This difference 
was not statistically significant after adjustment for the creatinine clearance at 
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baseline (P=0.51). In all subgroups but one, the average creatinine clearance was 
stable or had increased after 1 year (Table 6.3). The creatinine clearance of 
patients with bilateral stenosis who were randomized for Med-PTRA, had 
decreased by -4.2 ± 13.5 mL/min. This occurred despite the fact that six of these 
11 patients underwent angioplasty after 3 months of follow-up. On the other 
hand, the creatinine clearance of the patients with bilateral stenosis who were 
randomized for PTRA, had improved substantially after one year by +10.0 ± 15.7 
mL/min (P=0.03). For patients with unilateral stenosis, the average creatinine 
clearance had improved somewhat in both treatment groups (+1.3 ± 12.5 
mL/min in the angioplasty group and +4.3 ± 15.5 mL/min in the drug therapy 
group). The difference in treatment effect on renal function between the patients 
with bilateral stenosis and those with unilateral stenosis was statistically significant 
(interaction term, P=0.007). For none of the other subgroups, a clear difference 
between the PTRA group and the Med-PTRA group was found. 
Discussion 
Our main finding was that patients with atherosclerotic bilateral stenosis had an 
evident benefit of immediate intervention compared to drug therapy followed by 
intervention after 3 months, if needed. These patients had a normal or mildly 
impaired renal function at study entry. After 1 year of follow-up, their renal 
function had improved if intervention had taken place immediately after the 
diagnosis, whereas it had deteriorated if intervention had been performed after 3 
months in case of persistent hypertension or a decline in renal function. This 
finding is consistent with the studies reporting that patients with bilateral stenosis 
have an increased risk of progressive renal dysfunction.21 ,22 The patients with 
bilateral stenosis also seemed to benefit most from immediate intervention with 
regard to blood pressure controL 
We did not find any other subgroup with a clear benefit of immediate 
intervention, either with regard to blood pressure control or with regard to 
preservation of renal function. A serious limitation of our study, however, was 
the lack of statistical power for detecting small differences in treatment effects 
per subgroup.14 Our study should therefore be regarded as e2,.'Ploratory. 
Nevertheless, this is the only study reporting on treatment effects in these 
subgroups of patients with atherosclerotic renal artery stenosis so far. Another 
prospective study to confirm these results may not be feasible, given the large 
numbers of patients needed per subgroup to reach statistical significance. 
The results of the treatment strategies with regard to preservation of renal 
function may have been influenced in a number of ways. First, the assessment of 
renal function with the creatinine clearance according to the Cockcroft formula 
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was rather crude. Unfortunately, no other data were available by which the renal 
function could have been assessed more accurately. Also, the use of ACE 
inhibitors, AT1 antagonists and diuretics could have affected the renal function, 
especially in patients with bilateral stenosis. Whereas AT1 antagonists were not 
used at all, ACE inhibitors and diuretics were used by comparable proportions of 
the patients in the treatment groups and were used only in low dosages. Patients 
with bilateral disease benefited by immediate intervention whereas they used 
ACE inhibitors twice as often as the patients with bilateral disease who were 
allocated to medication. 
A benefit of immediate intervention for preservation of renal function may 
have been hidden for the subgroups of patients with a positive captopril-renin 
challenge test, with an abnormal renogram, and with recently developed 
hypertension. The patients with these characteristics, who were allocated to initial 
medication, had a relatively worse renal function at baseline, and, consequently, 
could have gained more from treatment than the patients who were allocated to 
immediate intervention. However, the actual benefit in renal function after 1 year 
seemed larger in the patients who received medication only in the subgroup with 
recent hypertension. 
Another limitation was that the treatment strategies in this study did not 
include renal artery stent placement. Stent placement is superior to angioplasty 
alone on theoretical grounds. Until now, only one randomized study was 
published that compared stent placement with angioplasty alone.s Although this 
study reported superior vessel patency and a lower restenosis rate after stent 
placement, the clinical outcomes after stent placement were similar to those after 
angioplasty alone. The follow-up in this study was limited to 6 months, however. 
Based on the available evidence of this randomized study, we suppose that our 
conclusions would have been similar if additional stent placement would have 
been included in both treatment arms. 
Percutaneous intervention can successfully control blood pressure in 
patients with renovascular (i.e., renin-dependent) hypertension.24 Reviews of 
medical therapy for renovascular hypertension have shown, however, that 
modern antihypertensive drugs, such as angiotensin-converting enzyme (ACE) 
inhibitors and calcium channel blockers, can achieve adequate blood pressure 
control in a large proportion of patients with renovascular hypertension.zs 
Renovascular hypertension is supposed to be more likely in patients in whom the 
plasma renin activity is increased after stimulation with captopril ( captopril-renin 
challenge test),15 in patients with an abnormal renogram after stimulation with 
captopril,19 and in patients with recently developed hypertension_19,20 In these 
subgroups, immediate intervention did not have an apparent benefit over 
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restricting intervention to those patients in whom hypertension persisted or renal 
function declined after 3 months of drug therapy. This benefit, if any, is small and 
probably does not outweigh the risks of complications and cost of intervention 
for patients in whom blood pressure can be controlled medically. 
Successful intervention may preserve or even restore the renal function in 
patients with atherosclerotic renal artery stenosis whose renal function is already 
deteriorating.26-30 For patients with a normal or mildly impaired renal function, 
however, it is unclear if and when intervention should be performed to prevent 
progressive renal failure, because the rate of progressive narrowing of the renal 
artery and the associated rate of progressive renal failure is generally slow.31 Our 
study shows that intervention should not be postponed in patients with bilateral 
stenosis, even if their renal function is not impaired as yet. This result is in 
agreement with a prospective study on disease progression, showing that renal 
survival was lowest in patients with bilateral stenosis, especially in case of an 
occluded renal artery on one side.21 Severe unilateral stenosis, on the other hand, 
did not seem to justify immediate intervention in our study. Although severe 
stenoses are more likely to progress than less advanced lesions, 31 renal 
insufficiency develops mainly in patients in whom the entire renal mass is 
affected.25 Even in patients with severe stenosis, bilateral disease is present in a 
minority of cases (in our sample, 34%). Stenosis could be expected to develop in 
the contralateral kidney, however, although this process is unpredictable and may 
take a long time.32 
In conclusion, intervention should be performed immediately in hypertensive 
patients with atherosclerotic renal artery stenosis and a normal or mildly impaired renal 
function if bilateral disease is di~onosed. In the remaining patients, aggressive drug 
therapy followed by intervention in a selection of patients after 3 months is a sensible 
treatment strategy. In this way, unnecessary interventions can be avoided in a 
considerable number of patients. Clinicians should be wary of disease progression, 
however, especially in patients with severe unilateral disease. 
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Abstract 
Oijective: The reproducibility and validity of a hypertension-specific questionnaire 
and a generic health questionnaire (the MOS Short-form General Health Survey) 
were evaluated for measuring the quality of life in a randomized controlled trial 
comparing balloon angioplasty and long-term medication in patients with 
hypertension and renal artery stenosis. 
Methods: The health questionnaires were filled out by 97 patients with hypertension 
on stable medication. The reproducibility of the questionnaires was assessed by 
intraclass correlation coefficients (ICCs). Pearson's correlation coefficients were 
calculated between the scales of the questionnaires to evaluate the validity. 
&suits: Medication had been changed to eliminate side effects in an earlier phase of 
treatment. Only 7% of the patients reported non-compliance with the medication 
regime. Most patients suffered from physical symptoms, but the impact of long-
term antihypertensive medication on the quality of life was not substantial. The 
reproducibility was good for most scales (ICC >0.70), except for the role and social 
functioning scales. All correlations between the scales of the questionnaires were 
statistically significant and no contradictory correlations were found. 
Conclusion: The health questionnaires together form a reproducible and valid 
instrument for measuring the quality of life of hypertensive patients on stable 
medication. 
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Introduction 
The quality of life of patients on antihypertensive medication is affected by side-
effects of antihypertensive drugs and may also be impaired by concomitant 
diseases and by labelling the patient with a diagnosis of hypertension.1-5 The 
diagnosis and treatment of hypertension can affect both physical and 
psychological well-being and influence work performance and leisure activities.6 
In clinical trials on treatment of hypertension the quality of life is an important 
treatment outcome, because side-effects of treatment may endanger the patient's 
compliance to the prescribed medication regimen.2,3,7 
The quality of life is one of the treatment outcomes in an ongoing randomized 
multicenter trial in the Netherlands, comparing the effects of balloon angioplasty of 
the renal artery and long-term antihypertensive medication after 1 year in patients 
with hypertension and renal artery stenosis (the 'Dutch Renal Artery Stenosis 
Intervention Cooperative' or 'DRASTIC' study).8 As in regular clinical practice, the 
medication is changed in case of side-effects before intake in the trial. Therefore, 
the quality of life of these patients on stable medication is believed to be less 
impaired than that of patients participating in clinical trials studying the treatment 
results and side effects of new antihypertensive drugs. 
In the DRASTIC study physical symptoms associated with a high blood 
pressure or antihypertensive treatment and the effect of treatment on lifestyle are 
measured by means of a hypertension-specific questionnaire developed by Bulpitt, 
hereafter called the Hypertension Questionnaire.9 This questionnaire has been used 
in several trials comparing treatment results and side-effects of antihypertensive 
drugs.10 The MOS Short-form General Health Survey11 is used to measure in a 
concise way the psychological well-being and health perceptions as well as other 
relevant aspects of quality of life that may be affected by treatment and long-term 
complications of hypertension. 
Versions of these questionnaires in the Dutch language are validated in a 
population of ambulant hypertensive patients on stable antihypertensive 
medication. The following questions are addressed: What is the quality of life of 
patients with hypertension on stable medication? Are the questionnaires a valid 
method for measuring quality of life in these patients? And how reproducible are 
the questionnaires when used in this patient group? 
Patients and methods 
Study population 
The questionnaires were filled out by 101 consecutive visiting patients treated for 
hypertension at the outpatient clinic of the Department of Internal Medicine of the 
Rotterdam University Hospital. New patients were not included. The majority of 
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patients had essential hypertension, whereas less than a quarter suffered from 
renovascular hypertension. Patients with other forms of secondary hypertension 
were not included. Four patients were excluded because they did not use stable 
antihypertensive medication. All data were collected at the outpatient clinic of the 
hospital. After the patient had filled out the questionnaires, the medication was 
recorded and the sitting blood pressure was measured three times with a standard 
sphygmomanometer. The mean of the blood pressure measurements was used for 
statistical analysis. Patients were scheduled to return within two weeks for a second 
study visit. Ninety-five patients returned after an average interval of 16 ± 16 days 
(mean ± SD) between visits. 
Quality of life measurement 
The Hypertension Questionnaire9 contains a checklist of 30 items on physical 
symptoms attributed to hypertension or to side effects of antihypertensive drugs 
(Appendix A). This list was extended with eight other potential side effects of 
antihypertensive drugs commonly used in our hospital (questions marked with '*' in 
Appendix A). The symptom complaint rate was calculated as the number of 
positively scored symptoms divided by the total number of non-missing symptom 
items. A question on compliance to the prescribed medication was included. 
Another 15 questions cover the patient's perception of the effects of 
antihypertensive treatment on lifestyle. States of disability are calculated from the 
scores on both sections of the questionnaire in a health index ranging from 0 
(death) to 1 (perfect health)9.12. The questionnaire was translated into Dutch by 
three clinicians of our hospital. Differences between translations were settled in 
agreement. 
The MOS Short-form General Health Survey (or MOS Survey)11 is a 20-item 
generic health questionnaire measuring quality of life on 6 scales: physical 
functioning (6 items), role functioning (2 items), social functioning (1 item), 
psychological well-being and health perceptions (both 5 items), and pain (1 item) 
(Appendi'C B). The instrument was translated into Dutch by two independent 
translators and differences between translations were settled in agreement_13,l4 To 
enable the measurement of levels of impairment, the items covering physical 
functioning and role functioning were limited to the past month. Since the 
influence of hypertension and antihypertensive medication on psychological well-
being has been stressed,6 the psychological well-being scale was extended with three 
items concerning irritability, anxiety and listlessness (questions marked with '*' in 
Appendix B). For each scale, a score between 0 and 100 was calculated. High scores 
reflect better health, except for the pain scale where a high score indicates more 
pain_11 
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Data analysis 
Apart from the symptom complaint rate, scores on the health scales were calculated 
only if all items of the scale were filled out. To study whether the symptom 
complaint rate was related to the blood pressure, the number of prescribed 
antihypertensive drugs or the patient's age, Pearson's product-moment correlation 
coefficients were computed. The symptom complaint rate was also compared 
between patients using specific types of antihypertensive drugs and patients not 
using these drugs and between male and female patients by Student's T-tests. These 
patient characteristics were combined in a multiple linear regression model with the 
symptom complaint rate as the outcome variable. Factors influencing psychological 
well-being were studied in a similar way. Statistical testing was two-sided with a 
significance level of 5%. 
The internal consistency of the multi-item scales of the MOS Survey was 
determined with Cronbach's a-coefficient. An a-coefficient of 0.70 or higher was 
considered sufficient for assessments on a group level. 15 
The reproducibility was assessed by the intraclass correlation coefficient (ICC) 
in a subgroup of 71 patients who used exactly the same medication on both study 
visits (test-retest group).16 The ICC is preferable to Pearson's correlation 
coefficient, since the ICC also takes into account systematic differences between 
measurements.H It is important to check for systematic differences when assessing 
the reproducibility of health status measures, because systematic changes in health 
status measures are known to occur as a learning effect or as an effect of 
participating in a study.16 For measuring attitudes like quality of life estimations on a 
group level, ICCs of 0.70 or higher are considered to be adequate.18 
Since there is no gold standard for quality of life measurement, the validity of 
the questionnaires was judged by studying relations between the scales of the 
questionnaires (convergent validity).18•19 These relations were assessed by Pearson's 
correlation coefficients. 
Results 
Patient characteristics 
Ninety-seven patients filled out the questionnaires on the first study visit. Half of 
the patient group was male and the age was 57 ± 11 years (mean ± SD). The 
systolic blood pressure (SBP) was 162 ± 27 mm Hg and the diastolic blood 
pressure (DBP) 97 ± 14 mm Hg. Most of the patients used two to five different 
kinds of antihypertensive drugs. Monotherapy was prescribed to only one quarter 
of the patients. Various kinds of drugs were prescribed: ACE inhibitors (in 62% of 
patients), diuretics (in 49%), calcium antagonists (in 46%), ~-adrenoreceptor 
antagonists (in 35%), and centrally acting drugs (in 2%). Seven percent of the 
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Table 7.1. Quality of life: scores on the Hypertension Questionnaire at the flrst 
study visit. 
Health scale 
Mean complaint rate± SD [scored range] 
Mean health index± SD [scored range] 
Health state 
Perfect health 
Minor dissatisfaction 
Discomfort 
Minor disability 
Major disability 
Disablement 
Confined to the house or worse 
Score 
28% ± 18% 
0.87 ± 0.13 
2% 
49% 
9% 
10% 
19% 
11% 
0% 
No. of patients 
[0-76%] 97 
[0.63-1.00] 80 
80 
2 
39 
7 
8 
15 
9 
0 
patients reported they had failed to take the prescribed dose because of perceived 
side effects in the past month. This proportion did not differ between patients on 
monotherapy and patients on a polydrug regimen (X2-test, P=0.94). 
At the second study visit the blood pressure was virtually unchanged (change 
in SBP 1.1 ± 18.5 mm Hg and change in DBP 0.7 ± 11.8 mm Hg) in the 71 
patients who used the same medication at both study visits (test-retest group). This 
group did not differ from the total group of 97 patients with respect to gender, age, 
blood pressure and medication. 
Quality of life measurement 
Hypertension Questionnaire 
All but two patients reported one or more symptoms mentioned in the 
questionnaire (8 ± 5 symptoms). The most common symptoms were flushing of 
face and neck (in 52% of patients), light-headedness or faintness (in 51%), 
sleepiness during the day (in 45%), blurring of vision (in 42%), and headaches (in 
40%). The mean symptom complaint rate was 28% ± 18% (Table 7.1). 
The symptom complaint rate was weakly correlated with the DBP (correlation 
coefflcient=0.20, P=0.03). No signiflcant correlations were found with the SBP, the 
number of antihypertensive drugs, or the patient's age. The symptom complaint 
rate of patients using ACE inhibitors, diuretics, calcium antagonists, or ~­
adrenoreceptor antagonists did not differ from that of patients who did not use that 
speciflc type of antihypertensive drug. Female patients scored a higher complaint 
rate than male patients (31% and 24% on average; Student's T-test, P=0.04). In a 
multiple regression model, only 5% of the variance of the symptom complaint rate 
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Table 7.2. Quality of life: scores on the scales of the MOS Survey at the first 
study visit. 
Scale Items Patients Score Scored a 
(N) (N) (mean± SD) range 
Physical functioning 6 88 58± 32 0-100 0.81 
Role functioning 2 93 72±44 0-100 0.92 
Social functioning 1 92 83 ±22 20-100 
Psychological well-being 8 93 72 ± 19 23-100 0.89 
Health perceptions 8 87 60 ±23 5-100 0.84 
Pain 1 92 34± 32 0-100 
was accounted for by age, gender, blood pressure, and medication. Analogous to 
the univariate results, only gender had a statistically significant regression 
coefficient, whereas the other variables did not correlate significantly with the 
symptom complaint rate. 
Eleven percent of the patients were unemployed for medical reasons, 21% 
were unable to go to work or do usual jobs in and around the house for more than 
three days in the past month, and 26% stated that their hypertension or its 
treatment interfered with their hobbies or life. Although the health index was high 
(0.87 ± 0.13), only 2 patients enjoyed perfect health (Table 7.1). 
MOS Survey 
The 6 scales of the MOS Survey were completed by more than 90% of the patients. 
The majority of patients scored in ranges reflecting good health, but patients scored 
over a wide range on all scales (Table 7.2). All multi-item scales, measuring physical 
and role functioning, psychological well-being and health perceptions, had a-
coefficients above 0.80. The patients scored 72 ± 19 on the psychological well-
being scale. Psychological well-being scores were not related to the patient's blood 
pressure, medication, age, or gender. 
Reproducibility 
The reproducibility between the study visits was assessed in the test-retest group 
of 71 patients (Table 7.3). The ICC was 0.88 for the symptom complaint rate and 
0.76 for the health index of the Hypertension Questionnaire. Of the scales of the 
MOS Survey, psychological well-being and health perceptions had the highest 
ICC (0.88 and 0.81, respectively), followed by the scales measuring physical 
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Table 7.3. Reproducibility and validity of the health scales. 
CR HI PF RF SF PWB HP Pain 
Complaint rate (CR) * 0.88 
Health index (HI) * 0.59 0.76 
Physical functioning (PF) t -0.69 -0.54 0.76 
Role functioning (RF) t -0.45 -0.62 0.46 0.57 
Social functioning (SF) t -0.63 -0.58 0.64 0.45 0.63 
Psychological well-being (PWB) t -0.43 -0.48 0.42 0.36 0.42 0.88 
Health perceptions (HP) t -0.64 -0.51 0.56 0.44 0.50 0.54 0.81 
Paint 0.57 0.23 -0.28 -0.31 -0.34 -0.37 -0.36 0.69 
The intraclass correlation coefficients on the diagonal are estimates for the reproducibility of the health 
scales. The product-moment correlation coefficients off the diagonal are estimates for the convergent 
validity between health scales. 
* Scale of the Hypertension Questionnaire. 
t Scale of the MOS Survey. 
functioning (ICC=0.76) and pain (ICC=0.69). For the social and role functioning 
scales, low ICCs were found (0.63 and 0.57, respectively). 
Validity 
Correlations between the health scales of the questionnaires were all statistically 
significant. The absolute correlation coefficients were between 0.23 and 0.69 (fable 
7.3). The symptom complaint rate of the Hypertension Questionnaire was 
negatively correlated with the scores on the MOS scales measuring psychological 
well-being scale and health perceptions (correlation coefficient = -0.43 and -0.64 
respectively, P<0.0001).The scales within the questionnaires also correlated 
significantly and no contradictory correlations were found. 
Discussion 
In this study, the quality of life of a group of consecutive visiting hypertensive 
patients of an outpatient university clinic was measured. The patients were aware of 
their high blood pressure and used long-term antihypertensive medication. The 
majority of the patients used two or more different kinds of antihypertensive drugs. 
Patients with polydrug treatment may be somewhat over represented due to the 
clinical setting, but this makes the study population very suitable to evaluate the 
impact of antihypertensive drug treatment on the quality of life. Only 7% of the 
patients reported non-compliance with the prescribed medication regimen because 
of perceived side-effects. Since the compliance was not objectively verified, the 
non-compliance rate may be underestimated due to patients giving socially desirable 
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answers. Nevertheless, we assume that the compliance had been enhanced by 
previously changing the medication because of perceived side effects. 
By inducing physical complaints, antihypertensive treatment can have a 
negative impact on the quality of life of patients with hypertensionN In this patient 
group, however, the number of physical symptoms did not differ between various 
drug regimens. These results confirm the finding of other studies that the number 
of physical complaints does not differ between various treatment regimens after 
elimination of intolerable side effectsJ,ZO Furthermore, the reported non-
compliance rate did not vary between patients on monotherapy and patients using 
more than one type of drug. As mentioned in the literature, the blood pressure and 
gender were related to the number of physical complaints, but no relation with age 
was found.1·7•19 The medication, blood pressure, gender, and age together accounted 
for only a small part of the variation in the symptom complaint rate of these 
patients on long-term antihypertensive medication. Since most of the physical 
complaints listed in the questionnaire are not specific for hypertension, conditions 
other than hypertension may account for much of the unexplained variation.s,G 
The relationship between hypertension and psychological well-being has been 
studied from different viewpoints.4-7 In this study, variation in psychological well-
being scores between patients cannot be explained by labelling or self-selection, as 
patients were aware of their high blood pressure before entering the study. 
Differences in psychological well-being scores were not explained by the 
medication. Effects of medication on specific psychological features could 
nevertheless be obscured, because these aspects of psychological well-being were 
not measured on separate scales.6•21 The most plausible explanation for differences 
in psychological well-being scores is the presence or absence of co-morbidity,5 since 
the psychological well-being was negatively associated with the number of physical 
complaints. 
Although no clinically relevant change in quality of life due to medication is 
expected in clinical trials involving hypertensive patients on stable medication, the 
quality of life still is an important outcome measure in these trials. Decreases in 
quality of life may be expected due to complications of invasive treatment. 
Furthermore, the occurrence of long-term complications of hypertension, like 
coronary heart disease and stroke, may differ between treatment strategies after 
follow-up, leading to considerable differences in the quality of life between study 
groups.5,10 
The reproducibility of the health scales was studied in a subgroup of 71 
patients who used exactly the same medication on both study visits. Their quality of 
life was assumed to be stable over the two study visits. For the majority of these 
patients, the interval between the study visits exceeded one week. We therefore 
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assume that most of them were not able to duplicate their answers to the 
questionnaires by memory. The reproducibility of most health scales was 
satisfactory, although that of the role and social functioning scales was not as good. 
The underlying health concepts of these two scales harbour different aspects, which 
are covered in only two items and one item, respectively. Therefore, these scales 
may lack specificity. 
Because no gold standard for quality of life is available, the convergent validity 
of the health questionnaires was assessed by calculating correlation coefficients 
between the health scales. High correlations cannot be expected between various 
scales, because they address different dimensions of quality of life. No 
contradictory correlations were found between the health scales and all correlations 
were statistically significant. We therefore provisionally conclude that the health 
questionnaires used in this study render a valid representation of the quality of life 
in patients with hypertension on long-term medication. 
We conclude that the two health questionnaires together form a valid and 
reproducible instrument for measuring the quality of life in hypertension, which can 
be used to detect clinically relevant changes in quality of life caused by hypertension 
itself or by complications of therapy. 
References 
1. Bulpitt CJ, Dollery CT, Carne S. Change in symptoms of hypertensive patients after 
referral to hospital clinic. Br Heart]. 1976;38:121-8. 
2. Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Long-
term surveillance for adverse effects of antihypertensive drugs. JAMA. 
1985;253:3263-8. 
3. Medical Research Council Working Party on Mild-to-Moderate Hypertension. 
Adverse reactions to bendrofluazide and propranolol for the treatment of mild 
hypertension. Lzncet. 1981;2:539-43. 
4. Alderman MH, Lamport B. Labelling of hypertensives: a review of the data. J Cfin 
Epidemiol 1990;43:195-200. 
5. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients 
with chronic conditions. Results from the Medical Outcomes Study. JAMA. 
1989;262:907-13. 
6. Bulpitt CJ, Fletcher AE. Importance of well-being to hypertensive patients. Am J Med 
1988;84:S40-6. 
7. Turner RR Role of quality of life in hypertension therapy: implication for patient 
compliance. Cardiology. 1992;80:S11-22. 
8. Van Jaarsveld BC, I<rijnen P, Bartelink AKM, et al. The Dutch Renal Artery 
Stenosis Intervention Cooperative (DRASTIC) Study: rationale, design and 
inclusion data.] Hypertens. 1998;16:S21-7. 
9. Bulpitt CJ, Fletcher AE. The measurement of quality of life in hypertensive patients: a 
practical approach. Br J Cfin Pharmacal 1990;30:353-64. 
106 
V aliclity of quality of life measurements 
10. Fletcher A, Bulpitt C. Measuring quality of life in hypertension. In: Walker SR, Rosser 
RM, eds. Oualiry of life assessment: Kry issues in the 1990s. Dordrecht: Kluwer Academic 
Publishers, 1993;321-32. 
11. Stewart AL, Hays RD, Ware JE. The MOS Short-form General Health Survey. 
Reliability and validity in a patient population. Med Care. 1988;26:724-35. 
12. Fanshel S, Bush JW. A health status index and its application to health services 
outcome. Oper Res. 1970;18:1021-66. 
13. Kempen GIJM. Het meten van de gezondheidstoestand van ouderen. Een toepassing 
van een Nederlandse versie van de MOS-schaal. Tijdschr Gerontol Geriatr. 1992;23:132-
40. 
14. Kempen GIJM. The MOS Short-form General Health Survey: single item vs multiple 
measures ofhealth-related quality of life: some nuances. P.[YcholRep. 1992;70:608-10. 
15. Nunnally JC. P.[Ychometric theory. New York: McGraw Hill, 1978. 
16. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status 
measures. Statistics and strategies for evaluation. Control Clin Trials. 1991;12:142S-8S. 
17. Dunn G. Design and ana!Jsis of reliability studies. Oxford: Oxford University Press, 1989. 
18. Crocker L, Algina J. Introduction to classical and modem test theory. New York: Holt, 
Rinehart and Winston Inc., 1986. 
19. Fletcher AE, Bulpitt CJ. Measurement of quality of life in clinical trials of therapy. 
Cardiology. 1988;75:41-52. 
20. Bulpitt CJ, Dollery CT. Side-effects of hypotensive agents evaluated by a self-
administered questionnaire. BMJ. 1973;3:485-90. 
21. Monk M. Psychologic status and hypertension. Am J Epidemiol. 1980;112:200-8. 
107 

The effect of treatment on 
health-related quality of life in 
patients with hypertension and 
renal artery stenosis 
P Krijnen, BC vanJaarsveld, MGM Hunink,JDF Habbema 
Submitted for publication 
Chapter 8 
Abstract 
Background: The quality of life in patients with hypertension is considered to be 
impaired mainly by side effects of antihypertensive-drug therapy. Because balloon 
angioplasty for renal artery stenosis has a medication-sparing effect, it may lead to 
an improvement in quality of life. The objective of the study was to compare the 
effect of antihypertensive-drug therapy and balloon angioplasty on quality of life 
in patients with hypertension and renal artery stenosis. 
Methods: We compared the quality of life in 56 patients randomized to balloon 
angioplasty to that in 50 patients randomized to antihypertensive-drug therapy 
after 3 and 12 months of follow-up. Quality of life was measured using a 
questionnaire on physical symptoms associated with hypertension and 
antihypertensive drugs, and two generic health questionnaires (N[OS Survey and 
EuroQol instrument). 
Results: After follow-up, the patients who underwent angioplasty used less 
antihypertensive drugs than the patients who were treated with antihypertensive 
drugs only (mean ± SD, 2.5 ± 1.0 versus 1.9 ± 0.9 drugs after 3 months, 
P=0.002). They reported similar physical complaints, however, and a similar 
quality of life. The results after 12 months of follow-up were the same. 
Conclusion: For patients with hypertension and renal artery stenosis, the decrease 
in antihypertensive medication after intervention is too small to lead to a 
detectable improvement in quality of life. 
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Introduction 
Health-related quality of life is often studied as an outcome of clinical research.1 
Treatment of a clinical condition may improve the quality of life in patients, but it 
may also decrease the quality of life due to side effects or complications. 
Hypertension, especially in the mild to moderate stages, generally is an 
asymptomatic condition. Treatment of hypertension with antihypertensive drugs, 
however, can have side effects that impair quality of life.2.3 Physical complaints 
such as headache, dizziness, nausea, drowsiness, diarrhea, and impotence are 
commonly acknowledged side effects of antihypertensive drugs.4 Also, some of 
these drugs have been associated with psychological side effects, such as 
depression.z 
The objective of this study was to assess the effect of treatment on the 
quality of life in patients with hypertension and renal artery stenosis. We 
compared the quality of life in patients with atherosclerotic renal artery stenosis 
who were treated with or without balloon angioplasty. Angioplasty can lead to 
improvement or even cure of hypertension.5 As a consequence, patients who 
benefit by intervention may need less or even no antihypertensive drugs after the 
procedure, and may therefore be expected to experience an improvement in their 
quality of life. 
Patients and methods 
Patients 
We compared the quality of life in patients who participated in the therapeutic 
phase of the 'DRASTIC' study.6 In this phase of the study, which was described 
in detail in Chapter 5, 106 patients were included with drug-resistant hypertension 
( defmed as diastolic blood pressure of 9 5 mm Hg or more despite a standardized 
regimen of 2 antihypertensive drugs on three consecutive visits) and 
angiographically proven atherosclerotic renal artery stenosis of SO% or moreJ 
The patients were randomly allocated to balloon angioplasty (N=S6) or to 
increased antihypertensive-drug therapy (N=SO). 
Quality of life 
Quality of life was measured before randomization and after 3 and 12 months of 
follow-up, using three questionnaires. The first questionnaire was a questionnaire 
for recording physical symptoms associated with hypertension or antihypertensive 
treatment and the effect of treatment on lifestyle.8 The second questionnaire was a 
validated Dutch version of the 'MOS Short-form General Health Survey' (MOS 
Survey).9,10 This generic health questionnaire measures six dimensions of quality of 
life: physical functioning, role functioning, social functioning, psychological well-
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being, health perceptions, and pain. Scores on these scales range between 0 and 
100, with higher scores reflecting a better health. Dutch versions of these two 
questionnaires were validated in Chapter 7. The third questionnaire was a validated 
Dutch version of the 'EuroQol' instrument.11 This generic health questionnaire 
measures the ability to walk, the ability to perform daily activities, depression, 
anxiety, and pain on a 3-point scale. The scores on these aspects of quality of life 
are combined to describe general health status, which can be linked to a preference 
(utility) for the health status obtained from the general population.12,13 The utilities 
range between 0 (worst imaginable health status) and 100 (best imaginable health 
status). 
Data analysis 
We used regression analysis to compare the quality of life between the patients 
randomized to angioplasty or drug therapy after 3 and 12 months of follow-up. In 
the analyses, the scores at 3 or at 12 months were used as the dependent variable, 
and treatment group (angioplasty or medication) as the independent variable. 
Quality of life scores before randomization were entered as a covariate into the 
regression models to correct for baseline differences between the treatment groups. 
Comparisons over time within patient groups were tested with the paired Student's 
T-test. 
Results 
The treatment groups were comparable with regard to age and sex, and with 
regard to blood pressure and antihypertensive medication at the time of 
randomization (see Table 5.1, Chapter 5). After 3 months of follow-up, the 
treatment groups had similar blood pressure levels, but the patients in the drug-
therapy group used more antihypertensive drugs than the patients in the 
angioplasty group (mean ± SD, 2.5 ± 1.0 and 1.9 ± 0.9 drugs, respectively; 
P=0.002). According to the study protocol, 22 of the 50 patients in the drug-
therapy arm of the trial received angioplasty during the remaining follow-up 
period of another 9 months, either because of inadequate blood pressure control 
or because of a decline in renal function. At the end of the study, the blood 
pressure levels of the treatment groups were similar. The drug use in the drug-
therapy group was higher than in the angioplasty group (2.4 ± 0.9 and 1.9 ± 0.9 
drugs, respectively; P=0.002). 
The quality of life before randomization was comparable between the 
treatment groups (Table 8.1). After 3 months of follow-up, the number of 
physical complaints in the angioplasty group seemed to have decreased more than 
in the drug-therapy group, but the difference was not statistically significant 
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Table 8.1. Scores on the physical symptoms list, EuroQol index, and six scales of 
the MOS Survey for patients randomized to balloon angioplasty (N=56) and drug 
therapy (N=SO) measured before randomization ('TO') and changes in scores after 
3 and 12 months of follow-up ('T3-TO' and 'T12-TO', respectively). Higher scores 
reflect better health, except for physical symptoms. (Differences in) scores are 
expressed as mean±SD. Data on physical symptoms were complete. Data on 
quality of life scales were missing for 28% to 50% of the patients. 
Questionnaire Angioplasty group Drug-therapy group 
TO T3-TO T12-TO TO T3-TO T12-TO 
Physical symptoms 6.8±5.8 -3.4±6.8 -2.2±6.2 5.9±6.9 -1.1±6.9 -1.0±8.4 
MOS Survey 
Physical functioning 52±29 10±26 2±24 48±33 5±19 11±20 
Role functioning 57±49 17±53 21±49 56±48 21±35 17±49 
Social functioning 80±25 11±25 -2±26 73±34 0±22 13±33 
Psychological well-being 68±16 7±11 8±12 72±16 2±11 3±9 
Health perceptions 50±24 6±18 7±20 49±28 7±17 9±19 
Pain 69±35 8±31 6±37 60±37 10±17 7±27 
EuroQol index 
Overall well-being 80±16 9±15 6±13 80±19 8±11 7±14 
(P=0.09). After 12 months, the patients in both groups reported a similar number 
of physical complaints. For the generic questionnaires (EuroQol index and scales 
of the MOS Survey), the average scores after 3 and 12 months of follow-up were 
similar to the baseline measurement or had improved in both treatment groups 
(Table 8.1). No differences between the treatment groups in change in these 
quality of life scores after follow-up could be demonstrated after correction for 
the baseline scores (P>0.10), except for the MOS-social functioning scale. The 
difference in change in scores on the latter scale was borderline significant at both 
3 and 12 months (P=0.06), but at 3 months the angioplasty group had the better 
scores, and at 12 months the drug-therapy group. 
Discussion 
The quality of life in patients with hypertension is considered to be impaired 
mainly by side effects of antihypertensive drug treatment.2•3 We hypothesized to 
find an improvement in quality of life for patients with hypertension and renal 
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artery stenosis who were treated by percutaneous intervention (balloon 
angioplasty) compared to patients who received antihypertensive-drug therapy 
only, because the patients who were treated by angioplasty needed less or even no 
drug therapy after intervention (Chapter 5). The patients in the angioplasty group 
did seem to have less physical complaints after 3 months of follow-up, but the 
difference was too small to be confirmed statistically. We also expected but did 
not find an improvement of the generic health measures in the angioplasty group 
compared to the drug-therapy group. Apparently, the decrease in medication due 
to intervention, which amounted to less than 1 drug on average, was too small to 
lead to a meaningful and detectable improvement in the measures of quality of 
life that were used in our study. 
In a large community-based population, it was found that patients with 
hypertension who used less antihypertensive medication reported a better health 
status.14 Our data, however, did not confirm this finding. At baseline, the number 
of antihypertensive drugs was not statistically significantly associated with any of 
the quality of life scales, probably because there was little variation in the number 
of prescribed drugs. Although the patients in our study used up to 5 different 
antihypertensive drugs at the same time, the majority used 2 or 3 drugs (59% and 
24% of the patients, respectively). 
The comparison between the quality of life in the groups with and without 
percutaneous intervention after 3 months was straightforward. The comparison 
between the treatment groups after 12 months of follow-up, however, was 
complicated by the fact that after 3 months of follow-up nearly half of the 
patients in the drug-therapy group underwent angioplasty because of 
unsatisfactory blood pressure control or a decline of renal function. So, the 
comparison at 12 months was not one between patients with or without 
percutaneous intervention. The patients who were allocated to drug therapy but 
underwent angioplasty during follow-up, were clinically worse off at baseline with 
respect to blood pressure and medication use (Table 5.3, Chapter 5). These 
patients also seemed to be somewhat worse off with regard to the number of 
reported physical complaints and general health status, although this could not be 
confirmed statistically due to the small number of patients with non-missing data 
in each group (data not shown). 
Patients with hypertension have a lower appreciation for their general health 
than persons of the same age without hypertension_14 In a community-based 
population, the persons with hypertension valued their general health status as 83 
(95% confidence interval, 81-85) on a scale from 0 (lowest valuation) to 100 
(highest valuation).14 The average valuation of general health in our group of 
hypertensive patients as measured by the EuroQol index at baseline was 80 (95% 
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confidence interval, 76-84). This estimation must be appreciated as somewhat 
low, because we used valuations for the health states descriptions given by the 
general public, which are generally lower than those of the patients themselves. 
The improvement of the valuation of the general health status in our study group 
after follow-up was not statistically significant. We do not have a clear 
explanation for such an improvement other than that of a study effect. 
In conclusion, the medication sparing effect of intervention in patients with 
hypertension and renal artery stenosis is too small to lead to a meaningful 
improvement in quality of life for these patients. 
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Abstract 
Back.ground: The objective of the study was to compare the cost-effectiveness of 
various treatment strategies for patients with drug-resistant hypertension without 
severe renal failure, who have findings suggestive of significant renal artery 
stenosis on CTA or MRA. 
Methods: Clinical decision analysis was used to compare antihypertensive 
medication (reference strategy) to six strategies involving confirmation of renal 
artery stenosis by intra-arterial angiography and percutaneous intervention. 
Intervention for atherosclerotic renal artery stenosis consisted of percutaneous 
transluminal angioplasty (PTA) with or without selective stent placement, or 
primary stent placement. Our multi-state transition (Markov) model combined 
individual patient data and data from the literature to weigh short-term 
complications and cost of percutaneous intervention against long-term risks and 
cost of hypertension and renal insufficiency. The model simulated the quality-
adjusted life expectancy, lifetime costs and incremental cost-effectiveness ratios 
for 60-year-old men (base-case analysis). 
Results: In the base-case analysis, medication yielded the lowest effectiveness (9 .33 
QALYs) and highest cost (€107,200). Compared to medication, quality-adjusted 
life expectancy increased by 72 to 75 days if PTA was performed without stent 
placement, and by 108 to 112 days if selective or direct stent placement was 
performed. For some age groups, PTA with selective stent placement was the 
most effective and least costly strategy. For other age groups, it was more cost-
effective to treat with medication first and to perform intra-arterial procedures 
only if blood pressure control failed or renal function deteriorated. The 
differences in cost and effectiveness between these strategies were very small. 
The results were sensitive to variation in the risk of end-stage renal disease. 
Conclusions: For patients with drug-resistant hypertension and findings suggestive 
of renal artery stenosis on CTA or MRA, the cost-effectiveness of performing 
direct angiography and subsequent intervention is comparable with that of 
starting with medication first. If an intervention is performed, atherosclerotic 
stenosis should be treated with PTA followed by stent placement in the same 
session if the PTA procedure fails. 
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Introduction 
Renal artery stenosis is the most frequent cause of secondary hypertension and an 
increasingly important cause of end-stage renal disease.1 Patients are generally 
evaluated for the presence of renal artery stenosis if they have drug-resistant 
hypertension or progressive renal failure. The definite diagnosis is based on intra-
arterial angiography, which is a relatively costly imaging technique and has a risk 
of morbidity and mortality. Non-invasive imaging techniques such as computed 
tomography angiography (CTA) and magnetic resonance angiography (l\ffiA) are 
commonly used to select patients for intra-arterial angiography. According to a 
meta-analysis,2 the sensitivity and specificity of CTA and gadolinium-enhanced 
MRA for finding significant renal artery stenosis on intra-arterial angiography are 
more than 90%. 
Percutaneous transluminal angioplasty (PTA) with or without stent 
placement is an effective therapy for restoring renal artery patency.3 However, for 
the majority of patients with renal artery stenosis, namely those with stenosis 
caused by atherosclerosis,1 the optimal treatment strategy is still uncertain. In a 
meta-analysis of the results of the study described in Chapter 5 and two other 
randomized controlled trials comparing PTA to medical treatment,4,5 the benefit 
of PTA with respect to blood pressure control was small.6 In our study, there was 
some indication that PTA was beneficial for preserving renal function (Chapter 
5). Also, the advantage of additional stent placement is still unclear. In a 
randomized trial comparing stent placement to PTA, stent placement led to 
superior vessel patency but not to better blood pressure control or better 
preservation of renal function.7 In these randomized studies, long-term 
complications of hypertension and progressive renal failure were not measured 
and costs were not taken into account. 
Purpose of this study was to compare the cost-effectiveness of various 
treatment strategies for patients with drug-resistant hypertension without severe 
renal failure, who have findings suggestive of significant renal artery stenosis on 
CTAorMRA. 
Patients and methods 
A decision analytic model was developed to compare the costs, effectiveness and 
cost-effectiveness of seven treatment strategies for patients with drug-resistant 
hypertension (defined as diastolic blood pressure >95 mm Hg while using 2 
antihypertensive drugs) and findings suggestive of significant renal artery stenosis 
(>SO%) on CTA or MRA. Patients with severe renal failure (defined as a serum 
creatinine concentration >200 f!mol/L) were not considered for the analysis 
because their condition requires an intervention without delay.8 
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The model combined self-collected data and data from the literature on 
short-term and long-term risks, benefits, and costs to prec:lict quality-adjusted life 
expectancy, lifetime costs, and incremental cost-effectiveness (CE) ratios. For the 
sake of simplification, several assumptions were made (see below). The model 
was programmed in DATA Pro Treeage Release 7 (Treeage Software, Inc., 
Williamstown, MA). 
Model and modelling assumptions 
Treatment strategies 
In the reference strategy, all patients were treated with aggressive antihypertensive 
mec:lication without any form of revascularization (strategy Med). The other six 
strategies involved intra-arterial angiography followed, if a stenosis was present, 
by percutaneous intervention in the same session. Intervention for patients with 
stenosis due to fibromuscular dysplasia was always PTA without stent 
placement.9,10 Atherosclerotic stenoses were treated with PTA without stent 
placement (strategy PTA), PTA with stent placement only in case of elastic recoil 
immec:liately after dilation (strategy PTA-SelectiveStent) or direct stent placement 
(strategy Stent). In the other three strategies involving intervention, the initial 
therapy was antihypertensive mec:lication, and intra-arterial angiography and 
intervention were only performed if a clinical inc:lication for intervention was 
present (strategies Med-PTA, Med-PTA-SelectiveStent, and Med-Stent). The 
criteria for a clinical inc:lication for intervention were inadequate blood pressure 
control (defined as c:liastolic blood pressure >95 mm Hg using three drugs, or 
> 100 mm Hg using two drugs) or renal failure (defined as serum creatinine 
concentration > 150 1-1mol/L or an increase in serum creatinine concentration 
>20 flmol/L). 
After an intervention, patients received antihypertensive mec:lication if blood 
pressure control was inadequate. For every patient with renal artery stenosis, a 
maximum of two interventions were modelled. 
Model 
We developed a multistate transition (Markov) model to simulate patients who 
were followed over time and to estimate the prognosis resulting from each 
treatment strategy.11 Patients moved among a limited number of predefined 
health states, starting in one of three health states reflecting blood pressure level 
and renal function 3 months after intervention or antihypertensive mec:lication. 
'Clinical success' was defined as c:liastolic blood pressure <90 mm Hg and serum 
creatinine <150 1-1mol/L. 'Clinical improvement' was defined as c:liastolic blood 
pressure 90-110 mm Hg and serum creatinine <150 1-1mol/L. 'Clinical failure' was 
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defined as diastolic blood pressure > 110 mm Hg and/ or serum creatinine > 150 
f!mol/L. 
Patients were at risk for cardiovascular disease (stroke and myocardial 
infarction) and for end-stage renal disease, which was assumed to necessitate 
dialysis therapy for the remaining lifetime. After these events, the quality of life 
was reduced and the mortality risk was increased. Percutaneous intervention 
involved a procedure-related mortality risk, and a procedure-related risk of stroke, 
end-stage renal disease and other major complications. The benefits of 
percutaneous intervention involved better blood pressure control and better 
preserved renal function, which decreased the risk of cardiovascular disease and 
end-stage renal disease. 
Data sources and data assumptions 
In the model, the predictive value of a positive CTA or MRA in the group of 
patients with drug-resistant hypertension was 83%.2,12 In 80% of the patients with 
stenosis, atherosclerosis was the underlying cause.1,12 
Model estimates on treatment outcomes and costs were based on the data of 
two large prospective studies on diagnosis and treatment of renal artery stenosis 
in the Netherlands, the 'DRASTIC' study and the 'RADISH' study.13 Model 
estimates concerning percutaneous intervention, and risks of cardiovascular 
complications and end-stage renal disease were based on data from the literature. 
Key parameters are given in Table 9.1 (probabilities and rates) and in Table 9.2 
(utilities and costs). 
Intervention 
Technical failure of a procedure was assumed to occur if the stenosis could not 
be passed with the catheter or in case of elastic recoil when the vessel was dilated 
and no stent was placed. So, stent placement resulted in a higher technical success 
rate than PTA.14 If technically successful, however, the clinical outcomes after 
stent placement and after PTA were similarJ We assumed that a second 
procedure would not be attempted if a procedure failed technically. The nature 
and rate of complications of PTA and stent placement were the same_7,l4 Also, 
the risks and benefits of first and second interventions were assumed not to 
differ. 
Morbidity and mortality 
The risk of cardiovascular complications (stroke and myocardial infarction) and, 
for patients without a significant stenosis, the risk of end-stage renal disease were 
assumed to depend on the diastolic blood pressure level_lS,lG For patients with a 
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Table 9.1. Rates and probabilities. 
Variable 
Stenosis 
% In patients with drug-resistant hypertension 
Sensitivity ofMRA/CTA 
Specificity ofMRA/CTA 
% Stenosis due to fibromuscular dysplasia 
Intra-arterial angiography 
Mortality 
Chronic renal failure * 
Stroke 
Major complication (other than the above) t 
Intervention 
Mortality 
Chronic renal failure * 
Stroke 
Major complication (other than the above) t 
Technical success of 
PTA 
in patients with atherosclerotic stenosis 
in patients with fibromuscular dysplasia 
Stent placement 
Treatment results after medical therapy :1: 
Successful § 
Improved II 
Failed~ 
Indication for intervention** 
After 3 months 
After 12 months 
Treatment results after intervention :1: 
Successful § 
Improved II 
Failed~ 
Indication for intervention after 12 months ** 
Base case (Range) References 
0.20 (0.17-0.24) 12 
0.9 5 (0.80-1) 2 
0.95 (0.80-1) 2 
0.16 (0.09-0.23) 12 
0.0003 (0.0002-0.0004) 28 
0.0002 (0-0.0004) 29 
0.0012 (0.0003-0.0035) 30 
0.013 (0.004-0.030) 13 
O.Ql (0-0.02) 14 
0.003 (0.0003-0.01 07) 31 
0.0044 (0.0009-0.0129) 31 
0.088 (0.072-0.1 06) 32 
0.77 (0.68-0.86) 14 
0.94 (0.89-0.98) 33,34,35 
0.98 (0.95-1.0) 14 
0.10 (0.03-0.22) DRASTIC database 
0.66 (0.51-0.79) DRASTIC database 
0.24 (0.13-0.38) DRASTIC database 
0.61 (0.42-0.77) DRASTIC database 
0.70 (0.50-0.86) DRASTIC database 
0.18 (0.09-0.31) DRASTIC database 
0.66 (0.51-0. 78) DRASTIC database 
0.16 (0.08-0.28) DRASTIC database 
0.27 (0.13-0.46) DRASTIC database 
It was assumed that one third of the severe reactions to the use of contrast media reactions 
would result in chronic renal failure. 
Including branch renal artery injury (2.2%), main renal artery damage (2.4%), puncture site 
injury (2.3%), embolization (1.1 %), nephrectomy (0.3%), and other major complication 
(0.5%). 
For patients with atherosclerotic renal artery stenosis, after 3 months of follow-up. 
Diastolic blood pressure <90 mm Hg and serum creatinine <150 [.Lmol/L. 
Diastolic blood pressure 90-110 mm Hg and serum creatinine <150 flmol/L. 
~ Diastolic blood pressure > 110 mm Hg and/ or serum creatinine > 150 [.Lmol/L. 
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antihypertensive drugs or >100 mm Hg on 2 drugs) and/or failure of renal function (serum 
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Table 9.1 (continued). 
Variable 
Events 
Stroke (annual risk) 
Diastolic blood pressure <90 mm Hg 
Diastolic blood pressure 90-110 mm Hg 
Diastolic blood pressure > 110 mm Hg 
Myocardial infarction (annual risk) 
Diastolic blood pressure <90 mm Hg 
Diastolic blood pressure 90-110 mm Hg 
Diastolic blood pressure >110 mm Hg 
End-stage renal disease (annual risk) 
Diastolic blood pressure < 90 mm Hg 
Diastolic blood pressure 90-110 mm Hg 
Diastolic blood pressure > 110 mm Hg 
For stenosis patients, before intervention 
For stenosis patients, after intervention 
Base case (Range) 
0.0011 (0.0008-0.0015) 
0.0025 (0.0018-0.0034) 
0.0101 (0.0064-0.0150) 
0.0044 (0.0037-0.0051) 
0.0095 (0.0080-0.0112) 
0.0136 (0.0093-0.0192) 
0.00011 (0.00003-0.00028) 
0.00051 (0.00030-0.00082) 
0.00122 (0.00087-0.00166) 
0.027 (0.01 0-0.062) 
0.0016 (0.0003-0.0045) 
References 
15 
15 
15 
15 
15 
15 
16 
16 
16 
17 
36 
significant stenosis, the risk of end-stage renal disease was increased, especially if 
percutaneous intervention was not performed.17 The risk of cardiovascular 
complications and the associated mortality risks were increased after a previous 
cardiovascular event and in case of chronic dialysis therapy. If cardiovascular 
events and chronic renal failure did not occur, the mortality risk was equal to that 
of standard life tables of the Dutch general population according to age and sex. 
Quality of life 
The quality of life of the patients in the model was assumed not to depend on the 
type or the amount of antihypertensive medication (Chapter 8). Temporary 
quality of life adjustments were made to take into account the diminished quality 
of life as a result of undergoing an intra-arterial procedure, and during the first 
year after myocardial infarction. The quality of life was decreased permanently for 
patients on chronic dialysis therapy and after stroke. 
Costs 
Estimates for costs of percutaneous interventions and of medical treatment were 
based on detailed cost calculations performed in the RADISH study.13 Estimates 
for costs of complications of intervention and costs of long-term complications 
were based on the literature. Patients who suffered from major stroke, were 
assumed to be admitted into a nursing home for their remaining lifetime. Costs 
were expressed in 2000 Euros (€1 = US$1.20). 
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Table 9.2. Health related quality of life values and costs. 
Variable 
Quality of life 
Antihypertensive-drug therapy 
Duration of experienced discomfort (days) 
Intra-arterial angiography 
PTA (with or without stent placement) 
Disutility from invasive procedure during the 
days of experienced discomfort 
After myocardial infarction (for 1 year) 
After major stroke 
On dialysis therapy 
Costs (in 2000 Euros) 
Antihypertensive medication (annual cost) 
DBP<90mmHg 
DBP;::90mmHg 
Intra-arterial angiography* 
PTA t 
for fibromuscular dysplasia 
for atherosclerotic renal artery stenosis 
Stent placement t 
Complications of intra-arterial procedures 
Procedure-related mortality 
Other major complications t 
Treatment after stroke 
Treatment after myocardial infarction 
Start dialysis therapy 
Nursing home (annual cost) 
Dialysis therapy (annual cost) 
Including one night of hospital admission. 
Base case (Range) 
0.85 (0.80-0.90) 
0.94 (0-2) 
5.34 (1-10) 
0.56 (0.4-0.8) 
0.72 (0.6-0.8) 
0.37 (0.33-0.41) 
0.45 (0.43-0.56) 
3,487 (2,441-4,533) 
3,693 (2,585-4,801) 
1,359 (951-1,767) 
2,717 (1,902-3,532) 
2,762 (1,933-3,591) 
4,778 (3,345-6,211) 
2,416 (1,691-3,141) 
704 ( 493-915) 
11,281 (7,897-14,665) 
5,000 (3,500-6,500) 
7,686 (5,380-9,992) 
52,509 (36,756-68,262) 
62,020 (43,414-80,626) 
t Weighted average for unilateral and bilateral procedures. 
t Assumed to involve two extra days of hospitalization. 
Cost-effectiveness analysis 
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Effectiveness was measured as quality-adjusted life-years (QALY's).18 With regard 
to cost-effectiveness, the analysis took the perspective of the Dutch health care 
system and included hospital costs and physician costs for medical treatment, 
percutaneous intervention, and long-term complications (cardiovascular events, 
nursing home, end-stage renal disease, and dialysis therapy). Future years and 
costs were discounted at an annual rate of 3%.19 
A strategy was considered superior by dominance if it was more effective 
and cost-saving compared to another strategy.18 If a strategy was more effective 
but also more expensive than another strategy, the incremental CE ratio was 
calculated by dividing the additional cost of the strategy by its additional 
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effectiveness. In the Netherlands, the threshold incremental CE ratio is 
somewhere between €33,000/QALY (i.e., the incremental CE ratio for heart 
transplantation, which was considered acceptable)20 and €54,000/QALY (i.e. the 
incremental CE ratio for lung transplantation, which was not considered 
acceptable)21 . In this study, incremental CE ratios below €50,000/QALY were 
considered acceptable. 
In the base-case analysis, the remaining lifetime of a 60-year-old male patient 
was simulated 100,000 times (first-order Monte Carlo simulation). We also 
studied the effect of age and sex on the outcome of the model. Furthermore, the 
effect of the uncertainty in the key parameters (Tables 9.1 and 9.2) was explored 
by varying the estimates over plausible ranges in one-way and two-way sensitivity 
analyses. Plausible ranges for probabilities, rates and utilities consisted of 95% 
confidence intervals. Plausible ranges for costs were expressed as the base-case 
estimate plus or minus 30%. 
Results 
Base-case analysis 
The quality-adjusted life expectancy for the reference strategy cons1stmg of 
treatment with antihypertensive medication only (strategy Med) was 9.33 QALY's 
(Table 9.3). Compared to medication only, the strategies involving PTA without 
stent placement (strategies Med-PTA and PTA) increased the quality-adjusted life 
expectancy by 72 and 75 quality-adjusted days, respectively. The strategies 
involving stent placement (strategies Med-PTA-SelectiveStent, Med-Stent, PTA-
SelectiveStent, and Stent) increased the quality-adjusted life expectancy by 108 to 
112 quality-adjusted days. The lifetime costs of the strategies ranged from 
€100,200 for the strategy PTA-SelectiveStent to €107,200 for the medication only 
strategy (strategy Med). The strategy PTA-SelectiveStent was superior by 
dominance, which means that it had a larger (or equal) effectiveness and a lower 
cost than the other six strategies. The differences between the strategies involving 
stent placement, however, were small. 
Analysis for age and sex 
The outcome of the model was sensitive to variation in the patient's age. Varying 
age, the preferred strategy was either PTA-SelectiveStent or Med-PTA-
SelectiveStent, but the differences in both effectiveness and costs were very small 
(maximally 10 quality-adjusted days and less than €1000) for both male and 
female patients (Table 9.4). 
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Table 9.3. Cost (Euros), effectiveness (QALY's), and incremental CE ratios of 
treatment strategies for 60-year-old male patients with drug-resistant hypertension 
and fmdings suggestive of renal artery stenosis on MRA or CTA. 
Treatment strategy Cost Effectiveness Incremental 
(Euros) (QALY's) CE ratio 
Med 107,200 9.329 Dominated* 
Med-PTA 101,600 9.527 Dominated* 
PTA 102,100 9.534 Dominated* 
Med-Stent 102,200 9.626 Dominated* 
Med-PTA-SelectiveStent 100,300 9.626 Dominated* 
Stent 102,200 9.636 Dominated* 
PTA -SelectiveStent 100,200 9.636 
* More expensive and less effective than another treatment strategy. 
Sensitivity analyses 
The strategy PTA-SelectiveStent remained superior by dominance when we 
varied most of the key parameters in the model (Tables 9.1 and 9.2) across their 
plausible ranges, or had an incremental CE ratio of less than €15,000/QALY 
compared to strategy Med-PTA-SelectiveStent. The model outcome was 
sensitive, however, to changes in the risk of end-stage renal disease for patients 
with stenosis before intervention. Med-PTA-SelectiveStent was more cost-
effective than PTA-SelectiveStent if the annual risk of end-stage renal disease was 
2% or lower. The differences between the two strategies were small, however, for 
all plausible values, both with regard to effectiveness (difference maximally 10 
quality-adjusted days) and lifetime costs (difference less than €1000). We found 
similar results when both the risks of end-stage renal disease before and after 
intervention were varied simultaneously in a two-way sensitivity analysis. 
Discussion 
On the basis of the best estimates for the model parameters, the most cost-
effective treatment strategy for our base-case, a 60-year-old male patient with 
findings suggestive of significant renal artery stenosis on CTA or MRA, was to 
perform intra-arterial angiography and, if the presence of a stenosis was 
confirmed, to perform a percutaneous intervention in the same session. Our 
results suggested that patients with atherosclerotic renal artery stenosis should 
preferably receive a stent only if PTA fails. For other age groups, however, it was 
more cost-effective to start with antihypertensive medication, and to perform the 
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Table 9.4. Cost (Euros) and effectiveness (QALY's) for the treatment strategies 
PTA-SelectiveStent and Med-PTA-SelectiveStent and the difference in cost 
(Euros) and effectiveness (quality-adjusted days) between the two strategies, for 
male and female patients of different ages. 
Males PTA-SelectiveStent Med-PTA -SelectiveStent Difference in * 
Age Cost Effectiveness Cost Effectiveness Cost Effectiveness 
(Euros) (QALY's) (Euros) (QALY's) (Euros) (days) t 
40 142,900 13.507 142,700 13.521 +200 -5 
50 125,300 11.890 125,200 11.902 +100 -4 
60 100,200 9.636 100,300 9.626 -100 +4 
70 70,700 6.946 70,400 6.954 +300 -2 
80 41,900 4.352 42,700 4.352 -800 0 
Females PTA -SelectiveStent Med-PTA-SelectiveStent Difference in * 
Age Cost Effectiveness Cost Effectiveness Cost Effectiveness 
(Euros) (QALY's) (Euros) (QALY's) (Euros) (days) t 
40 149,700 14.143 149,800 14.114 -100 +10 
50 135,600 12.898 135,400 12.900 +200 0 
60 115,200 11.044 115,500 11.073 -300 -10 
70 87,800 8.513 87,000 8.514 +800 0 
80 53,000 5.441 52,800 5.448 +200 -2 
Strategy PTA-SelectiveStent compared to strategy Med-PTA-SelectiveStent. 
t Adjusted for quality of life. 
intra-arterial procedure only if blood pressure was inadequately controlled or if 
renal function deteriorated. The discrepancies in the outcomes of the model 
between age groups were probably due to the fact that the differences in both 
cost and effectiveness between these strategies were very small. 
We studied whether the outcome of the model was sensitive to the 
uncertainty in the key parameters in our model. As in the base-case analysis, the 
treatment strategy of direct intervention with selective stent placement was the 
most effective and least expensive strategy in most of the sensitivity analyses, or 
had an incremental CE ratio well within the ranges of what society generally is 
willing to pay. For low values of the risk of end-stage renal disease, however, it 
was more cost-effective to start with antihypertensive medication, but again the 
differences in costs and effectiveness were very small. 
127 
Chapter 9 
A limitation of our analysis was that the treatment strategies were not 
modeled separately for patients with unilateral disease and patients with bilateral 
disease for lack of data on model parameters for these subgroups. Ideally, this 
distinction is made because the risk of progressive renal failure seems to be 
determined primarily by the presence of unilateral or bilateral stenosis.22 As found 
in our trial (Chapter 6) and in other studies,8 patients with bilateral stenosis are at 
risk for rapid deterioration of renal function and should receive invasive 
treatment without delay, even if their renal function is not impaired as yet. These 
observations are consistent with our results. In the base-case analysis, the optimal 
strategy was to perform an intervention in all patients with a stenosis. This result 
was sensitive, however, to uncertainty in the risk of end-stage renal disease before 
intervention. If the value for the risk of end-stage renal disease was low, which is 
probably the case for patients with unilateral stenosis, the optimal strategy was to 
treat medically first, and to perform an intervention only in patients with 
inadequate blood pressure control or progressive renal failure. 
Several assumptions were made in our analysis. The most important one was 
that we assumed that stent placement has a higher technical success rate 
compared to PTA alone but that, if technically successful, these procedures lead 
to similar clinical outcomes. It is well-established that stent placement is superior 
to PTA with respect to immediate vessel patency and, to a lesser extent, 
prevention of late restenosis.14,23 Nevertheless, stent placement does not seem to 
improve the short-term clinical outcomes compared to PTAJ Also, the relation 
between vessel patency and clinical outcomes after intervention in the short-term 
has not been established.24 In the long-term, however, stent placement may 
preserve renal function better than PTA due to a lower rate of restenosis, but 
data to support this theory are not available. Although our analysis was 
conservative with respect to the benefit of stent placement, the treatment 
strategies involving stent placement were more effective than the strategies 
involving PTA only. In our model, stent placement increased the effectiveness by 
more than one month compared to PTA. If, in fact, stent placement is not only 
superior to PTA with respect to the technical success rate but also with respect to 
the prevention of end-stage renal disease in the long-term, the preference for 
stent placement over PTA is strengthened. 
Another consequence of our assumption on the limited benefit of stent 
placement was that the strategies involving direct stent placement (e.g., strategy 
Stent) differed from the strategies involving selective stent placement (e.g., 
strategy PTA-SelectiveStent) only with respect to costs but not with respect to 
effectiveness. The additional cost of stent placement for every patient with a 
stenosis amounted to €2000 for direct stent placement compared to selective 
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stent placement. If our assumption does not hold and stent placement not only 
improves the technical success rate but also the long-term clinical outcomes of 
technically successful procedures, then direct stent placement in all patients with 
renal artery stenosis could be the most cost-effective strategy. 
In hypertensive patients with atherosclerotic renal artery stenosis, the benefit 
of PTA on blood pressure control is disappointing.6 Moreover, intra-arterial 
procedures carry a risk of serious complications.14-25 For this reason, we included 
three treatment strategies in our model in which intra-arterial procedures were 
not performed in every patient, but only if a clinical indication for intervention 
was present. A clinical indication was assumed to be present if the blood pressure 
was inadequately controlled or if the renal function was severely impaired or had 
deteriorated. Compared with these strategies, the benefit of the strategies 
involving intra-arterial procedures in all the patients was small. For instance, 
immediate stent placement was only 4 quality-adjusted days more effective and 
€30 less expensive compared with initial medical therapy. 
At present, there is no standard approach for the treatment of hypertensive 
patients with atherosclerotic renal artery stenosis. Whereas some clinicians feel 
that every stenosis should be treated,26 the wait-and-see approach has also been 
advocated for certain patient groups.23,27 Our analysis indicates that for patients 
with drug-resistant hypertension and fmdings suggestive of significant renal artery 
stenosis on CTA or MRA, the cost-effectiveness of direct angiography and 
intervention is comparable to that of treating medically first and performing an 
intra-arterial procedure only if blood pressure control fails or renal function 
deteriorates. If an intervention is performed, atherosclerotic renal artery stenosis 
should be treated with PTA followed by stent placement in the same session if 
the PTA procedure fails. 
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General discussion 
Chapter 10 
The aim of the studies in this thesis was to contribute to the optimization of 
diagnosis and treatment of renal artery stenosis. The research questions on 
diagnosis were: 
What is the interobserver ~crreement of captopril renography for the 
detection of renal artery stenosis? 
What is the value of clinical characteristics for predicting the probability of 
renal artery stenosis in patients suspected of this condition? 
The research questions concerning treatment were: 
Are the clinical outcomes for patients with hypertension and atherosclerotic 
renal artery stenosis after balloon angioplasty better than those after drug 
therapy? 
What is the cost-effectiveness of different treatment strategies for patients 
with hypertension and atherosclerotic renal artery stenosis? 
In this chapter, the findings of the studies are summarized and discussed. Then, 
the state of the art is presented. Finally, conclusions are drawn and 
recommendations for further research are given. 
Study findings 
Diagnosis of renal artery stenosis 
Renography 
At the begin of our studies in the early 1990's, intra-arterial digital subtraction 
angiography was commonly used as reference standard to determine presence of 
renal artery stenosis. Renography was used as a screening test to select patients 
for angiography. The diagnostic accuracy of renography was variably described 
between studies, however, with sensitivity ranging between 70% and 100%, and 
specificity ranging between 60% and 100%.1-4 In Chapter 2 of this thesis, 
interobserver agreement in the judgment of renographic parameters was studied 
in 658 renograms obtained with the use of 99mTc-mercaptoacetyltriglycine (99mTc-
MAG3) after challenge with captopril to examine whether this was a possible 
explanation for variation in the diagnostic accuracy. We found considerable 
variation between observers in their judgment of the renographic parameters. 
Some parameters could be assessed reliably with high agreement, e.g. the pattern 
of the time-activity curves, but others could not, e.g. cortical retention. The 
overall judgment on presence of renal artery stenosis was reliable, but the 
interpretation of the reno grams was difficult when pelvic retention was suspected 
and when bilateral stenosis was present. 
We conclude from these findings that there is considerable interobserver 
variability in the judgment of captopril renography. The interobserver variability 
in clinical practice is probably larger than what we found, because the three 
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observers in our study had a broad experience and discussed their scoring 
method beforehand. Also, the renograms in our study were made in a research 
setting, which makes it more likely that the patient preparation and renographic 
procedure were performed in a more careful and standardized manner than in a 
routine hospital setting.s The interobserver variability in the judgment of 
captopril renography may have contributed to the variation in diagnostic accuracy 
of renography for finding renal artery stenosis. 
Other causes for tbis variation in diagnostic accuracy of renography have 
been proposed as well. These refer to the differences between studies regarding 
patient selection, choice of radiopharmaceutical, the way renography is performed 
(with or without captopril challenge, or in a two-step procedure), diagnostic 
criteria, and choice of reference standard (angiography or clinical response to 
successful intervention).4-8 We can comment on two of these other causes for 
variation in diagnostic accuracy on the basis of our research. With regard to 
diagnostic criteria, we studied the value of the separate renographic parameters 
for predicting presence of renal artery stenosis on angiography. As described in 
Chapter 2, the relative importance of the renographic parameters for predicting 
presence of stenosis was virtually the same for the three nuclear medicine 
physicians in our study. Beside the judgment of the separate renographic 
parameters, the physicians also gave their overall judgment on presence or 
absence of stenosis. Although no specific diagnostic criteria were defined for tbis 
assessment, the sensitivity and specificity of the overall judgment was comparable 
between the three physicians (65-70% and 84-94%, respectively, for fmding renal 
artery stenosis of 80% or more on angiography). In a logistic regression model, 
the separate renographic parameters had no additional value in predicting 
presence of stenosis when the overall judgment was already taken into account 
(unpublished data). Apparently, the physicians had integrated the available 
information on the renographic parameters to form their overall judgment. From 
tbis we may conclude that the use of prespecified diagnostic criteria does not 
necessarily diminish the variation in diagnostic accuracy. 
It has been argued that the usefulness of renography is underestimated if 
angiography is used as reference. After all, on the basis of the angiographic 
images no distinction can be made between stenoses that are responsive to 
successful intervention and those that are not.8-9 For tbis reason, it has been 
proposed that renography should be used not to select hypertensive patients for 
angiography, but to select hypertensive patients with anatomically proven stenosis 
for intervention.s In our treatment trial, which was described in Chapter 5, 
however, we did not find evidence that the response to intervention can be 
predicted on the basis of renography. Blood pressure levels after angioplasty were 
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the same for patients with an abnormal and with a normal renogram before 
treatment.10 
We believe that renography is not a useful screening test to select patients 
with hypertension for further dia_,anostic workup or for decisions on treatment, 
because the diagnostic accuracy is disappointing. In addition, the test is complex 
with regard to both the procedure and the interpretation, is costly, and is difficult 
to standardize. 
Prediction rule 
In Chapter 3 of this thesis, a prediction rule for renal artery stenosis was 
introduced. After a literature study, we selected nine clinical characteristics 
indicative of renal artery stenosis, which were included as predictors in a 
multivariable logistic regression model to predict the probability of stenosis. To 
facilitate the use of the model in clinical practice, a prediction rule was 
constructed. In the prediction rule, each clinical characteristic is assigned a score. 
These scores can be added into a sum score that, through the logistic formula, 
corresponds with a predicted probability of stenosis. The predicted probabilities 
and their 95% confidence intervals can also be read from a graph. The prediction 
rule was reliable and discriminated well between patients with and without 
stenosis (area under the ROC curve, 0.84). The rule can support the selection of 
patients for renal angiography. For example, if angiography had performed only 
in patients whose predicted probability of stenosis was 10% or more, the number 
of patients undergoing angiography would have been reduced to 61%. However, 
1 of every 10 stenoses would have been missed (sensitivity, 90%). If a cutofflevel 
of 30% was chosen, the sensitivity and specificity were comparable to those of 
renography (68% and 87%, respectively). 
A limitation of the prediction rule was that it did not discriminate well 
between patients without stenosis and patients with stenosis due to fibromuscular 
dysplasia. Atherosclerotic renal artery stenosis and fibromuscular dysplasia share 
some risk factors such as presence of an abdominal bruit and a short duration of 
the hypertension. In addition, atherosclerotic renal artery stenosis has several 
other distinct risk factors such as vascular disease and smoking. Additional risk 
factors for fibromuscular dysplasia, on the other hand, are limited to sex and 
age.11-13 Patients with fibromuscular dysplasia are therefore identified less easily. 
However, if a conservative cutoff level for the predicted probability of stenosis 
(5%) was chosen above which patients would have been referred for angiography, 
every patient with fibromuscular dysplasia in our study would have been 
identified. Even so, further diagnostic workup should be performed in young 
female patients with drug-resistant hypertension even if the prediction rule 
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predicts a low probability of stenosis, particularly because fibromuscular dysplasia 
is amenable to angioplasty. 
Some risk factors for stenosis were not included in the prediction rule. For 
instance, race was dropped from the multivariable regression model. This was 
done for statistical reasons, because the study population consisted mainly of 
Caucasian patients. Renovascular hypertension is known to be rare in black 
hypertensive patients.14 In our study population, black ethnicity was indeed 
associated with a low risk of stenosis (univariable odds ratio, 0.1). Physicians 
should take this into consideration when they consider performing angiography 
in black patients with hypertension even if the prediction rule predicts a high 
probability of stenosis. 
The predictions of the rule were valid for the patients that were used for its 
development ('apparent validity'). The predicted probabilities agreed well with the 
observed probabilities (goodness-of-fit test, P=0.79) and the rule discriminated 
well between patients with stenosis and those without stenosis (area under the 
ROC curve, 0.84). Most of the patients (422/460) were selected for the 
development sample because they had drug-resistant hypertension. The 
remaining 38 patients were included because their serum creatinine concentration 
increased during ACE-inhibitor therapy. Renal function impairment on ACE-
inhibitor therapy is a strong risk factor for renal artery stenosis in hypertensive 
patients.15 This was reflected by the fact that the predicted probabilities of 
stenosis for patients with this characteristic were higher than for the patients with 
drug-resistant hypertension (mean ± SD, 45% ± 34% and 21% ± 20%, 
respectively). Therefore, a rise in creatinine concentration during ACE inhibitor 
therapy in patients with hypertension may justify immediate referral to renal 
angiography.10 It might have been more appropriate to develop the prediction 
rule only for patients with drug-resistant hypertension. The development sample 
consisted mainly of patients with drug-resistant hypertension, however. 
Therefore, the prediction rule was also valid for this subgroup. As expected, the 
predicted probabilities agreed well with the observed probabilities (goodness-of-
fit test, P=0.99), and the discriminative value of the prediction rule was only 
slightly lower than in the entire study population (area under the ROC curve, 
0.82). 
We internally validated the prediction rule by bootstrapping techniques to 
assess the validity of the prediction rule in similar patients. Bootstrap samples 
were drawn from the original sample with replacement. The model development 
procedure (selection of predictors, estimation of logistic regression coefficients) 
was followed in each bootstrap sample. The resulting logistic regression models 
were tested in the original sample. This test indicates the expected optimism in 
137 
Chapter 10 
Table 10.1. Summary of the results on the discriminative ability of the prediction 
rule in de development sample and in the validation sample. 
Predicted probability of stenosis in patients, mean ± SD: 
without renal artery stenosis (n) 
with renal artery stenosis (n) 
with atherosclerotic stenosis (% of n with stenosis) 
with fibromuscular dysplasia (% of n with stenosis) 
Area under the ROC curve (95% confidence interval) 
Development 
Sample (N=460) 
15 ± 16 (354) 
49 ± 29 (106) 
52± 29 (84) 
34 ± 26 (16) 
0.84 (0.79-0.89) 
Validation 
Sample (N=180) 
13 ± 13 (145) 
26 ± 20 (35) 
32 ± 22 (63) 
14 ± 10 (37) 
0.71 (0.61-0.81) 
performance when the original model is applied in patients similar to those in the 
development sample. 
We also validated the rule in separate participating hospitals. The 
discriminative ability of the prediction rule for most hospitals was similar to that 
of the entire development sample, although some had only a small number of 
patients. 
Finally, we studied the validity of the prediction rule in 180 patients who 
were treated recently in other hospitals. This study was described in Chapter 4. 
The predictions of the rule in this validation sample were reliable (goodness-of-fit 
test, P=0.87), but the discriminative ability was disappointing (area under the 
ROC curve, 0.71; Table 10.1). This was partly to be expected, because prediction 
rules often do not perform as good as in patients of other settings.16 In the case 
of our prediction rule, however, there are several reasons that may have 
contributed to the disappointing discriminative ability. First, the definitions of 
vascular disease and smoking differed between the development sample and the 
validation sample. Second, we verified from the medical records of the patients 
from one hospital that abdominal bruits were underreported in the validation 
sample. This meant that the prevalence of some risk factors was underestimated 
in the validation study, which lowered the discriminative ability of the prediction 
rule. Third, the proportion of patients with stenosis due to fibromuscular 
dysplasia was unusually high in the validation sample (i.e., over twice as high as 
expected).J7 Since the predictions were lower for these patients than for the 
patients with atherosclerotic stenosis (Table 10.1), the overrepresentation of these 
patients in the validation sample decreased the discriminative ability of the 
prediction rule. 
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In our attempt to develop a valid prediction rule for renal artery stenosis, we 
have complied with accepted methodological standards for constructing such a 
tool as best we could.18 Furthermore, we validated the rule internally and 
externally.19 A limitation of our external validation, however, was that the 
validation sample was relatively small. This is a common problem in validation 
studies.zo Further studies are therefore required for more flrm conclusions on the 
validity and usefulness of the prediction rule. Until its validity is demonstrated 
more convincingly, the rule should be used with a conservative cutoff value and 
can reliably exclude a only small proportion of patients from angiography. 
Treatment of renal artery stenosis 
Balloon angioplasty versus drug therapy 
The Chapters 5 through 8 of the thesis described the flndings of a randomized 
controlled trial comparing clinical outcomes of 106 patients with atherosclerotic 
renal artery stenosis of 50% or more on angiography, who were randomly 
allocated to balloon angioplasty (N=56) or drug therapy (N=SO). Inclusion 
criteria were hypertension resistant to a standardized regimen of two 
antihypertensive drugs or a rise in serum creatinine during treatment with an 
ACE inhibitor. All patients had a normal or mildly impaired renal function. The 
outcome measures of the trial were blood pressure (primary outcome), 
antihypertensive medication, and renal function (Chapters 5 and 6), and quality of 
life (Chapters 7 and 8). The outcomes were evaluated after 3 and 12 months of 
follow-up. To comply with the concern that untreated renal artery stenosis may 
lead to irreversible renal failure, the design of the trial was pragmatic. The study 
protocol allowed that the patients who were allocated to medication, could 
receive angioplasty after 3 months if the blood pressure control was inadequate 
or if the renal function deteriorated. 
Effect on blood pressure 
Blood pressure levels in the balloon angioplasty group after 3 months were not 
significantly lower than in the drug-therapy group (Chapter 5): 169 ± 28/99 ± 12 
and 17 6 ± 31/101 ± 14, respectively (P=0.25 for systolic blood pressure and 
P=0.36 for diastolic blood pressure). The patients in the angioplasty group used 
less antihypertensive medication. The blood pressure lowering capacity of 
angioplasty was that of approximately 1 deflned daily dose of medication, which 
corresponds with the daily average maintenance dose of one drug.21 Although the 
blood pressure levels at baseline did not differ between the treatment groups, it 
would have been more proper to adjust for the baseline values in the analysis.22 
When we corrected for the blood pressure levels at baseline, the differences 
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between the treatment groups after 3 months again were not statistically 
significant (P=0.14 for systolic blood pressure and P=0.09 for diastolic blood 
pressure). 
The power of our study to detect a small benefit of angioplasty was low 
because of the relatively small sample size. After publication of the findings, the 
results after 3 months in the DRASTIC trial were combined with the data of two 
smaller randomized trials23,24 in two separate meta-analyses.25,ZG These other trials 
compared blood pressure and renal function after 6 months of follow-up in 55 
and 49 patients with hypertension and atherosclerotic renal artery stenosis, who 
were allocated to drug therapy or to angioplasty (in one trial with or without stent 
placement). Both meta-analyses showed a modest but statistically significant 
positive effect of angioplasty on blood pressure. Compared to the drug-therapy 
group, the average reduction in blood pressure in the angioplasty group was 6.3 
mrn Hg (95% confidence interval, 0.8-11.7 mrn Hg) larger for systolic blood 
pressure, and 3.3 mrn Hg (95% confidence interval, 0.4-6.2 mrn Hg) for diastolic 
blood pressure.zs So, the short-term advantage of balloon angioplasty with respect 
to blood pressure control in patients with hypertension and atherosclerotic renal 
artery stenosis is small at most. It is questionable, however, whether the actual 
effect of angioplasty on blood pressure is clinically relevant, and not yet known 
whether the effect is sustained over a longer period of time. 
In our trial, we were not able to evaluate the effect of drug therapy in the 
long term because the study protocol allowed angioplasty to be performed in the 
medication group after 3 months. Of the 50 patients assigned to drug therapy, 22 
underwent angioplasty during follow-up because of persistent hypertension or 
loss of renal function. The comparison between the angioplasty group and drug-
therapy group after 12 months was in fact a comparison between the treatment 
strategies of immediate angioplasty and of initial drug therapy followed by 
angioplasty if necessary. After 12 months, the blood pressure levels did not differ 
between the treatment strategies. This was also the case after correction for the 
blood pressure levels at baseline (P=0.51 for systolic blood pressure and P=0.06 
for diastolic blood pressure). The medication-sparing effect of angioplasty was 
less evident after 12 months. With respect to blood pressure control in the long 
term, our results argue in favor of the more conservative treatment strategy of 
aggressive drug treatment and proceeding to angioplasty only if hypertension 
persists or renal function declines. 
Renal artery stenosis is considered to be hemodynamically significant when 
the degree of stenosis is at least 60%27,28 or 70%.1,8 The disappointing effect of 
angioplasty on blood pressure cannot be explained, however, by the fact that we 
had also included patients with stenosis between 50% and 70%. In our 
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angioplasty group, blood pressure control was not associated with severity of 
stenosis at baseline. This finding was supported by the fact that blood pressure 
control after angioplasty was similar for the patients with an abnormal renogram 
and the patients with a normal renogram at baseline. Another possible 
explanation for the disappointing effect of angioplasty on blood pressure control 
was that restenosis had occurred in nearly half of the patients who underwent 
angioplasty. One could argue that additional stent placement in the angioplasty 
group would have improved the blood pressure response to intervention, because 
stent insertion has been shown to improve vessel patency.29 This argument does 
not seem to apply, however, because restenosis was not associated with the blood 
pressure response after 12 months. These data were referred to in Chapter 5, but 
were presented in detail in another publication.10 The absence of an association 
between vessel patency and blood pressure response was also found in another 
Dutch study comparing angioplasty with and without stent placement.29 
In Chapter 6, we evaluated the possible benefit of immediate angioplasty as 
opposed to performing angioplasty only in case of inadequate blood pressure 
control or deterioration of renal function in five subgroups of patients. These 
subgroups concerned patients with a supposedly good response to intervention 
(patients with a positive captopril-renin challenge test, an abnormal captopril 
renogram, and recently developed hypertension), and patients with a supposed 
risk for rapid disease progression (patients with bilateral stenosis, and severe 
stenosis). As a rule, secondary analyses for subgroup effects should be interpreted 
with caution, because these analyses are usually not included beforehand in the 
study design and lack statistical power.30,31 For this reason, we restricted the 
number of subgroups before the analysis. The choice of subgroups for analysis 
was dictated by the assumed benefit of angioplasty in the specific patient groups. 
Indeed, a lack of power to detect small but relevant differences between the 
treatment strategies within the subgroups was a major limitation of our subgroup 
analysis. The patients with bilateral stenosis seemed to benefit from immediate 
angioplasty in terms of diastolic blood pressure compared to the patients with 
unilateral stenosis, but the difference in blood pressure change was not 
statistically significant. 
Effect on renal function 
Balloon angioplasty is considered useful for preserving and even re-establishing 
renal function in patients with renal artery stenosis.32-36 However, there is a lack 
of randomized studies comparing renal function of patients treated with or 
without angioplasty. Although the DRASTIC study was designed to evaluate the 
effect of treatment on blood pressure, we also compared the patients randomized 
141 
Chapter 10 
for angioplasty and for drug therapy with respect to the serum creatinine levels 
and the creatinine clearance as rough indicators for the glomerular filtration rate 
(Chapter 5). Both the serum creatinine level and creatinine clearance were better 
in the angioplasty group after 3 months. The benefit remained present after 
correction for the baseline values (unpublished data). After 12 months, when 
nearly half of the drug-therapy group had received angioplasty, the renal function 
in the two groups was similar. These findings seem to confirm that angioplasty 
may be useful to preserve renal function. It is still unknown, however, whether 
this effect might be sustained in the long term. 
In the subgroup analysis described in Chapter 6, the patients with bilateral 
stenosis who received immediate angioplasty had an evident benefit compared to 
similar patients who were assigned to initial drug therapy. The creatinine 
clearance had improved substantially after 12 months in the first group (+10.0 ± 
15.7 mL/min), whereas it had decreased somewhat in the latter group (-4.2 ± 
13.5 mL/min; P=0.03). For patients with unilateral stenosis, the change in 
creatinine clearance did not differ between the treatment strategies. The 
difference in treatment effect was statistically significant between the patients 
with bilateral stenosis and those with unilateral stenosis (test for interaction,31 
P=0.007). Our results justify that intervention is not delayed in patients with 
bilateral stenosis even if the renal function is not severely compromised as yet. 
"Whether this effect is real and can be maintained in the long term, however, is 
unknownY Stent placement may be helpful in this respect, although the benefit 
of stent placement over angioplasty was not established in a randomized 
comparison. 29 
Effect on quality of life 
In Chapter 7, we studied the reproducibility and validity of a Dutch version of a 
questionnaire measuring quality of life in patients with hypertension38 and of a 
generic quality of life questionnaire (the MOS Short-form General Health 
Survey)39 in patients with hypertension on stable medication. The reproducibility 
and validity of the questionnaires were considered satisfactory. In Chapter 8, we 
compared the angioplasty group and the drug-therapy group in our study 
regarding physical symptoms associated with hypertension or antihypertensive 
treatment and more general dimensions of quality of life. Because quality of life in 
patients with hypertension is considered to be impaired mainly by side effects of 
antihypertensive-drug therapy and because angioplasty has a medication-sparing 
effect, we expected to find that the patients in the angioplasty group experienced 
a better quality of life after follow-up. This was, however, not the case. The 
difference in medication between the treatment groups (1.9 ± 0.9 drugs in the 
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angioplasty group and 2.5 ± 1.0 drugs in the drug-therapy group) was too small 
to lead to a difference in the number of physical complaints let alone to a 
difference in scores on the more general dimensions of quality of life. In fact, we 
did not find an association between the number of antihypertensive drugs and any 
of the quality of life measures in the study. This was probably due to the fact that 
the medication in the study group was modified in case of serious side effects. 
From these results it is apparent that quality of life considerations do not justify the 
choice of angioplasty over drug therapy. 
Cost-effectiveness of treatment strategies for renal artery stenosis 
In the Chapters 5 through 8, we studied the effect of angioplasty on blood 
pressure and renal function in patients with drug-resistant hypertension and 
atherosclerotic renal artery stenosis up to one year. In Chapter 9, we also wanted 
to take the long-term effects of treatment and costs into account to study the 
optimal treatment strategy for these patients. There is considerable uncertainty 
regarding the long-term effects of intervention, however, because the data are 
scarce and come from non-randomized studies and different patient populations. 
The cost of treatment has been estimated only in the short term.4° Furthermore, 
we wanted to study stent placement as a treatment option for renal artery 
stenosis. 
In Chapter 9, we combined patient data from our own study and data from 
the literature in a decision analytic model to weigh short-term complications and 
cost of percutaneous intervention against long-term risks and cost of 
hypertension and renal insufficiency.41 To make the strategies compatible with 
current clinical practice, the model included patients who had drug-resistant 
hypertension and findings of renal artery stenosis on computed tomography 
angiography (CTA) or magnetic resonance angiography (MRA). The model 
simulated the quality-adjusted life expectancy, lifetime costs and incremental cost-
effectiveness ratios for a large cohort of patients. It compared treatment strategies 
involving percutaneous intervention (balloon angioplasty and direct or selective 
stent placement) to a reference strategy of antihypertensive medication only. The 
strategies involving intervention differed for the patients with atherosclerotic 
renal artery stenosis. Treatment for patients with fibromuscular dysplasia was 
always balloon angioplasty.42 
Medication only yielded the lowest effectiveness (9.33 QALYs) and the 
highest cost (€107,200). Angioplasty increased the effectiveness by about 75 days, 
and direct or selective stent placement increased the effectiveness by about 110 
days. The lifetime costs of the treatment strategies involving intervention did not 
differ much (between €100.200 and €102.200). For some age groups, angioplasty 
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with selective stent placement was the most effective and least costly strategy. For 
other age groups, it was more cost-effective to treat with medication first and to 
perform intra-arterial procedures only if blood pressure control failed or renal 
function deteriorated. The differences in cost and effectiveness between these 
two strategies were very smalL 
Decision analytic models have several limitations. First, these models make 
simplifying assumptions in order to keep the model tractable. In our model, for 
instance, the effects of treatment on blood pressure and renal function were 
combined and categorized in three levels. In reality, these effects are more subtle 
and probably interrelated.43 The assumptions we made in the model, however, 
applied to all treatment strategies. This enabled us to compare the strategies all 
the same. 
Another limitation of decision analytic models is that the input of such 
models is generally obtained from different sources. The incidence rates for 
cardiovascular complications of hypertension in our model, for instance, were not 
obtained from a study on patients with hypertension and renal artery stenosis, but 
from a community-based study.44 So, it is questionable whether these incidence 
rates apply to the patients in our modeL Extensive sensitivity analyses were 
performed to explore the uncertainty of the key parameters in our modeL These 
analyses showed that the model outcomes were rather robust. Only for different 
values of the risk of end-stage renal disease, it was uncertain whether it was more 
cost-effective to perform angioplasty with selective stent placement in all the 
patients with atherosclerotic renal artery stenosis, or to perform this procedure 
only in case of inadequate blood pressure control or progressive renal failure. The 
differences in costs and effectiveness, however, were small. 
In general, decision analysis can be a useful tool if risks and costs in the 
short term and the long term have to be weighed, especially if these risks and 
costs are uncertain.41 Decision analytic models can be used to explore which 
additional information is needed most to make better evidence-based decisions in 
clinical practice. This, in turn, suggests important clinical research. With respect 
to the treatment of atherosclerotic renal artery stenosis, our model suggested that 
it is cost-effective to perform intra-arterial angiography in every patient with renal 
artery stenosis on CTA or MRA, with subsequent intervention if the presence of 
stenosis is confttmed. For patients with atherosclerotic stenosis, stent placement 
seems more cost-effective than angioplasty alone. More information on the long-
term risks of renal artery stenosis is needed, however, especially on which patients 
are at risk for progressive renal failure, and for which patients intervention offers 
a sustained benefit. 
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State of the a.rt 
Since the start of our studies in the early 1990's, changes have taken place in the 
diagnostic approach and treatment of renal artery stenosis. We believe that our 
studies contributed to some of these changes. The main developments are 
commented on in the following sections. 
Diagnostic approach of renal artery stenosis 
Diagnostic tests for renal artery stenosis can roughly be subdivided into imaging 
tests showing the presence and degree of stenosis and tests that identify 
hemodynamically significant stenosis. With respect to imaging tests, intra-arterial 
angiography is replaced more and more by less invasive imaging techniques such 
as MRA or CTA, although these tests have disadvantages such as a risk of 
nephrotoxicity (CTA) and high cost (MRA).45 In a sample of unselected patients 
who received diagnostic workup for renal artery stenosis in recent years in three 
Dutch hospitals, the final di~onosis was made by conventional angiography in 
only 4%. Instead of angiography, CTA was performed in 92%, and MRA in 4% 
of the patients (unpublished data). Although a recent meta-analysis involving a 
small number of published studies suggested that the diagnostic performance of 
CTA and gadolinium-enhanced MRA compared to conventional angiography was 
excellent,46 there is insufficient evidence as yet to replace conventional 
angiography by CTA or MRA as the reference standard for the diagnosis of renal 
artery stenosis. 
With respect to tests for identifying hemodynamically significant stenosis, 
renography is performed less frequently for the detection of renal artery stenosis 
in patients with hypertension in the Netherlands. In our recent sample of 
unselected patients receiving diagnostic workup for renal artery stenosis, 
renography was performed for this purpose in only 12% of the patients 
(unpublished data). Other proposed tests, such as the captopril renin challenge 
test and renal vein renin measurements, do not qualify for use as a screening test 
for renal artery stenosis because they are not sufficiently accurate.10,47,4S At 
present, color doppler ultrasonography seems the most promising test for 
predicting the response to revascularization.45,49 
In recent guidelines, for the diagnosis of renal artery stenosis,42 seven 
indications for intra-arterial angiography for the evaluation of renal artery stenosis 
are formulated. These indications are based on findings of non-invasive vascular 
imaging, patient characteristics such as onset of hypertension and age, and signs 
of loss of renal function. 
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Therapeutic approach of renal artery stenosis 
Balloon angioplasty is generally considered the most appropriate treatment for 
patients with hypertension and stenosis due to fibromuscular dysplasia_17,42,S0,51 
For hypertensive patients with atherosclerotic renal artery stenosis, however, 
considerable controversy still exists. In these patients, intervention often reduces 
but rarely eliminates the need for antihypertensive medication, and can lead to 
atheroembolization if widespread atherosclerotic plaques are present. 51 It remains 
difficult to predict which of these patients will have a favourable response to 
intervention with respect to blood pressure control. The lack of data on the 
results of intervention in the long term adds to the uncertainty. 
On the basis of our trial and those of others,23,Z4 the general tendency to 
perform an intervention in all patients seems to be shifting towards a more 
conservative approach in which aggressive medical treatment is started 
first.17,37,42,51,52 Medical treatment should aim for blood pressure control and 
prevention of cardiovascular complications. For that reason, it should not only 
include antihypertensive drugs but also lipid lowering agents and antiplatelet 
agents. Patients who are treated medically should also be monitored carefully for 
disease progression.17,37,51 
According to recent guidelines,42 an intervention is indicated if hypertension 
is likely to be cured (e.g., in young patients), is refractory to medication or 
accelerated or malignant, or if renal function deteriorates. Other indications are 
recurrent 'flash' pulmonary oedema and unstable angina. 42 Furthermore, an 
intervention should be performed in patients with bilateral stenosis or with 
unilateral stenosis with a solitary functioning kidney (e.g. after nephrectomy or in 
case of occlusion of the renal artery in the contralateral kidney).53 
The benefit of stent placement over angioplasty in patients with 
atherosclerotic renal artery stenosis remains a debated issue. Although stent 
placement has a higher technical success rate and lower rate of restenosis,29,54,ss 
the superiority of stents over angioplasty in terms of blood pressure has not been 
demonstrated.29 The benefit of stents with respect to preservation of renal 
function, especially in the long term, still has to be determined.29,37 Recent 
guidelines state that stent placement is indicated for atherosclerotic stenosis 
located in the ostium of the renal artery and in case of a failed angioplasty 
procedure or restenosis after a initially successful angioplasty procedure.42 
Contraindications for stent placement have also been formulated, however, such 
as presence of sepsis or inelastic stenosis.42 
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Conclusions 
Conclusions with regard to the diagnosis of renal artery stenosis: 
The interobserver agreement of captopril renography for the detection of 
renal artery stenosis varies considerably and depends on the renographic 
parameters that are used as diagnostic criteria. This, together with the 
complexity of the test, makes renography unsuitable as a screening test to 
select hypertensive patients for further diagnostic workup. 
Clinical characteristics are of value for predicting the probability of renal 
artery stenosis in patients with drug-resistant hypertension. Combined into a 
prediction rule for renal artery stenosis, they can be used reliably to select 
hypertensive patients for angiography. If used with a conservative cutoff 
value, the prediction rule can exclude a small proportion of the patients from 
angiography. 
Conclusions with regard to treatment of renal artery stenosis: 
In patients with hypertension and atherosclerotic renal artery stenosis 
without severe renal failure, the blood pressure lowering effect of balloon 
angioplasty is not relevantly better than that of drug therapy, but angioplasty 
has a small medication-sparing effect. Balloon angioplasty seems to preserve 
renal function in the short term, especially in patients with bilateral stenosis. 
Based on the available data on short-term and long-term costs and effects of 
treatment, it is cost-effective to perform intra-arterial angiography and 
intervention in hypertensive patients without severe renal failure who have 
flndings of renal artery stenosis on CTA or MRA. Patients with 
atherosclerotic renal artery stenosis should preferably be treated with 
angioplasty followed by stent placement in the same session if the angioplasty 
procedure fails. 
Recommendations 
Diagnostic workup for renal artery stenosis is indicated for patients with 
drug-resistant hypertension. The prediction rule for renal artery stenosis 
should be integrated in the diagnostic workup of patients suspected of renal 
artery stenosis. A conservative cutoff level for the predicted probability of 
stenosis (<5%) should be adhered to below which patients are excluded from 
further workup. The rule should be validated more extensively, before a more 
lenient cutoff value can be reliably used. The value of the combination of the 
prediction rule with CTA or MRA might be studied to select patients for 
intra-arterial angiography and intervention more efficiently. 
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Given the available evidence, patients with drug-resistant hypertension and 
substantial atherosclerotic renal artery stenosis (50% or more in lumen 
diameter) should receive an intervention. Large prospective randomized trials 
are needed, however, to compare the costs and effects of different treatment 
strategies with angioplasty and direct or selective stent placement. These trials 
should focus on the effect of treatment on renal function, particularly in the 
long term. 
More research is needed to flnd methods for identifying patients who are 
likely to beneflt from intervention. Besides the development of complex 
clinical methods, such as intra-arterial pressure measurements to flnd criteria 
for hemodynamically significant stenosis, epidemiological data could be used 
to flnd predictors of a successful response to intervention. 
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Summary 
This thesis describes studies on ~onosis and treatment of renal artery stenosis in 
patients with drug-resistant hypertension. In Chapter 1, the clinical problem of renal 
artery stenosis is discussed. Renal artery stenosis, a narrowing of the renal artery, is a 
potential cause of secondary hypertension. For this reason, it is important to di~onose 
a stenosis, so that treatment can be initiated. Treatment of patients with hypertension 
and renal artery stenosis may potentially prevent cardiovascular complications and 
renal insufficiency. The research questions on diagnosis concerned (1) the 
interobserver agreement of captopril renography for the detection of renal artery 
stenosis, and (2) the value of clinical characteristics for predicting the probability of 
stenosis in patients with drug-resistant hypertension. The research questions on 
treatment concerned (1) the comparison of clinical outcomes after balloon angioplasty 
versus drug therapy for patients with drug-resistant hypertension and atherosclerotic 
renal artery stenosis, and (2) the cost-effectiveness of several treatment strategies in this 
patient group. 
Diagnosis of renal artery stenosis 
Diagnostic testing for renal artery stenosis is common in hypertensive patients 
with difficult-to-treat hypertension. Given the low prevalence of stenosis in these 
patients together with the invasiveness of the current reference test, digital 
subtraction angiography, selection of patients for angiography is desirable by 
means of a non-invasive diagnostic test. The Chapters 2 through 4 of the thesis 
describe studies on such tests for renal artery stenosis. 
In Chapter 2, the interobserver agreement of captopril renography is 
evaluated. We found considerable variation between observers in their judgment 
of renographic parameters. Some parameters could be assessed reliably with high 
agreement, e.g. pattern of the time-activity curves, but others were difficult to 
assess, e.g. cortical retention. We concluded that interobserver variability offers 
one of several explanations for differences in the diagnostic test performance of 
captopril renography that are found between studies. 
In Chapter 3, another way of selecting hypertensive patients for angiography 
is introduced. We developed a clinical prediction rule on the basis of readily 
available, clinical characteristics to predict the probability of renal artery stenosis 
in patients with drug-resistant hypertension. The prediction rule was reliable and 
discriminated well between patients with and without stenosis, although patients 
with stenosis due to fibromuscular dysplasia were less well identified than patients 
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with atherosclerotic renal artery stenosis. The di~onostic accuracy of the rule was 
comparable to that of renography. 
Before the prediction rule can reliably be used in clinical practice, it has to be 
validated in another clinical setting. Chapter 4 describes such an external 
validation study. The predicted probabilities of stenosis for the patients in the 
validation sample again agreed well with the observed probabilities, but the ability 
to discriminate between patients with and without stenosis was disappointing 
compared to that in the development sample. In part, this was due to the 
unusually high prevalence of patients with fibromuscular dysplasia in the 
validation sample, who can be identified less well by the prediction rule. Even in 
this patient sample, where the discriminative ability was underestimated, the 
prediction rule had some clinical usefulness: if only patients with predicted 
probabilities of stenosis of 5% or more were referred for renal angiography, the 
number of referrals was reduced by 20%, while less than 10% of the patients with 
a stenosis were missed. We concluded that the prediction rule is a useful tool to 
quantify the probability of renal artery stenosis. The rule is an alternative for 
renography in the selection of hypertensive patients for angiography. If the 
prediction rule is used with a conservative cutoff value, patients can be excluded 
reliably from further diagnostic workup for renal artery stenosis. 
Treatment of renal artery stenosis 
Balloon angioplasty is often performed to lower blood pressure in hypertensive 
patients with renal artery stenosis. For the majority of the patients, i.e. patients 
with stenosis on the basis of atherosclerosis, however, the long-term effect of 
angioplasty on blood pressure is uncertain. The Chapters 5 through 8 describe the 
findings of a randomized controlled trial comparing clinical outcomes of 106 
patients with atherosclerotic renal artery stenosis who were randomly allocated to 
balloon angioplasty (N=56) or to drug therapy (N=SO). Inclusion criteria were 
hypertension resistant to a standardized regimen of two antihypertensive drugs or 
a rise in serum creatinine during treatment with an ACE inhibitor, and an 
otherwise normal or mildly impaired renal function. In accordance with the study 
protocol, 22 of the 50 patients in the drug-therapy group underwent angioplasty 
after 3 months, because of persistent hypertension or deterioration of renal 
function. We found no statistically significant differences in blood pressure at 3 
months and at 12 months (Chapter 5). The patients in the drug-therapy group 
however used significantly more antihypertensive medication at 3 months. Renal 
function at 3 months in the angioplasty group was improved compared to the 
drug-therapy group, but was similar after 12 months of follow-up. We concluded 
that angioplasty had little advantage over drug therapy with regard to blood 
154 
Summary 
pressure control. There was some evidence, however, that angioplasty was 
beneficial for preserving renal function. 
In Chapter 6, a secondary analysis of the trial data was performed to identify 
subgroups of patients who might benefit from angioplasty compared to initial 
medication (followed by angioplasty if needed, after three months). Changes in blood 
pressure and renal function after 1 year were studied for patients with a positive 
captopril-renin challenge test, with an abnormal captopril renogram, with recendy 
developed hypertension, with bilateral stenosis, and with severe stenosis. Patients with 
bilateral stenosis benefited more from immediate angioplasty with regard to 
preservation of renal function and, to a lesser extent, with regard to blood pressure 
control. So, with the exception of patients with bilateral stenosis, intervention can be 
postponed until hypertension persists despite increased medication or until renal 
function deteriorates. 
Chapters 7 and 8 discuss the quality of life of patients with hypertension. In 
Chapter 7, we evaluated the reproducibility and validity of a Dutch questionnaire on 
physical symptoms associated with hypertension and antihypertensive drugs and of a 
generic health questionnaire (the MOS Survey) in hypertensive patients on stable 
medication. The reproducibility and validity were considered satisfactory. In 
Chapter 8, we evaluated whether the medication-sparing effect of angioplasty in our 
randomized trial led to an improved quality of life. The patients in the angioplasty 
group did not report less physical complaints, or a better quality of life than the 
patients in the drug-therapy group. Evidendy, angioplasty had no advantage over drug 
therapy regarding the patients' quality of life. 
In Chapter 9, we developed a decision analytic model to assess the cost-
effectiveness of seven treatment strategies for patients with drug-resistant hypertension 
without severe renal failure, who have findings suggestive of significant renal artery 
stenosis on CTA or MRA. In the model, the short-term complications and cost of 
percutaneous interventions (balloon angioplasty with or without stent placement) were 
weighed ~aainst the long-term risks and cost of hypertension (myocardial infarction, 
stroke) and renal dysfunction (end-stage renal disease). The treatment strategies that 
included only angioplasty increased the quality-adjusted life expectancy by more than 
70 days and decreased cost compared to treatment with medication only. The 
treatment strategies that included stent placement increased the life expectancy more 
than 100 days and were similarly cost saving. Immediate intervention had no evident 
benefit over performing intra-arterial procedures only if blood pressure control failed 
or renal function deteriorated. 
The thesis is concluded with a general discussion on the findings of the 
presented studies (Chapter 1 0). This final chapter also gives recommendations on 
further diagnostic and therapeutic research. 
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Samenvatting 
Dit proefschrift beschrijft een aantal studies naar de di~onostiek en behandeling van 
nierarteriestenose bij patienten met therapieresistente hypertensie. In Hoofdstuk 1 
wordt het klinische probleem nierarteriestenose besproken. Nierarteriestenose, een 
vemauwing van de niers~oader, is een mogelijke oorzaak van secundaire hypertensie. 
Het is om deze reden be~orijk om vast te stellen dat een stenose aanwezig is zodat 
een behandeling kan worden ingesteld. Behandeling van patienten met hypertensie en 
nierarteriestenose kan mogelijk voorkomen dat cardiovasculaire complicacies optreden 
en dat nierinsufficientie ontstaat. De vraagstellingen van het onderzoek over 
di~onostiek betroffen (1) de mate van overeenkomst in de beoordeling van captopril 
renografie tussen beoordelaars voor het vaststellen van nierarteriestenose, en (2) de 
waarde van klinische patientkenmerken voor het voorspellen van de kans op 
nierarteriestenose bij patienten met therapieresistente hypertensie. De vraagstellingen 
over behandeling betroffen (1) de vergelijking van klinische uitkomsten na ballon-
angioplastiek en na medicatie bij patienten met therapieresistente hypertensie en 
atherosclerotische nierarteriestenose, en (2) de vergelijking van de kosten-effectiviteit 
van verschillende behandelingsstrategieen voor deze groep patienten. 
Diagnostiek van nierarteriestenose 
Het is gebruikelijk om diagnostiek naar nierarteriestenose te verrichten bij 
patienten met moeilijk behandelbare hypertensie. V anwege de lage prevalentie 
van nierarteriestenose in deze groep patienten en het invasieve karakter van de 
huidige gouden standaard test, de digitale subtractie-angiografie, is selectie van 
patienten voor angiografie gewenst door middel van een niet-invasieve 
diagnostische test. De hoofdstukken 2, 3 en 4 van het proefschrift beschrijven 
studies naar zulke testen voor nierarteriestenose. 
In Hoofdstuk 2 wordt de mate van overeenkomst tussen beoordelaars in de 
beoordeling van captopril renografie bestudeerd. We vonden aanzienlijke variatie 
in de beoordelingen van de renografische parameters. V oor sommige parameters 
werd een hoge overeenkomst in beoordeling vastgesteld, zoals voor het patroon 
van de tijd-activiteitscurve, maar andere parameters, zoals corticale retentie, 
waren moeilijk te beoordelen. We concludeerden dat verschillen in de 
beoordeling van renografische parameters een verklaring zijn voor de verschillen 
in de diagnostische waarde van captopril renografie die in de literatuur zijn 
gerapporteerd. 
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In Hoofdstuk 3 wordt een andere manier ge1ntroduceerd voor het 
selecteren van patienten met hypertensie voor angiografie. We ontwikkelden een 
klinische predictieregel op basis van direct beschikbare klinische kenmerken om 
de kans op nierarteriestenose te voorspellen voor patienten met therapieresistente 
hypertensie. De predictieregel was betrouwbaar en maakte goed onderscheid 
tussen patienten met en zonder stenose. Patienten met nierarteriestenose 
veroorzaakt door fibromusculaire dysplasie werden door de predictieregel echter 
minder goed ge1dentificeerd dan patienten met nierarteriestenose veroorzaakt 
door atherosclerose. De predictieregel werd intern gevalideerd. De diagnostische 
nauwkeurigheid van de predictieregel bleek vergelijkbaar te zijn met die van 
renografie. 
V oordat de predictieregel betrouwbaar kan worden gebruikt in de klinische 
praktijk, moet deze worden gevalideerd in een andere klinische setting. 
Hoofdstuk 4 beschrijft een dergelijke externe validatiestudie. De voorspelde 
kansen op stenose voor de patienten in de validatiesteekproef kwamen opnieuw 
goed overeen met de waargenomen kansen, maar het vermogen van de 
predictieregel om onderscheid te maken tussen patienten met en zonder stenose 
was teleurstellend vergeleken met dat in de steekproef waarin de regel ontwikkeld 
was. Dit kon deels worden toegeschreven aan de ongewoon hoge prevalentie van 
patienten met fibromusculaire dysplasie in de validatiesteekproef, aangezien deze 
patienten door de predictieregel minder goed kunnen worden gei:dentificeerd. 
Echter, zelfs in deze steekproef, waarin het onderscheidend vermogen van de 
regel werd onderschat, was de predictieregel enigszins bruikbaar: als aileen 
patienten met een voorspelde kans op stenose van 5% of meer werden 
doorverwezen voor angiografie, werd het aantal verwijzingen gereduceerd met 
20%, terwijl minder dan 10% van de patienten met een stenose werd gemist. De 
conclusie luidt dat de klinische predictieregel een bruikbaar middel is om de kans 
op nierarteriestenose te kwantificeren. De regel is een alternatief voor renografie 
bij de selectie v~ patienten met hypertensie voor angiografie. Onder de 
voorwaarde dat een conservatief afkappunt wordt gekozen, kan de predictieregel 
betrouwbaar worden gebruikt om bij een deel van de patienten af te zien van 
verdere diagnostiek naar de aanwezigheid van nierarteriestenose. 
Behandeling van nierarteriestenose 
Ballonangioplastiek wordt vaak toegepast bij pattenten met nierarteriestenose 
voor de behandeling van hypertensie. V oor de overgrote meerderheid van de 
patienten, namelijk voor hen bij wie de stenose veroorzaakt is door 
atherosclerose, is het effect van ballonangioplastiek op de bloeddruk op de lange 
termijn echter onzeker. In de hoofdstukken 5 tot en met 8 van dit proefschrift 
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worden de bevindingen beschreven van een gerandomiseerde studie waarin de 
klinische uitkomsten werden vergeleken van 106 patienten met atherosclerotische 
nierarteriestenose die op basis van het toeval waren toegewezen aan 
ballonangioplastiek (N=56) of aan antihypertensieve medicatie (N=SO). De 
inclusiecriteria waren hypertensie ondanks behandeling met twee anti-
hypertensieve geneesmiddelen of een toename van de serum creatinine 
concentratie tijdens behandeling met een ACE remmer, en verder een normale of 
licht gestoorde nierfunctie. In overeenstemming met het studieprotocol 
ondergingen 22 van de 50 patienten in de medicatiegroep na 3 maanden alsnog 
ballonangioplastiek vanwege persisterende hoge bloeddruk of vanwege een 
verslechtering van de nierfunctie. We vonden geen statistisch significante 
verschillen in bloeddruk na 3 maanden en na 12 maanden follow-up (Hoofdstuk 
5). De patienten in de medicatiegroep gebruikten echter significant meer 
antihypertensieve medicatie na 3 maanden follow-up. De nierfunctie van de 
patienten in de angioplastiekgroep was na 3 maanden verbeterd ten opzichte van 
de medicatiegroep, maar was vergelijkbaar na 12 maanden follow-up. We 
concludeerden dat ballonangioplastiek slechts een klein voordeel biedt ten 
opzichte van medicatie wat betreft de behandeling van hypertensie. Er waren 
echter wel aanwijzingen dat ballonangioplastiek meerwaarde heeft voor het 
behoud van de nierfunctie. 
Hoofdstuk 6 beschrijft een secundaire analyse van deze gegevens voor het 
identificeren van subgroepen van patientcn die mogelijk voordeel hebben van 
ballonangioplastiek ten opzichte van initiele medicatie met, indien nodig, 
angioplastiek na 3 maanden. Veranderingen in bloeddruk en nierfunctie na 1 jaar 
werden bestudeerd voor patienten met een positieve captopril test, met een 
abnormaal captopril renogram, met recent ontstane hypertensie, met bilaterale 
stenose, en met ernstige stenose. Patienten met bilaterale stenose hadden 
voordeel van onmiddellijke ballonangioplastiek wat betreft het behoud van de 
nierfunctie en, in mindere mate, wat betreft bloeddrukcontrole. Met uitzondering 
van patienten met bilaterale stenose kan interventie dus worden uitgesteld totdat 
blijkt dat de bloeddruk niet gecontroleerd kan worden met meer medicatie of 
totdat de nierfunctie verslechtert. 
In de hoofdstukken 7 en 8 werd de kwaliteit van leven van patienten met 
hypertensie bestudeerd. In Hoofdstuk 7 evalueerden we de reproduceerbaarheid 
en de validiteit van een Nederlandstalige vragenlijst over lichamelijke klachten die 
geassocieerd worden met hypertensie en antihypertensieve geneesmiddelen en 
van een vragenlijst voor het meten van de algemene gezondheidstoestand (de 
MOS-20 vragenlijst) bij patienten met hypertensie die behandeld werden met 
stabiele medica tie. We oordeelden dat de reproduceerbaarheid en validiteit van 
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deze vragenlijsten voldoende waren. In Hoofdstuk 8 werd bestudeerd of het 
medicatiesparende effect van ballonangioplastiek in onze gerandomiseerde studie 
leidde tot een verbetering van de kwaliteit van leven. De patienten in de 
angioplastiekgroep rapporteerden noch een lager aantallichamelijke klachten, noch 
een betere kwaliteit van leven vergeleken met de medicatiegroep. Klaarblijkelijk 
bood ballonangioplastiek geen voordeel boven medicatie wat betreft de kwaliteit 
van leven van de patienten. 
In Hoofdstuk 9 werd de kosten-effectiviteit berekend van zeven 
behandelingsstrategieen voor patienten met moeilijk behandelbare hypertensie 
zonder nierfalen, bij wie een significante nierarteriestenose wordt vermoed op 
grond van CTA of MRA. In deze studie werd gebruik gemaakt van een 
besliskundig model. In het model werden de complicaties en kosten van 
percutane interventies (ballonangioplastiek met of zonder stentplaatsing) op de 
korte termijn afgewogen tegen de risico's en kosten van hypertensie op de lange 
termijn (myocard infarct en CV A) en van progressieve nierfunctieverslechtering 
(terminale nierinsufficientie). De behandelingsstrategieen met aileen bailon-
angioplastiek verhoogden de voor kwaliteit gecorrigeerde levensverwachting met 
meet dan 70 dagen en gingen gepaard met met een kostenbesparing vergeleken 
met een behandeling met aileen medicatie. De behandelingsstrategieen met 
stentplaatsing verhoogden de levensverwachting met meet dan 100 dagen en 
leidden tot een vergelijkbare kostenbesparing. Onmiddellijke interventie had geen 
duidelijk voordeel boven het aileen verrichten van intra-arteriele procedures 
ingeval van persisterende hypertensie of nierfunctieverslechtering. 
Het proefschrift wordt afgesloten met een discussie van de bevindingen van 
de beschreven studies (Hoofdstuk 10). In dit laatste hoofdstuk worden ook 
aanbevelingen gedaan voor verder onderzoek op het terrein van de diagnostiek en 
behandeling van nierarteriestenose. 
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Appendix A. Hypertension Questionnaire -Dutch version 
Questions marked with '*' have been added to the original questionnaire. 
Het is de bedoeling dat u per vraag een antwoordcategorie omcirkelt of een getal invult. 
1. Heeft u zich de laatste maand wel eens licht in het hoofd, Ja Nee 
of duizelig gevoeld ? 
Indien met nee beantwoord, verder gaan met vraag 4. 
2. Treedt deze lichthoofdigheid of duizeligheid Ja Nee 
alleen op als u rechtop staat ? 
3. Hoeveel uur per dag had u last van minder dan 1 uur 
lichthoofdigheid of duizeligheid in 1-2 uur 
de laatste maand ? meer dan 2 uur 
4. Heeft u zich de laatste maand overdag vaak Ja Nee 
slaperig gevoeld ? 
5. Hoeveel uur slaapt u gewoonlijk per 24 uur ? OJ uur 
6. Heeft u de laatste maand last gehad van een zwak gevoel Ja Nee 
in de benen? 
7. Heeft u de laatste maand weleens bemerkt wazig te zien ? Ja Nee 
8. Wordt u kortademig als u met mensen van uw eigen leeftijd Ja Nee 
op vlak terrein een wandeling maakt ? 
9. Heeft u aan het eind van de dag gezwollen enkels ? Ja Nee 
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10. Vergeleken met mens en van uw eigen leeftijd, 
looptu dan: 
11. 
12. 
13. 
14. 
15. 
Hoe vaak heeft u gewoonlijk ontlasting? 
(in 1 van beide hokjes een getal invu!len) 
Is uw ontlasting vaak breiig of vloeibaar ? 
Had u de laatste maand vaak last van verstopping ? 
Hoe vaak staat u gemiddeld 's nachts op 
om te plassen ? 
Heeft u de laatste maand last gehad van een droge mond ? 
Indien met nee beantwoord, verder gaan met vraag 17. 
16. Ondervindt u hinder van een droge mond 
bij het spreken of eten ? 
langzamer 
sneller 
ongeveer even snel 
maalper dag 
of maal per week 
Ja 
Ja 
0 keer 
1 keer 
2keer 
meer dan 2 keer 
Ja 
17. Heeft u de laatste maand last gehad van een nare smaak in de mond ? Ja 
18.* Heeft u de laatste maand last gehad van smaah.-verlies ? Ja 
19. Heeft u de laatste maand last gehad van een verstopte of lopende neus ? Ja 
20. Heeft u de laatste maand last gehad van een prikkelhoest? Ja 
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21. Vergeleken met mensen van uw eigen leeftijd, 
is uw concentratievermogen dan: beter dan het gerniddelde 
22. 
23. 
24. 
25. 
26. 
27. 
29.* 
30.* 
31. 
gerniddeld 
slechter dan het gerniddelde 
Heeft u de laatste maand last gehad van erg warm worden 
of van roodheid in het gezicht ? 
Heeft u de laatste maand last gehad van nachtrnerries ? 
Heeft u zich de laatste maand vaak rnisselijk gevoeld 
of moeten braken ? 
Heeft u de laatste maand last gehad van huiduitslag ? 
Heeft u de laatste maand last gehad van jeuk ? 
Heeft u last van "dode vingers" bij koud weer? 
Indien met nee beantJvoord, verder gaan met vraag 29. 
28. Zo ja, worden uw vingers daarna pijnlijk ? 
Heeft u de laatste maand last gehad van koude handen en voeten ? 
Heeft u zich de laatste maand vaak kouwelijk of rillerig gevoeld ? 
Heeft u de laatste maand last gehad van hoofdpijn ? 
Indien met nee beantJvoord, verder gaan met vraag 34. 
Ja 
Ja 
Ja 
Ja 
Ja 
Ja 
Ja 
Ja 
Ja 
Ja 
32. Zo ja, hoe vaak treedt hoofdpijn bij u op? 1 of meerdere malen per dag 
1-6x per week 
minder dan 1x per week 
Nee 
Nee 
Nee 
Nee 
Nee 
Nee 
Nee 
Nee 
Nee 
Nee 
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33. Op welk moment van de dag 
treedt deze hoofdpijn op ? bij het opstaan 
overdag, maar niet bij het opstaan 
in de avond 
34.* Heeft u de laatste maand last gehad van droge, pijnlijke ogen ? Ja Nee 
35. * Heeft u de laatste maand last gehad van hartkloppingen ? Ja Nee 
36.* Heeft u de laatste maand spierkrampen gehad ? Ja Nee 
37.* Heeft u de laatste maand gewrichtsklachten gehad? Ja Nee 
38. * Heeft u de laatste maand last gehad van benauwdheid of kortademigheid? Ja Nee 
39.* Heeft u de laatste maand tabletten laten staan vanwege bijwerkingen? Ja Nee 
De volgende vragen gaan over uw sexuele leven. Wij weten dat deze informatie erg persoonlijk is. 
Toch zijn we in aile aspecten van uw welbevinden gemteresseerd en we zouden het op prijs stellen 
als u de vragen wilt beantwoorden. We willen nogmaals benadrukken dat de door u gegeven 
informatie vertrouwelijk behandeld wordt. 
40. Is uw interesse in sex de laatste tijd verminderd 
hetzelfde of groter 
41. Heeft u sexuele gemeenschap ? Ja Nee 
Indien met nee beantJvoord, verder gaan met vraag 4 2. 
Indien met )a beantJvoord, verder gaan met vraag 4 3. 
42. Is de reden dat u geen gemeenschap heeft op een of andere manier Ja Nee 
gerelateerd aan uw gezondheid ? 
Ga verder met vraag 44. 
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43. Hoe vaak heeft u gemeenschap ? aantal malen per week 
(graag 1 hokje invu//m) aantal malen per maand 
aantal malen per jaar 
Aanvullende vragen voor mannen: 
44. Heeft u problemen met de erectie? Ja Nee 
45. Heeft u problemen met de zaadlozing? Ja Nee 
De volgende vragen hebben betrekking op uw dagelijkse activiteiten. 
46. Kruis het antwoord aan dat het beste uw beroep beschrijft: 
in loondienst 
zelfstandig werkzaam 
niet in loondienst, maar werkzaam in de huishouding 
of belast met de verzorging van familieleden 
werkloos (om niet-medische reden) 
arbeidsongeschikt (AA W /WAO) 
gepensioneerd 
47. Als u in loondienst bent of zelfstandige bent, hoeveel dagen heeft u de OJ 
laatste maand wegens ziekte niet kunnen werken ? (graag het aanta/ dagen invu//en) 
48. Heeft uw gezondheid u in de laatste maand belemmerd om uw normale Ja Nee 
werkzaamheden in huis of in de tuin uit te voeren ? 
Indien met nee beanhvoord, verder gaan met vraag 50. 
49. Hoeveel dagen heeft u in de laatste maand door ziekte OJ 
deze werkzaamheden in huis of in de tuin niet kunnen uitvoeren ? 
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50. 
53. 
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Heeft u hobbies? 
Indien met nee beantwoord, verder gaan met vraag 53. 
51. Zo ja, wat zijn uw hobbies ? 
52. Vormt uw gezondheidstoestand de laatste tijd een belemmering 
bij het uitoefenen van uw hobbies ? 
Vormt uw gezondheidstoestand nog op andere manieren 
een belemmering in uw dagelijks !even ? 
54. Zo ja, op welke manier ? 
Ja Nee 
Ja Nee 
Ja Nee 
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Appendix B. MOS Survey- Dutch version 
Questions marked with '*' have been added to the original questionnaire. 
Wilt u bij iedere vraag 1 antwoordmogelijkheid aankruisen. 
Als u een vraag niet precies kunt beantwoorden, geef dan het best mogelijke antwoord 
1. Hoe is in het algemeen uw gezondheid ? Uitstekend 
Erggoed 
Goed 
Redelijk 
Slecht 
De volgende vragen gaan over eventuele beperkingen ten gevolge van uw gezondheid. 
Heeft uw gezondheidstoestand u de afgelopen maand beperkt in een van de volgende activiteiten ? 
Ja, emstig Ja,een Nee, 
Beperktin: beperkt beetje helemaal 
beperkt niet beperkt 
2. .. zeer inspannende activiteiten zoals 
optillen van zware voorwerpen, hardlopen, 
of deelname aan inspannende sporten ................ D D D 
3. .. wat minder inspannende activiteiten zoals 
een tafel verplaatsen, boodschappen dragen .......... D D D 
4. .. een heuvel oplopen of enkele ttappen lopen ...... D D D 
5. .. buigen, tillen, of bukken .................................... D D D 
6. .. een blokje om lopen ..................................... D D D 
7. .. eten, aankleden, douchen of een bad 
nemen of naar het toilet gaan .......................... D D D 
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8. Heeft u de afgelopen maand vanwege uw gezondheid 
uw werk niet kunnen do en of huishoudelijke karwei*s 
niet kunnen doen ? 
9. Heeft u de afgelopen maand vanwege uw gezondheid 
bepaalde werkZflamheden niet kunnen doen ? 
10. Hoe vaak heeft uw gezondheid u de afgelopen maand beperkt 
in uw sociale activiteiten (zoals op bezoek gaan bij vrienden 
of naaste familie) ? 
11. Heeft u de afgelopen maand lichamelijke pijn gehad? 
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Ja 
Af en toe 
Nee 
Ja 
Af en toe 
Nee 
Altijd 
Heel vaak 
Redelijk vaak 
Soms 
Bijna nooit 
Nooit 
Geen pijn 
Zeer Iichte pijn 
Lichte pijn 
Matige pijn 
Hevige pijn 
Hieronder staan vragen over hoe u zich de afgelopen maand heeft gevoeld. 
Kruis telkens het antwoord aan dat het meest op u van toepassing is. 
Altijd Heel Redelijk Soms 
Hoe vaak in de afgelopen maand vaak vaak 
Appendix B 
Bijna Nooit 
nooit 
12. .. bent u erg nerveus geweest ? ......... D D D D D D 
13. .. heeft u zich kalm en rustig 
gevoeld? ......................................... D D D D D D 
14. .. heeft u zich neerslachtig en 
somber gevoeld ? .......................... D D D D D D 
15 ... heeftuzichgelukkiggevoeld? .... D D D D D D 
16. .. heeft u zich zo somber gevoeld 
datnietsukonopvrolijken? ........... D D D D D D 
17.* .. was u snel gelrriteerd ?................. D D D D D D 
18.* .. heeftuzichangstiggevoeld? ...... D D D D D D 
19.* .. heeftuzichlusteloosgevoeld? .... D D D D D D 
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Tot slot willen we u nog een paar andere vragen over uw gezondheid stellen. 
I<ruis hieronder het antwoord aan dat het best uw situatie weergeeft. 
Absoluut Grotendeels Ben erniet 
waar waar zekervan 
Grotendeels Beslist 
niet waar niet waar 
20. Ik ben een beetje ziek........................ D D D D D 
21. Ik ben zo gezond als ieder 
anderdieikken............................... D D D D D 
22. Mijn gezondheid is uitstekend......... D D D D D 
23. Ik voel me de laatste tijd slecht........ D D D D D 
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